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Thesis 
A. Abstract 
Objectives of the studies were to test (1) whether ischemic postconditioning (IPostC) 
is protective in post-myocardial infarct (MI)-remodelled and one-kidney one-clip 
(1K1C) hypertensive rat hearts, (2) whether isoflurane-induced late cardioprotection 
is preserved in post-infarct remodelled hearts, (3) whether volatile anesthetics also 
provide protection in various clinical scenarios. We found that (1) IPostC prevented 
ischemia/reperfusion injury and improved cardiac function in both diseased heart 
models. The protection was abolished by PI3K inhibition. Western blot analysis and 
in vitro kinase assays identified protein kinase B (PKB)/Akt but not extracellular-
signal regulated kinase 1/2 (ERK1/2) pathway as the main reperfusion injury salvage 
kinase pathway in this protection. (2) Isoflurane-induced late protection was 
preserved, but substantially shorter in post-infarct remodelled rat hearts. The 
protection was blocked by cyclooxygenase-2 inhibition. Impaired CREB activation 
and an increased level of the CREB antagonist ICER were associated with impaired 
cyclooxygenase-2 activity. Thus a shorter second window of protection occurs in 
remodelled hearts. In patients and healthy volunteers, volatile anesthetics favourably 
modulated gene expression and elicited anti-inflammatory and endothelial protective 
effects.  
Conclusions: (1) IPostC can protect hypertrophied hearts against I/R injury in a 
PI3K dependent way. (2) Isoflurane fails to mobilize cyclooxygenase-2-inducing 
CREB in remodelled hearts, which is associated with a shortening of the second 
window of protection. Therefore, volatile anesthetics are promising drugs potentially 
providing multi-organ protection. 
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A. Zusammenfassung  
Ziel der Studien war es (1) zu testen, ob ischämische Postkonditionierung (IPostC) 
auch protektiv wirkt in Herzen mit altem Herzinfarkt und hypertensiv-veränderten 
Herzen mit Hypertrophie, (2) zu testen, ob der Isofluran-induzierte Herzschutz auch 
in Infarkt-remodellierten Herzen effektiv ist, (3) zu testen, ob volatile Anästhetika 
auch am Patienten unter klinischen Bedingungen eine Schutzwirkung entfalten 
können.  Unsere Studien zeigen, dass (1) IPostC den 
Ischämie/Reperfusionsschaden auch in Infarkt Herzen und hypertensiv-veränderten 
Herzen deutlich vermindert.  Dieser Schutz kann durch Hemmung der PI3K 
aufgehoben werden.  Western blot Analysen und in vitro Kinase Assays zeigen, dass 
die Protein Kinase B nicht aber die extracellular-signal regulated Kinase (ERK1/2) 
eine wichtige Rolle spielt. (2) dass das „zweite“ oder späte Fenster des Isofluran-
induzierten Herzschutzes zwar vorhanden ist in kranken Herzen, doch deutlich 
kürzer ist als in gesunden Herzen.  Der Schutz kann komplett mit Cyclooxygenase-2 
Inhibitoren aufgehben werden.  Bei der Verkürzung des protektiven Fensters spielt 
eine verminderte Mobilisierung von CREB in den ICER-überexprimierenden Infarkt 
Herzen eine Rolle.  In Patienten und gesunden Probanden, modulieren volatile 
Anästhetika die Genexpression günstig und wirken dadurch entzündungshemmend 
und Endothel-schützend. 
Schlussfolgerungen: (1) IPostC schützt hypertrophierte Herzen gegen 
Ischämie/Reperfusionsschaden via PI3K-PKB Signalweg. (2) In kranken Herzen hat 
Isofluran eine kürzere Schutzwirkung.  Volatile Anästhetika scheinen daher 
vielversprechende Medikamente in der Therapie lebenswichtiger Organe zu sein, 
auch wenn sie vorgeschädigt sind. 
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B. Background 
Ischemia-reperfusion (I/R) injury 
For patients with an acute myocardial ischemia, clinical intervention like coronary 
artery bypass grafting is necessary to restore the blood flow and thus recover cardiac 
function. Observations on perioperative patients revealed that there is still some 
injury despite the timely treatment with clinical interventions. This is caused by the 
restoration of blood flow following ischemia and is called I/R injury 1.     
Biochemical and cellular changes during ischemia and reperfusion (see Fig.1)  
Decreased ATP generation and acidosis:  
Ischemia reduces blood flow to related tissue which causes not only a decreased 
oxygen supply but also the loss of washout of toxic metabolites from the respective 
tissue. With the loss of oxygen supply, oxidative phosphorylation stops and 
anaerobic glycolysis increases as a compensation, leading to a decrease of ATP 
production. At the same time, lactic acid accumulates and intracellular pH (pHi) 
decreases because of loss of efficient washout of metabolites 1,2.  
Accumulation of intracellular and mitochondrial calcium: 
In cardiomyocytes, cytosolic Ca2+ is usually maintained at a relatively low level (10-
100 nM) by transporting Ca2+ out of the cell and to the cisternae of the sarcoplasmic 
reticulum (SR), and by protein binding. Under physiological conditions, cytosolic Ca2+ 
increases by entry through plasma membrane Ca2+ channels, or release of Ca2+ from 
the SR via binding of Ca2+ to the ryanodine receptor (RyR) or via binding of inositol 
trisphosphate (IP3) to the inositol trisphosphate receptor (IP3R). Intracellular Ca2+ is 
pumped out of the cell via the plasma membrane calcium ATPase (PMCA) and the 
Na+/Ca2+ exchanger. The sarco-endoplasmic reticulum calcium ATPase (SERCA) 
transports Ca2+ into the SR. Mitochondria can also buffer Ca2+ by transporting the ion 
into the mitochondrial matrix via Ca2+ uniporters or out of mitochondria via Na+/Ca2+ 
exchangers 3. During ischemia, an increased amount of lactic acid and the decreased 
intracellular pH activate the Na+-H+ exchanger. As a result, the intracellular sodium 
concentration [Na+]i increases. The low ATP level leads to a decrease in activity of 
the ATP consuming Na+-K+-pump which further increases the intracellular 
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accumulation of sodium. The resultant lower outside-inside sodium gradient causes 
the Na+-Ca2+ exchanger to work in the reverse mode, pumping Na+ outside and Ca2+ 
into the cell 4. Ca2+ also enters the cell via the L-type Ca2+ channels. On the other 
hand, a decrease in ATP results in reduced activities of the Ca2+ pump in the plasma 
membrane and of the calcium ATPase (SERCA) in the sarcoplasmic reticulum. All 
these events lead to an increased cytosolic Ca2+. Mitochondrial Na+/Ca2+ exchangers 
operate in the reverse way, leading to an increased mitochondrial calcium Ca2+ 3.    
Generation of reactive oxygen species (ROS): 
In oxidative phosphorylation, oxygen is consumed and finally reduced to H2O. Most 
of the oxygen is reduced to H2O by the mitochondrial electron transport. While a 
small part of oxygen is partially oxidized to toxic reactive oxygen species. Under 
normal conditions, cells or tissues can tolerate small amounts of ROS and reduce 
ROS to H2O. However, under ischemia, this balance is destroyed, and during 
reperfusion, there is a burst of ROS generation 5. 
Fig.1 
A. Ischemia       
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B. Reprfusion 
 
Fig.1 Changes and consequences of cation fluxes during ischemia reperfusion: 
(A) Cessation of oxygen supply in ischemia leads to a loss of ATP production and an 
increase of reactive oxygen species (ROS) in the mitochondria. Reduced activity of 
the ATP consuming Na+-K+-pump lowers the outside-inside sodium gradient, Na+ 
accumulates in the myocyte and the resting membrane potential is lowered. With the 
development of acidosis, the Na+-H+-exchanger (NHX) further increases intracellular 
Na+. Under these conditions the Na+-Ca2+-exchanger (NCX) operates in the reverse 
mode, letting Ca2+ into the cell. Ca2+ also enters through the sarcolemmal L-type 
voltage-gated Ca2+-channel (L) as the resting membrane potential is low. The 
increased Ca2+ is taken up into the sarcoplasmic reticulum (SR) by the SR Ca2+-
pump SERCA2 (P) and released from there via two types of release channels, the 
ryanodine receptor channel (RYR) and the IP3 receptor channel (IP3R), leading to 
contraction. (B) Reoxygenation during reperfusion restores ATP production with a 
further boost of ROS. Reactivation of the Na+-K+-pump by ATP slowly restores the 
sodium gradient leading to normal cation fluxes with the NCX eventually extruding 
the excess of cytosolic Ca2+. During the early reperfusion phase when the 
intracellular Ca2+ level is still high, myocardial contracture (supercontraction of 
myocytes) may develop [Adopted from 4]. 
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Mitochondrial permeability transition (MPT):  
Mitochondria are the key determinants of cell survival and death under different 
conditions. Under normal (aerobic) conditions, the electron transport generates an 
electrochemical gradient across the inner mitochondrial membrane (IM), leading to 
the membrane potential ∆ϕm (≈ -200 mM) and the proton gradient (∆pH). The 
electrochemical gradient is critical for the ATP synthase to phosphorylate ADP to 
ATP. The maintenance of this gradient needs the IM to be relatively impermeable to 
ions. On the other hand, the mitochondrial permeability transition (MPT) [which is 
caused by the opening of mitochondria permeability transition pore (mPTP)] may 
lead to cell death and may play a critical role in I/R injury 6. mPTP is sensitive to high 
concentrations of Ca2+ and Pi, ROS, the depletion of ATP, and high pH. During 
ischemia, the accumulation of intracellular calcium, long-chain fatty acids, as well as 
ROS increase mitochondrial susceptibility to MPT. The mPTP remains closed during 
ischemia, possibly due to acidosis, elevated Mg2+ and depressed electron transport. 
At reperfusion, acidosis is corrected, leading to increased cellular pH. Normalized pH 
together with a further influx of calcium into the mitochondria and a burst of ROS lead 
to the uncontrolled opening of the mPTP 6, that is, MPT. MPT converts mitochondria 
from ATP producers to ATP consumers, accelerating cellular energy depletion and 
hasting cell death. mPTP opening also leads to matrix swelling, outer membrane 
rupture, release of apoptotic signalling molecules such as cytochrome c from the 
intermembrane space, and irreversible mitochondrial injury. Hausenloy et al.. showed 
for the first time that protection can be obtained by treatment with cyclosporin A, an 
inhibitor of mPTP, if administrated at the beginning of reperfusion 7. Many other 
studies investigating pre-and postconditioning showed that protective signalling 
pathways converge at the mitochondria level, especially the mPTP, both during pre- 
and postconditioning 8,9. 
Myocardial responses to acute ischemia 
The contractility of the cardiac tissues markedly reduced only a few seconds after the 
onset of ischemia because of decreased ATP content. Within minutes, intracellular 
acidosis develops, and Cellular Ca2+ concentration increases and cell swelling 
begins. Then cells undergo irreversible injury and cellular ultra-structure changes, 
which is followed by the release of cytoplasmic proteins such as troponins and CK-
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MB 4. Myocardial ischemia followed by reperfusion causes myocardial stunning or 
hibernation despite restoration of blood flow. Myocardial stunning is a reversible 
damage which is characterized by low contractility despite high coronary flow. 
Myocardial hibernation is an irreversible damage in which ventricular contractility is 
diminished as a consequence of reduced coronary blood flow 4. This leads to the 
metabolic remodelling of the tissue.  
 
Cardioprotection against I/R injury (see Fig.2) 
Myocardial preconditioning 
For decades, research efforts have been made to develop measures to alleviate or 
eliminate I/R injury. Murry et al. first reported that transient nonlethal episodes of 
ischemia conferred protection against a subsequent sustained episode of potentially 
lethal myocardial ischemia, reducing infarct size to 70-80% when compared to non-
preconditioned hearts. This is called ischemic preconditioning (IPC) 10. Since then, 
pharmacological agents were also shown to be able to mimic IPC. Among them, 
volatile anesthetics were found to be very effective 11.  
Myocardial postconditioning 
Recently, an alternative approach to cardioprotection was reported by Zhao et al. 12. 
This consists of a short series of repetitive cycles of brief reperfusion and re-
occlusion of the coronary artery applied immediately at the onset of reperfusion, and 
is termed “postconditioning” (IPostC). Studies indicated that recruitment and 
activation of the prosurvival kinases, i.e. phosphatidylinositol-3-OH kinase (PI3K)-Akt 
and the p42/p44 extracellular signal regulated kinases (ERK1/2), at the time of 
reperfusion, contribute to cardioprotection of both ischemic preconditioning and 
ischemic postconditioning. These prosurvival kinases are collectively called the 
reperfusion injury salvage kinases (RISKs) 13. We and other research groups found 
that pharmacological postconditioning (i.e. by volatile anesthetics) could induce 
cardioprotection during early reperfusion after myocardial ischemia through activation 
of PI3K-PKB/Akt pathway 14,15. Detailed mechanisms of pre- and postconditioning will 
be discussed later.  
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Fig.2 
 
 
 
Fig.2 Signalling for cardiac preconditioning: The signalling components depicted 
illustrate current knowledge regarding the mechanisms of early (left of dashed line) 
and delayed (right of dashed line) cardiac preconditioning. AlRed=aldose reductase; 
BCl-2=B-cell lymphoma 2; Bax=BCL2-associated X protein; Bad=proapoptic protein 
Bad; COX-2=cyclooxygenase type 2; CREB=cAMP response element binding 
protein; ERK1/2=extracellular signal regulated kinase 1/2; GSK3β=glycogen 
synthase kinase 3β; HIF1α=hypoxia-inducible factor 1α; HSP 27/70=heat shock 
protein 27/70; i/e/nNOS=inducible/endothelia/neuro nitric oxide synthase; JAK=janus 
kinase; MAPKs=mitogen activated protein kinases; NF-κB=nuclear factor-κB; 
PKC=Protein kinase C; STATs=signal transducers and activators of transcription; Src 
PTK=Src protein tyrosine kinase; MnSOD=manganese superoxide dismutase; 
R=receptors. 
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Late or delayed preconditioning  
Cardiac protective treatments elicited by preconditioning can only protect for 1-3 
hours 16. In 1993, Marber and his colleagues and Kuzuya and colleagues found that 
there is a second window of protection (also called late preconditioning), which 
occurs at about 12-24 hours after the cardioprotective treatments and lasts for up to 
72 hours 17,18. Physical stress (i.e. ischemia, heat stress, exercise) cause release of 
chemical signals [i.e. nitric oxide (NO), ROS, adenosine] that serve as triggers for the 
development of late preconditioning. Pharmacological stimuli (i.e. endotoxin and its 
derivatives, cytokines, ROS, NO donors, adenosine A1 or A2 agonists, KATP channel 
openers, delta opioid receptor agonists, alpha adrenergic receptor agonists) can also 
induce late preconditioning. These stimuli recruit the activation of different kinases 
[i.e. protein kinase C ε (PKCε), Src protein tyrosine kinases (Src PTKs), mitogen 
activated protein kinases (MAPKs), janus kinase 1/2 (JAK1/2)], leading to activation 
of transcription factors such as nuclear factor-κB (NF-κB), signal transducers and 
activators of transcription (STATs), hypoxia-inducible factor 1α (HIF1α), and cAMP 
response element binding protein (CREB), resulting in increased transcription and 
synthesis of cardioprotective proteins. Cyclooxygenase 2 (COX-2) is a rate limiting 
enzyme of prostaglandins, among which PGE2 and PGI2 are likely effectors of COX-
2 mediated cardiac protection 19. NO appears to act as both trigger and mediator of 
late preconditioning. All isoforms of NOS (iNOS, eNOS, and nNOS) are considered 
to be involved in late preconditioning 20,21. There are also some other proteins 
involved in the second window of protection, including aldose reductase (AlRed), Bcl-
2, heat shock protein (HSP) 27/70, manganese superoxide dismutase (Mn SOD) 22. 
 
Mechanisms of cardioprotection underlying pre- and postconditioning  
General remarks 
As mentioned above, multiple studies demonstrated that pre- or postconditioning 
converge on the RISK pathways at the time of myocardial reperfusion. The key 
members of the RISK pathways are: Akt/PKB, ERK1/2, and PKC-ε and their 
downstream targets. More and more observations results indicate that the mPTPs is 
the final target of the RISK pathways 23. As mPTP opens at the very beginning of 
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reperfusion, the various treatment options must be applied before ischemia or at the 
onset of reperfusion to protect the heart against I/R injury. mPTP inhibitors applied 
several minutes after the onset of reperfusion failed to protect the heart against I/R 
injury 24. 
Ischemic pre- and postconditioning (see Fig.3) 
Ischemic preconditioning can cause the release of endogenous substances such as 
adenosine, bradykinin, norepinephrine, and opioids. These substances work as 
triggers of preconditioning, leading to activation of a number of signalling cascades 
via G-protein coupled receptors (GPCRs) 4.  
Role of adenosine:  
Adenosine is the best studied endogenous trigger that can protect against I/R injury. 
There are four adenosine receptor subtypes (A1AR, A2AAR, A2BAR, and A3AR) 25. 
A1ARs and A2AARs are expressed in adult ventricular myocytes. Whether functional 
A3 or A2BAR receptors are expressed in these cells is not clear yet. Their activation 
reduces the level of reactive oxygen species and attenuates stunning in rat 
ventricular myocytes 26. Binding of adenosine to A1AR leads to activation of several 
kinase pathways, including PKC, MAPKs, and PI3K/Akt 27-29. These signalling 
pathways converge on mitochondrial targets such as mPTP and mKATP channels 7. 
Cardioprotection induced by IPC can be abolished by administration of a non-specific 
adenosine receptor blocker during reperfusion 30, indicating an important role of 
ligand-receptor binding in IPC. Additional studies revealed that this binding in IPostC 
is also required at the time of reperfusion 31-33.  
Role of bradykinin:  
Bradykinin is a vasodilator. A short preconditioning period of ischemia leads to a 
marked increase in tissue and plasma bradykinin levels 34.  Bradykinin B2 receptor 
blockers can abolish protection from IPC in rabbit hearts 35 and isolated rat hearts 36. 
Yang et al. showed that IPC did not confer cardioprotection in B2 receptor knock-out 
mice 37.  
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Fig.3 
 
Fig.3 Signaling pathways involved in ischemic pre- and postconditioning: 
Ischemic pre- or postconditioning treatments induce release of intrinsic triggers of 
cardioprotection such as adenosine, bradykinin, opioids, and norepinephrine. These 
triggers activate GPCRs, leading to activation of RISK signalling pathways like 
ERK1/2 pathway, Akt pathway, and/or PKC pathway. These pathways converge on 
the mPTPs to have their cardioprotective effects via several mediators: GSK3β, 
Bax/Bad, eNOS, and mKATP. Arrows indicate positive actation and lines with blunted 
ends (-) indicate inhibition. GPCR=G protein-coupled receptor; MEK1/2=mitogen 
activated kinase kinase 1/2; ERK1/2=extracellular signal regulated kinase 1/2; PI3K= 
phosphatidylinositol-3-OH kinase; PLC=phospholipases C; PKC=protein kinase C; 
Bax=BCL2-associated X protein; Bad=proapoptic protein Bad; GSK3β=glycogen 
synthase kinase 3β; NO=nitric oxide; eNOS=endothelial NO synthase; GC=guanylate 
cyclise; PKG=protein kinase G; mKATP=mitochondrial ATP dependent potassium 
channel. 
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Role of opioids:   
It has been shown that opiod receptor ligands such as morphine and fentanyl can 
mimic IPC 38,39. Administration of δ-opioid receptor antagonists abolished IPC 40.  
Role of norepinephrine:  
Administration of exogenous α-adrenoceptor agonist norepinephrine mimics 
preconditioning 41. And this protection can be blocked by a α-adrenenic blocker.  
RISK pathways:  
In 2004, Tsang Andrew and his colleagues found that activation of PI3K-Akt 
signalling pathway is required for IPostC in isolated perfused rat heart42. In 2005, 
additional work from the same group found that IPC induces phosphorylation of Akt 
and/or ERK-1/2 during both the preconditioning and the reperfusion phase in isolated 
perfused rat hearts. Inhibition of phosphorylation of these kinases at the time of 
reperfusion abolished the cardioprotection elicited by IPC 43. Some other studies 
further confirmed the important role of PI3K/Akt and ERK-1/2 in IPC and IPostC 
33,44,45.  The role of PKC in IPC induced cardioprotection is controversial. There are 
several subtypes of PKC. PKC-α, PKC-δ, and PKC-ε are expressed in the rat heart, 
and PKC-ε and PKC-η in the rabbit heart 46. In some studies, PKC-δ and PKC-ε were 
found to have opposite roles in cardioprotection. In isolated rat heart, administration 
of ϕεRACK, a specific PKC-ε activator, mimics ischemic preconditioning. 
Administration of δV1-1, a selective PKC-δ inhibitor, prevents reperfusion injury 47. 
One study indicates that PKC-ε isoform is an important member of the survival 
kinases in IPostC 48.  
End effectors:  
Evidence is accumulating that all RISK pathways converge on mPTP, preventing its 
opening, and thus alleviating I/R injury 2. The possible mechanisms through which 
the RISK pathways inhibit mPTP opening include: (a) glycogen synthase kinase 3β 
(GSK-3β): GSK-3β can phosphorylate VDAC and disrupt the binding of voltage 
dependent anion channel (VDAC) to Hexokinase II, leading to mPTP opening 49,50. 
Phosphorylation of GSK-3β at Serine 9 by Akt inhibits its activity and thus prevents 
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mPTP opening. (b) eNOS: On one hand, eNOS induces the generation of nitric 
oxide, which can suppress mPTP opening 51. On the other hand, eNOS can work 
through the PKG-PKC-ε-mKATP pathway, leading to the opening of mKATP channel 52. 
(c) Inhibition of pro-apoptotic proteins BAX/BAD 53,54. (d) Opening of mKATP channel 
can also prevent mPTP opening 55.  
Anesthetics induced pre- or postconditioning (see Fig.4) 
In 1976, Bland JH and his colleagues found for the first time that halothane protected 
the non-failing canine heart against experimental myocardial ischemia 56. Later on, 
many anesthetics (i.e. isoflurane, enflurane, sevoflurane, desflurane, opioids, 
ethanol) were found to have similar effects mimicking IPC 11. Volatile anesthetics are 
the most frequently used preconditioning drugs because they are used for general 
anesthesia. Till now, little is known about how volatile anesthetics work in the brain 
and other tissues and whether they have specific receptors or not. However, studies 
found that PKC activation, mKATP channels, and probably activation of G-protein 
coupled receptors (i.e. A1 adenosine receptor, adrenergic receptors) are involved in 
volatile anesthetics induced preconditioning 11. Cope DK 57 found that, 8-sulfophenyl 
theophylline, a non-specific adenosine receptor blocker, and chelerythrine, a specific 
PKC blocker, can inhibit halothane induced preconditioning in an in vivo rabbit model. 
Later on, studies reported that isoflurane induced preconditioning was inhibited by a 
non-specific adenosine receptor blocker in an in vivo rabbit mode, and was inhibited 
by an adenosine 1-specific receptor blocker in a dog model of regional ischemia. 
Desoflurane-induced preconditioning was reported to be inhibited by α-adrenergic 
blocker phentolamine, and, β-adrenergic blocker propranolol 58. PKC was also found 
to be involved in the protective effect of isoflurane against stunning 39. Using blockers 
of the sarcolemmal and mitochondrial KATP channels, studies indicate the 
involvement of both sKATP and mKATP channels in volatile-anesthetic induced 
preconditioning 11.   
Chiari PC and his colleagues 14 reported for the first time that, isoflurane, a volatile 
anesthetic, can induce postconditioning in rabbit hearts when applied at the early 
stage of reperfusion. This protection is dependent on the activation of PI3K-Akt 
signalling pathway. In the same year, Feng J and his colleagues reported that 
isoflurane can induce postconditioning in rat hearts through inhibiting opening of the 
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mPTP 15. Inhibition of GSK-3β, a downstream target of PI3K-Akt pathway, might be 
involved.  
Fig.4 
 
Fig.4 Signaling pathways involved in volatile anesthetic induced pre- and 
postconditioning: Volatile anesthetics activate RISK signalling pathways like Akt 
pathway, and/or PKC pathway through GPCRs or some unknown mechanisms. 
These pathways converge on the mPTPs to have their cardioprotective effects via 
several mediators: GSK3β, Bax/Bad, eNOS, and mKATP. Arrows indicate positive 
activation and lines with blunted ends (-) indicate inhibition. GPCR=G protein-coupled 
receptor; PI3K=phosphatidylinositol-3-OH kinase; PLC=phospholipases C; 
PKC=protein kinase C; Bax=BCL2-associated X protein; Bad=proapoptic protein 
Bad; GSK3β=glycogen synthase kinase 3β; NO=nitric oxide; eNOS=endothelial NO 
synthase; GC=guanylate cyclise; PKG=protein kinase G; PKCε=protein kinase C-
ε; mKATP=mitochondrial ATP dependent potassium channel. 
Other pharmacological mimics of pre- and postconditioning 
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Besides ischemic stimuli and anesthetics, there are many other pharmacological 
agents that are able to mimic pre- or postconditioning. Mostly, they are G-protein 
coupled receptor ligands (i.e. adenosine, bradykinin, opioids, adrenomedullin, 
glucagon like peptide 1, adrenomedullin, and urocortin); growth factors (i.e. 
transforming growth factor β-1, insulin, insulin like growth factor-1, and corticotrophin-
1); natriuretic peptides (atrial natriuretic peptide and brain natriuretic peptide); 
estrogens; erythropoietin (EPO); etc 23.  
 
Cardioprotection in the diseased hearts  
General remarks 
In clinical situations, elderly patients or patients with heart diseases are at a high risk 
of Ischemia/reperfusion (I/R) injury. Some clinical and experimental studies provide 
evidence that aging or diseased myocardium is less amenable to protective 
measures.              
Aged hearts:  
With increasing age, there is a decrease in the ability of the myocardium to tolerate 
ischemic or hypoxic stress 59. In 1996, Abete and colleagues reported that both 
single and multiple ischemic preconditioning can improve left ventricular function in 
adult (6 months old) rat hearts 60. However, neither treatment can protect the 
senescent rat hearts (24 months old). Even worse, an increased deleterious effect of 
I/R injury was reported in preconditioned aged rat hearts 61. In a clinical study, Abete 
and colleagues found that the presence of angina before acute myocardial infarction 
decreased the mortality in adults (< 65 years old) while not in elderly (> or = 65 years 
old) patients 62. Another clinical study found that the beneficial effects (lower creatine 
kinase levels and better survival) associated with prodromal angina is lost in elderly 
patients with acute myocardial infarction 63. Jiménez-Navarro M reported an opposite 
observation in which angina 1 week before a first infarction may protect against in-
hospital adverse outcomes, improving left ventricular function and decreasing the 
incidence of arrhythmias 64.  
Diabetes:   
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Diabetic hearts are more likely to develop vascular disease 65. There are two types of 
diabetes: insulin-dependent diabetes (IDD) and non-insulin-independent diabetes 
(NIDD). In 1996, Tosaki A reported a loss of protection by IPC in streptozotocin-
induced diabetic rat hearts 66. In diabetic (3 weeks after streptozotocin-alloxan) dogs, 
treatment with diazoxide, a specific mKATP opener, was unable to decrease infarct 
size induced by I/R injury 67. Another study found that isoflurane induced 
preconditioning was attenuated in diabetic dogs 68. In a clinical study, Ghosh S found 
that patients with poor left ventricular intervention, IDD or NIDD, cannot be protected 
by IPC 69. However, the application of diazoxide can mimic the protection in patients 
with poor left ventricular function except for patients with NIDD or IDD. In contrast, 
Liu et al. found that IPC decreases infarct size in NIDD rats (2 weeks after 
streptozotocin treatment) similarly as in normal hearts 70. Delayed preconditioning 
was also lost in a sheep model of alloxan-induced diabetes 71.   
Hyperlipidemia and atherosclerosis:  
It is well known that there is a close relationship between the increase in serum total 
cholesterol concentration and the morbidity and mortality of myocardial infarction 65. 
In an acute hypercholesterolemia rabbit model, coronary occlusion and reperfusion 
led to more extended myocardial infarction than in normal hearts 72. Szilvassy 
reported for the first time that pacing-induced preconditioning is lost in a rabbit model 
of hypercholesterolemia and atherosclerotic where rabbits were treated for 8 weeks 
with high dietary cholesterol 73. Interestingly, when these animals were reexposed to 
normal diet and when the serum lipid level recovered to normal level, the 
preconditioning treatment also regained its protective effect. In contrast, some 
studies showed an intact infarct size limiting effect of IPC in rabbits fed with a 
cholesterol-enriched diet 74, and in atherosclerotic ApoE/LDLr-/- double knockout mice 
fed with a cholesterol-enriched diet 75. Delayed preconditioning 76,77 was also shown 
to be lost in rabbits with hypercholesterolemia. Iliodromitis EK and colleagues found 
in a recent research that IPostC is ineffective in limiting infarct size in rabbits with 
hypercholesterolemia and atherosclerosis 78.   
 
Cardioprotection in remodelled hearts (see Fig.5) 
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Myocardial remodelling is an adaptive process to a variety of hemodynamic 
conditions associated with increased cardiac work. Short-term remodelling may result 
in a compensated cardiac function. Long-term remodelling may lead to heart failure. 
The remodelled myocardium changes in structure, morphology 79, metabolism 80, and 
cell signalling 81. These changes put the remodelled myocardium at particular risk 
when exposed to ischemia. Hypertensive left ventricular hypertrophy and infarct 
induced remodelling are among the most common types of remodelling. The 
following paragraphs will discuss these two forms of remodelling and analyze the 
cardioprotective treatments in remodelled hearts.     
Hypertensive left ventricular hypertrophy:  
Hypertension is often underlying left ventricle hypertrophy. In 1994, IPC was found to 
decrease infarct size in adeoxycorticosteroid-treated and salt-fed (DOCA-salt) 
hypertensive rats to the same extent as observed in normotensive rats 82. One year 
later, it was reported that IPC and adenosine can protect the spontaneously 
hypertensive rat heart 83, improving recovery of ATP, left ventricular end diastolic 
pressure (LVEDP), left ventricular developed pressure (LVDP), ±dP/dt, and coronary 
flow. The transgenic hypertensive rat heart can also be protected by IPC 84.  Aortic 
constriction modified hypertensive rat hearts were also shown to be protected by IPC 
85. However, IPC failed to protect patients with poor cardiac function 69. In genetically 
hypertensive rat model, ischemic preconditioning was unable to recover the coronary 
flow similarly to normotensive rat hearts 86. As for pharmacological preconditioning, 
Ebrahim Z found that bradykinin pre-treatment decreased infarct size less in DOCA-
salt hypertensive rat hearts than in normotensive hearts 87.   
Post infarct-remodelled myocardium:  
A rabbit heart remodelling model can be induced induced by coronary ligation two 
weeks before experimentation. Using such a model, Miki T first found that IPC is less 
protective in decreasing infarct size in remodelled hearts than in sham operated 
hearts 88. In follow-up studies, Miki T found that erythropoietin (EPO) can protect the 
remodelled hearts similarly to the sham hearts 89. Pharmacological postconditioning 
induced by isoflurane can also be used to protect post-infarct remodelled rat hearts 
90.  
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Fig.5 
A.                                                              B. 
               
 
Fig.5 Cardiac remodelling: Left anterior descending coronary artery was ligated, 
and infarct size was determined after 12 h using 1% triphenyltetrazolium chloride 
staining (A, upper panel). Viable myocardium is stained brick-stone red, whereas 
freshly infarcted myocardium is stained salmon pink. Note the black ties on the two 
basal transverse heart sections. A mean infarct size of 35 ± 5% was obtained (see 
also table 1). Six weeks after ligation, necrosis was replaced by scar tissue, and 
compensatory hypertrophy developed (A, lower panel). Chronic infarct is stained 
bright white. Western blot analysis of remodeling markers (B): atrial natriuretic 
peptide (ANP), α- and β-myosin heavy chains (α- and β-MHC), α-skeletal-actin (α-
sklactin). α-tubulin and total actin (pan-actin) were used as loading controls. 
Remod=postinfarct remodeled hearts; sham=sham-operated hearts. Data are given 
as mean±SD (n=5 in each group). *p < 0.05 versus sham. [Adopted from 90 ] 
 
Altered protection signalling in diseased hearts 
General remarks 
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Aged and diseased hearts have shown special changes in cardioprotective 
signalling, which might account for the impairment or loss of cardioprotection by 
traditional pre- or postconditioning. Some of the altered protection signalling in these 
hearts will be discussed in the following paragraphs. 
Aged hearts:  
Aging is associated with increased oxidative stress, reduced mitochondrial 
membrane potential, and reduced ATP synthesis 65. These changes may contribute 
to impaired energy reserve, impaired systolic and diastolic function and reduced 
tolerance to ischemic injury. The signalling and expression of cardioprotective 
proteins also change during aging, i.e., PKC 65, MAPK, heat shock protein 70 (HSP 
70), NOS, and sodium-hydrogen exchanger (NHE) 59. This may account for the 
decreased protection induced by IPC or pharmacological mimics. However, there are 
still treatments that successfully protected the aged heart. One effective intervention 
to protect aged hearts is to reduce energy demands during ischemia (for example 
during cardiac surgery) by β-adrenergic receptor blockers 91. Interestingly, regular 
exercise can protect against I/R injury in both old and young animals 92, probably due 
to the increased expression level of HSPs, improve antioxidant capacity, and / or 
elevation of other carioprotective proteins.     
Diabetes:  
It was reported that during the early phase of experimentally induced diabetes (2 
weeks) the diabetic heart is more resistant to ischemia/reperfusion 66. However, the 
severely ill diabetic heart is more susceptible to ischemia/reperfusion. Studies 
indicate that PKC activation may be responsible for the increased resistance to 
ischemia in the early stage of diabetes 93. Conversely, hyperglycemia is a risk factor, 
which contributes to the high susceptibility of diabetic hearts to ischemia/reperfusion. 
Hyperglycemia correlates with the motality after myocardial infarction in patients with 
or without diabetes 94-96. Infarct size was also shown to correlate with the extent of 
hyperglycemia in dogs with or without diabetes 67,97. Enhanced oxidative stress, 
accumulation of undesirable metabolites, and vascular dysfunction, may further 
contribute to high susceptibility of diabetic hearts to ischemia/reperfusion 93. 
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Activation of RISK pathways (Akt, ERK, PKC, etc) at the onset of reperfusion, 
mKATP channell opening, and preventation of mPTP opening are the critical events 
in cardiorotection induced by many treatments. Changes in all these events in the 
diabetic heart may interfere with protection by pre- and postconditioning. 
High blood glucose levels can abolish cardioprotection induced by IPC 98, anesthetic-
induced preconditioning 99, and delayed preconditioning 71. A recent study showed 
that hyperglycemia can also abolish anesthetic-induced postconditioning 100. One 
study showed that acute hyperglycemia leads to tyrosine nitration and apoptosis via 
increased iNOS gene expression and NO release in rat hearts 101). Another study 
showed that hyperglycemia can lead to tyrosine nitration of PI3K, resulting in Akt 
inactivation and thus blocking the prosurvival effect of VEGF 102.  
More cycles of preconditioning ischemia are required to gain similar activation of 
PI3K-Akt and protective effects in diabetic rat hearts than in normal hearts. This 
indicates that the impaired activation of PI3K-Akt pathway may be responsible for the 
loss of protection by IPC in diabetic hearts 103.  
In a study with human cardiac tissue (atrial appendages) from patients with poor left 
ventricular intervention, IPC was not protective 69. Interestingly, the application of 
diazoxide could restore the protection in patients with poor left ventricular function 
except in patients with non insulin dependent diabetes mellitus or insulin dependent 
diabetes mellitus, indicating that the failure to protect the heart by IPC is due to a 
dysfunction of the mKATP channel itself. 
Besides the altered signalling in diabetic hearts, cardioprotection in diabetes is 
considered to be affected by anti-diabetes drugs. Some KATP channel inhibitors are 
used as anti-diabetic drugs because they increase insulin secretion by blocking these 
channels in the pancreatic β-cell membrane. Were these drugs not specific for 
pancreatic KATP channels (i.e. glibenclamide), they can also inhibit the mKATP 
channels in cardiomyocytes. This may increase the cardiovascular risk for diabetic 
patients and may also explain why diabetic patients are less protected by IPC.  In 
contrast, the more selective pancreatic KATP channel inhibitors do not affect 
protection of preconditioning 104.   
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Treatment of diabetes with insulin activates the PI3K-Akt signalling pathway, one of 
the RISK pathways, and thus can avoid the blockade of KATP channels 65.    
Hyperlipidemia and atherosclerosis:  
The mechanisms by which hyperlipidemia affects the outcome of 
ischemia/reperfusion injury and cardioprotection induced by pre- and 
postconditioning is not very clear. Csont T and colleagues reported that there is a 
decrease in ischemia or heat shock induced HSP 70 expression in high cholesterol 
diet exposed rat hearts when compared to normal hearts 105. Failure to induce 
tetrahydrobioperin synthesis (an important cofactor of critical enzymes including 
iNOS) by ischemic preconditioning was reported in a hyperlipidemia rabbit model, 
which may be responsible for the loss of late preconditioning 77. Statins, the very 
commonly used antihyperlipidemic drugs, which inhibit biosynthesis of cholesterol, 
showed preconditioning mimicking effects 106. 
Altered protection signalling in remodelled hearts 
Hypertensive left ventricular hypertrophy: 
There is considerable controversy whether hypertensive hearts can be protected by 
ischemic or pharmacological preconditioning. Also, few studies investigated the 
mechanisms underlying cardioprotection in hypertrophied hearts. In a study where 
NO donor was used to induce preconditioning, the spontaneously hypertensive rat 
(SHR) hearts were not protected.  Further investigations found that NO induced 
cGMP expression in normotensive hearts but not in SHR hearts 107. 
Post infarct-remodelled myocardium: 
In a study where Miki T found that IPC is less protective in post-infarct remodelled 
rabbit hearts than in control hearts 88, chronic treatment of valsartan, an angiotensin 
II type 1 (AT1) receptor blocker, prevented remodelling and preserved the effect of 
IPC. This indicates that AT1 receptor activation is important for the loss of IPC in 
remodelled hearts. In the same study, application of diazoxide, the mKATP channel 
opener, protected both remodelled and healthy hearts, suggesting that the impaired 
mechanism in remodelled hearts is upstream of mKATP channel. In a follow up study 
by Miki T, PKC-ε activation in response to IPC was impaired in post-infarct 
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remodelled hearts 108.  In another study, PI3K/Akt activation by EPO receptor 
signalling was also shown to be impaired 89. The same study further indicates the 
activation of an alternative protective signalling pathway by EPO in these hearts. One 
study by Feng J and colleagues (our own laboratory) showed that PI3K/Akt signalling 
pathway is critical in isoflurane-induced postconditioning in a post-infarct remodelled 
rat heart model 90. 
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C. Hypothesis and results 
Part I: Ischemic postconditioning in hypertrophied myocardium and molecular 
mechanisms involved. 
Hypothesis:  
Remodelled hearts can be protected by ischemic postconditioning.  
Two remodelled rat heart models were used in these experiments:  
a. The myocardial infarction-induced cardiac hypertrophy and remodelling model        
b. The Hypertension- and overload-induced cardiac hypertrophy model [1-kidney-1-
clip (1K1C) hypertensive rat model]   
Results: 
1. Cardioprotection by ischemic postconditioning is preserved in 
hypertrophied myocardium 
a. IPostC prevented myocardial damage in both MI-remodelled and 1K1C hearts, as 
measured by decreased infarct size and lactate dehydrogenase release, and 
improved function.  
b. The maximal extent of infarct size reduction and left ventricular developed 
pressure (LVDP) achieved by IPostC were partially impaired in 1K1C 
hypertrophied hearts, but were unchanged in MI-remodelled hypertrophied hearts.  
c. The maximal inotropic functional recovery in 1K1C hearts was not different from 
that of healthy hearts, but was less improved in MI hearts. 
d. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway with LY294002 
abolished the protective effects of IPostC in both disease models and healthy 
hearts.  
2. Ischemic postconditioning activates PKB/Akt and its downstream targets 
GSK3β, eNOS, and p70S6K in a PI3K dependent manner in hypertrophied 
myocardium 
a. IPostC significantly increased phosphorylation of PKB/Akt and its downstream 
targets GSK3β, eNOS, and p70S6K in remodelled hearts. 
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b. IPostC-induced phosphorylation of PKB/Akt and its downstream substrates 
GSK3β, eNOS, and p70S6K were suppressed by LY294002. 
c. The activity of PKB/Akt was significantly elevated by IPostC compared to the 
ischemic control and completely abolished by LY294002. 
d. Phosphorylation and enzyme activity of PKB/Akt were partially increased by 
ischemia alone compared to the time-matched controls in both healthy and MI-
remodelled hearts. However, this was not observed in the 1K1C hearts.  
3. Cardioprotection by ischemic postconditioning in the remodelled 
myocardium does not primarily depend on ERK1/2 signaling 
a. In healthy hearts, phosphorylation of ERK1/2 was moderately increased by 
ischemia alone, and was further enhanced by IPostC. In 1K1C hearts, 
phosphorylation of ERK1/2 was not increased by ischemia alone but was 
increased by IPostC. In contrast, phosphorylation of ERK1/2 in the MI-remodelled 
hearts was strongly increased by ischemia alone, but was not further increased by 
IPostC. 
b. There was no increase in ERK1/2 activities by IPostC in both remodeling models 
as well as in healthy hearts.  
 
Part II: Delayed pharmacological preconditioning in remodelled rat hearts. 
Hypothesis:  
Delayed pharmacological conditioning is preserved in post-infarct remodelled rat 
hearts. 
Remodelled rat heart model:  
The myocardial infarction-induced cardiac hypertrophy and remodelling model        
Results:  
1. Post-infarct remodelling narrows the second window of protection after 
isoflurane preconditioning. 
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a. Isoflurane induced delayed preconditioning in both post-infarct remodelled hearts 
and healthy hearts. 
b. The second window of delayed preconditioning is narrower in remodelled hearts 
(24 h) than in healthy hearts (48 h). 
2. Late protection by isoflurane preconditioning is more vulnerable to 
cyclooxygenase-2 inhibition in remodelled myocardium 
a. Delayed protection by isoflurane is abolished or attenuated by inhibitors of COX-2 
(celecoxib and NS-398), but not by 12-lipoxygenase (cinnamyl-3,4-
dihydroxycyanocinnamate).  
b. Isoflurane-induced late preconditioning is partially inhibited by celecoxib, a 
clinically used COX-2 inhibitor, in healthy myocardium. However, this late 
protection is completely abolished by celecoxib in remodelled myocardium. 
3. Isoflurane-induced cyclooxygenase-2 expression and activity show 
alterations in remodelled hearts. 
a. In healthy hearts, COX-2 expression was increased 24 (1.5-fold) and 48 h (2.7-
fold) after isoflurane exposure, while in remodelled hearts, COX-2 expression was 
exclusively increased at 24 h, but not at 48 h. 
b. Isoflurane-induced COX-2 showed a shortened activation profile in remodelled 
hearts, which closely paralleled structural and functional protection. 
4. Isoflurane increased DNA binding activity of HIF1α but not CREB in post-
infarct remodelled hearts. 
a. DNA binding activity of HIF1α and CREB, but not NFκB or STAT3, increased at 
30 min after isoflurane treatment in healthy hearts.  
b. Isoflurane treatment only increased HIF1α DNA binding activity in remodelled 
hearts.  
c. ICER, an antagonist of CREB, was significantly increased in infarct remodelled 
hearts. 
 29
D. Discussion  
Part I 
In this study we show for the first time that hypertrophied hearts can also be 
protected against I/R injury by IPostC (see Fig.6). Although IPostC was previously 
reported to be ineffective in limiting infarct size in rabbits with hypercholesterolemia 
and atherosclerosis 78, our results are in accordance with a recent clinical study 109, in 
which the human myocardium of patients undergoing primary percutaneous coronary 
intervention was protected by repetitively inflating and deflating an angioplasty 
balloon within minutes of reperfusion.  
Fig.6 
A.                                                             B. 
                 
Fig.6 Infarct size (panel A), lactate dehydrogenase release (panel B) of healthy, 
1K1C, and MI-remodeled hearts: ISCH: hearts exposed to 40 min of test ischemia 
followed by 90 min reperfusion. IPostC: ischemic postconditioning. IPostC/LY: 
postconditioned hearts exposed to the PI3K inhibitor LY294002 (15 µmol/l) during 
first 15 min of reperfusion. CTL: time-matched perfusion. Data are mean±S.D. (n=5 
per group). *p<0.05 vs. ISCH and †p<0.05 vs. same treatment in healthy hearts. 
 
Previous studies have shown that the PI3K-PKB/Akt and ERK1/2 signalling pathways 
are the major survival kinase pathways involved in ischemic preconditioning and 
 30
postconditioning 13. However, the relative importance of the two kinase pathways in 
mediating the protection is not yet clear. A study investigating pharmacological 
postconditioning by 5′-(N-ethylcarboxamido) adenosine and bradykinin in isolated 
rabbit hearts suggests that PKB/Akt is upstream of ERK1/2 110, while a more recent 
study in isolated perfused rabbit hearts stresses the pivotal role of ERK1/2 instead of 
PI3K–PKB/Akt in IPostC-mediated protection 44. Another study reported that IPostC 
failed to protect against ischemic injury in pigs though both PKB/Akt and ERK1/2 are 
activated111. Here we show that PKB/Akt is markedly activated by IPostC in two 
hypertrophied heart models as well as in healthy hearts (see Fig.7). We also show 
that the phosphorylation levels of GSK3β, eNOS, and p70S6K, the downstream 
targets of PI3K-PKB/Akt pathway, are elevated by IPostC. Activation of PKB/Akt and 
phosphorylation of its downstream targets are tightly linked with functional and 
structural protection and are sensitive to inhibition by LY294002. Our results also 
provide evidence that the PKB/Akt pathway is critical in IPostC induced 
cardioprotection in hypertrophied heart models. In our experiments, we observed an 
increase in ERK1/2 phosphorylation by IPostC in healthy and 1K1C hearts. However, 
the catalytic activity of ERK1/2 was not elevated by IPostC in healthy and diseased 
hearts. These data suggest that PI3K–PKB/Akt but not ERK1/2 is the predominant 
mediator of IPostC-induced protection in both healthy and diseased hearts.   
We found some noteworthy differences in PKB and ERK1/2 signaling in different 
disease models. First, although the maximal activation of PKB/Akt can be achieved 
by IPostC in all three models, partial activation of PKB/Akt by ischemia alone was 
impaired in 1K1C hearts. This may explain why the maximal extent of infarct size 
reduction and the recovery of left ventricular developed pressure (LVDP) achieved by 
IPostC were partially impaired in 1K1C rat hearts. Second, the basal kinase activity 
of ERK1/2 in MI-remodelled hearts was different from that observed in healthy 
hearts. These suggest that the key players of the RISK pathways may be 
differentially regulated by different types of cardiac remodelling. Finally, the recovery 
of inotropy achieved by IPostC was impaired in MI-remodelled hearts. The reason for 
these differences is unclear.  
In summary, we show in our study that remodelled rat hearts with hypertrophy 
induced by infarction (permanent ligation of coronary artery) and 1K1C hypertension 
are still receptive to protection by IPostC.  Furthermore, we identified in these models 
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the PI3K–PKB/Akt signalling pathway as predominant mediator of IPostC-induced 
cardioprotection. 
Fig.7 
A. 
 
B.  
 
Fig.7 Phosphorylation status (panel A) and kinase activity (panel B) of protein 
kinase B/Akt (PKB): Representative Western blots and average density ratio of p-
PKBS473/total-PKB for each group. Data are mean±S.D. (n=4 per group). *p<0.05 vs. 
ISCH. 
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Part II 
In this study we found for the first time that isoflurane-induced late preconditioning is 
preserved in post infarct-remodelled rat hearts. However, the window of late 
preconditioning is shorter in the remodelled hearts: reduction in infarct size and 
improvement of functional recovery were observed only at 24 hours after isoflurane 
treatment, while in healthy hearts protection was still observed 48 hours after 
isoflurane treatment (see Fig.8).  
Fig.8 
A. Healthy 
 
B. Remodelled 
 
Fig.8 Infarct size in healthy (A) and remodelled (B) hearts: ISO24/48: hearts 
exposed to ischaemia-reperfusion 24 or 48 h after isoflurane preconditioning. 
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ISO24/48_CEL_high: preconditioned hearts treated with 1 µM celecoxib. 
ISO24/48_CEL_low: preconditioned hearts treated with 0.1 µM celecoxib. 
ISO24/48_CDC: preconditioned hearts treated with 0.5 µM cinnamyl 3,4-dihydroxy-
cyanocinnamate (CDC). ISO24/48_NS398: preconditioned hearts treated with 5 µM 
N-2-cyclohexyloxy-4-nitrophenyl-methane-sulphonamide (NS398). Final 
concentration of dimethyl sulphoxide (DMSO) was < 0.1%. The prefix SHAM in group 
names indicates respective groups without isoflurane preconditioning (oxygen alone). 
*p < 0.05 vs. SHAM24 groups. #p < 0.05 vs. SHAM48 groups. **p < 0.05 vs. high 
celecoxib concentration. Data are mean±SD (n=5 per group). 
 
Isoflurane-induced delayed preconditioning was mediated by COX-2 but not 12- 
lipoxygenase in both remodelled and healthy rat hearts. This is consistant with a 
previous report in which isoflurane-induced delayed preconditioning in healthy rabbits 
was inhibited by the COX-2 inhibitor celecoxib 112. We further found that the 
protection in both remodelled and healthy hearts was closely correlated with 
increased COX-2 protein level and activity. While isoflurane increased DNA binding 
activity of COX-2-inducing HIF-1α in healthy and remodelled hearts, it failed to 
increase DNA binding activity of CREB (also a COX-2-inducing transcription factor) in 
post-infarct remodelled hearts. This may account for the impaired expression and 
activation of COX-2 and thus the narrowing of the second window of protection in 
remodelled hearts. Furthermore, despite increased expression of COX-2, remodelled 
preconditioned hearts were much more vulnerable to the clinically used anti-
inflammatory drug celecoxib than healthy hearts (see Fig.9). This finding may be of 
clinical importance that patients at risk of cardiovascular complications should avoid 
using nonsteroidal anti-inflammatory medication.  
Compared to the early window of preconditioning, delayed (or the second window of) 
preconditioning has strong and more reliable anti-stunning and anti-infarct effects, 
and lasts for a longer time, making it more clinically relevant. Delayed preconditioning 
causes an increase of prostonoids in cardiac tissue via enhanced expression of 
COX-2, the rate limiting enzyme in the synthesis of prostaglandin 19, converting 
arachidonic acid to prostonoids. COX-2 is usually expressed at low levels in the heart 
113 but can be rapidly induced by activation of multiple transcription factors. 
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Prostanoids can open mKATP channels, the key players in cardioprotection 114, 
leading to cardioprotection. Inhibition of COX-2 abolishes the increase in tissue levels 
of prostanoids, anti-stunning effects, and infarct limiting effects of delayed 
preconditioning 115. Previous studies using healthy animal models of different species 
reported volatile anesthetics induced late preconditioning 116,117. Studies on the 
mechanisms of anesthetics-incuded delayed preconditioning identified reactive 
oxygen and nitrogen species as triggers 118, inducible nitric oxide synthase 119, 
endothelial nitric oxide synthase 120, and 12-lipoxygenase 121 as mediators, and 
sarcolemmal and mitochondrial KATP channels as end effectors 122. However, till now, 
only one study with healthy rabbit hearts indicated the role of COX-2 in isoflurane-
induced delayed preconditioning using the clinically used COX-2 inhibitor celecoxib 
112. Our present study confirms COX-2 as a critical mediator in isoflurane-induced 
delayed preconditioning in both healthy rat hearts and post-infarct remodelled 
myocardium. 
Fig.9  
A.                                                              B. 
   
Fig.9 Second window of protection in healthy and remodelled hearts: The 
panels show the second window of protection at 24 and 48 h after isoflurane 
exposure (APC) in healthy (A) and infarct remodelled (B) hearts in the absence (solid 
line) and presence (dashed line) of celecoxib (0.1 µM). 
 
The remodelled myocardium is at a high risk for further ischemic damage due to 
changes in structure 79, metabolism 80, and cellular signalling 123. Ischemic 
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preconditioning is reported to be less protective in the remodelled rabbit myocardium 
than in sham operated hearts 88. Several studies reported altered cardioprotective 
signalling in remodelled hearts 89,108. However, no data is available with respect to 
delayed pharmacologic or ischemic preconditioning in post-infarct remodelled hearts. 
Our previous studies on early classic isoflurane-induced preconditioning 124 and 
postconditioning in remodelled myocardium 90 found that protection against ischemia-
reperfusion injury was fully preserved. However, our present study indicates that 
ventricular remodelling makes the heart more vulnerable to ischemia-reperfusion 
injury. To study the mechanisms underlying this vulnerability, we tested a number of 
COX-2-inducing transcription factors to see whether their DNA-binding activity would 
be impaired in the diseased state. We observed increased DNA-binding activity of 
HIF 1α in both healthy and diseased hearts after isoflurane treatment. This is 
consistant with a previous report that isoflurane can increase protein levels of HIF 1α 
in rat myocardium 125. In contrast, the DNA binding activity of CREB was increased 
by isoflurane in healthy but not in remodelled hearts. This might be due to the 
increased expression of ICER, the transcriptional repressor and CREB-antagonist 
126, in remodelled hearts. However, our experiments can not exclude that other 
additional mechanisms contributed to the shorter duration of COX-2 upregulation in 
remodelled hearts.  
COX-2 inhibitors increase the number of cardiovascular complications specifically in 
patients with preexisting heart disease 127. A recent study in pig showed that peri-
infarct inhibition of COX-2 by celecoxib decreased myocardial function and increased 
left ventricular remodeling and mortality 128. In the current study, we also evaluated 
the effects of celecoxib on isoflurane-induced delayed cardiac protection. Our results 
showed that low concentrations of celecoxib are sufficiant to abolish delayed 
protection induced by isoflurane. From a translational point of view, our data further 
indicate that the use of COX-2 inhibitors should be minimized in patients with 
significant ventricular remodelling.  
Finally, the narrow window of isoflurane induced delayed preconditioning and the 
short period of elevated COX-2 expression imply that diseased myocardium requires 
more frequent intermittent preconditioning stimuli to maintain the protected state.  
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In summary, our study shows that remodelling in rat hearts impedes sustained 
expression and activation of COX-2 after isoflurane preconditioning, narrowing the 
second window of cardioprotection. Isoflurane increases DNA binding activity of 
HIF1α in both healthy and remodelled hearts, but fails to increase DNA binding 
activity of CREB in remodelled, ICER-overexpressing hearts. Our study further 
demonstrates that protection of remodelled myocardium is exceptionally vulnerable 
to COX-2 inhibitors. Thus, isoflurane-induced delayed cardioprotection varies with 
the disease state of the heart and concomitant medication. 
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Abstract
Objective: We tested whether ischemic postconditioning (IPostC) is protective in remodeled myocardium.
Methods: Post-myocardial infarct (MI)-remodeled hearts after permanent coronary artery ligation and one kidney one clip (1K1C)
hypertensive hearts of male Wistar rats were exposed to 40 min of ischemia followed by 90 min of reperfusion. IPostC was induced by six
cycles of 10 s reperfusion interspersed by 10 s of no-flow ischemia. Activation of reperfusion injury salvage kinases was measured using
Western blotting and in vitro kinase activity assays.
Results: IPostC prevented myocardial damage in both MI-remodeled and 1K1C hearts, as measured by decreased infarct size and lactate
dehydrogenase release, and improved function. The reduction in infarct size and the recovery of left ventricular contractility achieved by
IPostC was less in 1K1C hearts, but was unchanged in MI-remodeled hearts when compared to healthy hearts. In contrast, the recovery of
inotropy was unaffected in 1K1C hearts, but was less in MI-remodeled hearts. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway
with LY294002 abolished the protective effects of IPostC on both disease models and healthy hearts. Western blot analysis in conjunction
with in vitro kinase activity assays identified protein kinase B (PKB)/Akt but not p42/p44 extracellular-signal regulated kinase 1/2 (ERK1/2)
as the predominant kinase in IPostC-mediated cardioprotection in remodeled hearts. IPostC increased phosphorylation of the PKB/Akt
downstream targets eNOS, GSK3β, and p70S6K in remodeled hearts.
Conclusion: Our results offer evidence that IPostC mediates cardioprotection in the remodeled rat myocardium primarily via activation of the
PI3K–PKB/Akt reperfusion injury salvage kinase pathway.
© 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
Keywords: Cardiac remodeling; Ischemia–reperfusion injury; Postconditioning; Reperfusion injury salvage kinase; Cellular signaling
1. Introduction
Despite the powerful protective effects of precondition-
ing, the clinical application of this phenomenon has been
rather disappointing, mainly because preconditioning must
be instituted before the ischemic event [1]. In contrast, a
more promising approach to cardioprotection termed
“ischemic postconditioning” (IPostC) has been described
by Vinten–Johansen's group [2]. It consists of several cycles
of coronary occlusion/reperfusion started immediately at the
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onset of restoration of the coronary flow after prolonged
ischemia. Unlike preconditioning, postconditioning theoret-
ically allows unrestricted application in the clinical settings,
and thus has attracted much attention over the past years.
Importantly, some pharmacological agents can afford
comparable protection when applied during early reperfu-
sion (“pharmacological postconditioning”) [3–5].
Recent studies revealed that IPostC exerts its protective
effects through the recruitment of prosurvival kinases such as
phosphatidylinositol 3-kinase (PI3K)–protein kinase B
(PKB)/Akt and the p42/p44 extracellular signal-regulated
kinase 1/2 (ERK1/2) pathways (also termed reperfusion
injury salvage kinase or RISK pathway) at the time of
reperfusion [6]. So far, nearly all experimental studies have
evaluated IPostC in healthy juvenile hearts. However, this is
far from clinical reality, where a high number of elderly
patients with cardiovascular disease would benefit most from
protection by IPostC. Hypertensive left ventricular hyper-
trophy and post-myocardial infarct (MI)-remodeled hyper-
trophy account for most of the clinically relevant cases of
cardiac hypertrophy and remodeling. These hypertrophied
and remodeled hearts, even during the compensated state, are
at greater risk to suffer severe ischemic damage and may be
less amenable to protection by postconditioning [7]. We
therefore tested whether protection by IPostC would be
diminished or lost in two highly controlled experimental
models of markedly remodeled hypertrophic hearts.
The data provided in this study show for the first time that
cardioprotection by IPostC is preserved in the remodeled
myocardium after permanent coronary artery ligation and in
one kidney one clip (1K1C) hypertensive rat hearts. Using in
vitro kinase assays to directly measure PKB/Akt and ERK1/
2 activities, we further identified PI3K–PKB/Akt as the
predominant RISK pathway for IPostC-induced protection in
both disease models.
2. Methods
This study was conducted in accordance with the
guidelines of the Animal Care and Use Committee of the
University of Zurich, Zurich, Switzerland. All experimental
procedures conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes
of Health (NIH publication 85-23, revised 1996).
2.1. Cardiac hypertrophy models
Myocardial infarction (∼35% of left ventricular mass)
and subsequent hypertrophic remodeling was induced in
male adult (180–200 g, 8–9 weeks old) Wistar rats by
permanent ligation of the left anterior descending coronary
artery (LAD) under anesthesia, as previously described in
detail [8,9]. Sham-operated animals underwent the same
procedure except that the suture was passed under the
coronary artery without ligation. To induce hypertensive
cardiac hypertrophy, rats were subjected to right nephrecto-
my and a silver clip (0.2 mm passage) was placed around the
left renal artery under anesthesia (1K1C) [10]. Control sham
rats (1K) had right nephrectomy without application of a
clip. Rats of both disease models were sacrificed 6 weeks
after surgery, and the body weight and heart weight were
measured. Systolic blood pressure was measured in awake
rats by means of the tail-cuff method.
2.2. Histology
Left ventricular tissue samples were fixed with 3.6%
formaldehyde and embedded in paraffin. 3-μm sections at
mid-ventricular level were subjected to Gomori's silver
staining and nuclear fast red for visualization of individual
myocytes in the viable left ventricular wall. The stained
sections were analyzed by microscopy using image analysis
(Zeiss KS 400, Germany).
2.3. Experimental protocol of isolated perfused rat hearts in
the Langendorff apparatus
Six weeks after surgery, rats were heparinized (500 units
i.p.) and 15 min later decapitated. Hearts were removed and
perfused in a non-circulating Langendorff apparatus with
Krebs–Henseleit buffer gassed with 95% O2 and 5% CO2 at
pH 7.4 and 37 °C [4]. Experimental conditions including
coronary flow and temperature were carefully monitored
throughout the protocols. After equilibration, perfusion
pressure was set at 80 mm Hg and left ventricular end-
diastolic pressure (LVEDP) at 10 mm Hg. Spontaneously
beating hearts were exposed to 40 min of global no-flow
ischemia (test ischemia) followed by 90 min of reperfusion
(Fig. 1). IPostC was induced by six cycles of 10 s reperfusion
interspersed by 10 s no-flow ischemia immediately after test
ischemia. Five hearts were assigned to each of the following
six groups: (1) CTL, time-matched perfusion without
ischemia; (2) ISCH, test ischemia followed by 90 min
reperfusion; (3) ISCH/LY, application of the PI3K inhibitor
LY294002 (15 μmol/l) during the first 15 min of reperfusion;
(4) IPostC, immediately applied after prolonged test
ischemia; (5) IPostC/LY, application of LY for 15 min
starting immediately at reperfusion in postconditioned
hearts; and (6) vehicle, application of 0.02% dimethyl
sulfoxide (DMSO) vehicle without LY294002 during 15 min
of reperfusion. The following parameters were recorded: left
ventricular developed pressure (LVDP) and derivatives
(±dp/dt), left ventricular end-diastolic pressure (LVEDP),
epicardial ECG, coronary flow (CF), and perfusion pressure.
Infarct size was determined by 1% 2,3,5-triphenyltetrazo-
lium chloride staining after 90 min of reperfusion [4]. In
addition, myocardial damage was estimated by measuring
the release of lactate dehydrogenase (LDH) from necrotic
tissue, as previously described [8]. Briefly, the perfusate was
collected and LDH activity was determined by the Roche/
Hitachi 917 kit (sensitivity 6 U/l, intra- and interassay
coefficients of variance b1%). For Western blot analysis and
153M. Zhu et al. / Cardiovascular Research 72 (2006) 152–162
in vitro kinase assays, separate experiments (n=4 in each
group) were carried out and terminated after 15 min of
reperfusion.
2.4. mRNA extraction and real-time quantitative polymerase
chain reaction
Total RNAwas prepared using RNeasy Mini Kit (Qiagen).
First strand cDNAwas synthesized from 1.0 μg of total RNA
using SuperScript II reverse transcriptase (Invitrogen) and
oligo-dT as primer. Real-time quantitative PCR was per-
formed as previously described [8] using the following
primers: atrial natriuretic peptide (ANP), 5′–ATCAC
CAAGGGCTTCTTCCT–3′ (sense) and 5′–TGTTGGA
CACCGCACTGTAT–3′ (antisense); and α-skeletal actin
(α-skl-actin), 5′–CACGGCATTATCACCAACTG–3′
(sense) and 5′–CCGGAGGCATAGAGAGACAG–3′ (anti-
sense). α-Tubulin was used for normalization with the sense
and antisense primers 5′–CCATGCGTGAGTGTATCTCC–
3′ and 5′–GTGCCAGTGCGAACTTCATC–3′, respectively.
2.5. Western blot analysis
Western blot analysis was carried out as previously
described [8]. The antibodies used were from the following
sources: glycogen synthase kinase 3β (GSK3β), p70S6K,
endothelial nitric oxide synthase (eNOS), ERK1/2, phospho-
PKB/Akt (Ser473), phospho-GSK3β (Ser9), phospho-
p70S6K (Thr389), phospho-eNOS (Ser1177), phospho-
ERK1/2 (Thr202/Tyr204) (Cell Signaling Technology);
monoclonal antibodies against pan-actin (Chemicon) and
α-tubulin (Sigma); polyclonal antibody against ANP (Santa
Cruz); polyclonal antibody against α-skl-actin was a gift
from Dr. Christine Chaponnier (Department of Pathology,
University of Geneva, Geneva, Switzerland); polyclonal anti-
PKB/Akt antibody (Ab10) was a gift from Dr. Brian A.
Hemmings (Friedrich Miescher Institute, Basel, Switzerland).
2.6. Immunoprecipitation and in vitro kinase assay
Left ventricular non-infarcted tissue (transmural) was
extracted in ice-cold lysis buffer (25 mmol/l Tris–HCl, pH
7.4, 120 mmol/l NaCl, 2 mmol/l ethylenediamine tetraacetic
acid, 1% Triton X-100, 0.5% Nonidet P-40, 1 mmol/
l phenylmethylsulfonyl fluoride, 1 mmol/l benzamidine,
0.1 mmol/l sodium orthovanadate, 10 mmol/l sodium
fluoride, and 1 μmol/l microcystin-LR). Extracts were
centrifuged (16000×g, 30 min, 4 °C), and protein concen-
trations determined using the Bradford assay. Tissue extracts
(1 mg protein) were incubated at 4 °C for 2 h on a shaking
Table 1
Heart weight, body weight, and baseline cardiac function in the hypertrophic rat models
Rat model Healthy 1K1C model Infarct model
Sham (1K) 1K1C Sham MI-remod
HW (g) 1.203±0.089 1.204±0.070 1.927±0.191⁎ 1.150±0.104 1.598±0.083⁎
BW (kg) 0.309±0.018 0.291±0.022 0.289±0.017 0.302±0.020 0.296±0.020
HW/BW (g/kg) 3.900±0.280 4.172±0.442 6.684±0.695⁎ 3.817±0.401 5.428±0.413⁎
LVDP (mm Hg) 93.9±6.3 91.8±5.3 112.5±10.4⁎ 91±4.0 67.7±5.6⁎
CF (ml/min) 13.1±1.2 12.9±1.1 13.4±1.3 13.1±3.2 13.4±1.3
HR (beats/min) 290±22 294±17 293±17 293±14 295±17
HW: heart weight; BW: body weight; LVDP: left ventricular developed pressure; CF: coronary flow; HR: heart rate; healthy: age-matched rats (300 g) serving as
healthy controls. 1K1C: one kidney one clip rat model; sham (1K), nephrectomy without applying a clip (one kidney); MI-remod: postinfarct-remodeled rat
hearts (permanent coronary artery ligation); sham: sham-operated rats (a suture was passed under the coronary artery without ligation). Rats in the hypertrophic
model groups were used 6 weeks after surgery. Data are mean±S.D. (n=20 for sham (1K) and sham, n=30 for healthy, 1K1C, and MI-remod).
* pb0.001 vs. sham and healthy groups.
Fig. 1. Treatment protocols. ISCH: hearts exposed to 40 min of test ischemia
followed by 90 min reperfusion. IPostC: ischemic postconditioning was
induced by 6 cycles of 10 s reperfusion followed by 10 s no-flow ischemia
right at the onset of reperfusion after 40 min of test ischemia. IPostC/LY:
postconditioned hearts exposed to the PI3K inhibitor LY294002 (15 μmol/l)
dissolved in vehicle (0.02% dimethyl sulfoxide (DMSO)) during the first
15 min of reperfusion. CTL: time-matched perfusion. Infarct size was
determined by 1% triphenyltetrazolium staining at the end of experiments
(n=5 hearts per experimental group). In separate experiments (n=4 hearts
per experimental group), phosphorylation (by Western blotting) and activity
of PKB/Akt and extracellular-signal regulated kinase 1/2 (ERK1/2) were
assayed after 15 min of reperfusion.
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Fig. 2. Infarct size (panel A), lactate dehydrogenase release (panel B) and contractility parameters (panels C–F) of healthy, 1K1C, and MI-remodeled hearts. Left
ventricular developed pressure (LVDP) (panel C), +dp/dt (panel D), left ventricular end-diastolic pressure (LVEDP) (panel E), and −dp/dt (panel F) were
determined at 90 min of reperfusion and are indicated as percentage of baseline or mmHg (LVEDP). ISCH: hearts exposed to 40 min of test ischemia followed by
90 min reperfusion. IPostC: ischemic postconditioning. IPostC/LY: postconditioned hearts exposed to the PI3K inhibitor LY294002 (15 μmol/l) during first
15 min of reperfusion. CTL: time-matched perfusion. Data are mean±S.D. (n=5 per group). *pb0.05 vs. ISCH and †pb0.05 vs. same treatment in healthy
hearts.
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platform with 2 μg of either polyclonal anti-PKB (Ab10)
antibody coupled to 10 μl protein A-sepharose (Amersham
Biosciences) or monoclonal anti-ERK1/2 (Zymed, clone
ERK-7D8) coupled to 10 μl protein G-sepharose (Amersham
Biosciences). The immune-complexes were then washed 4
times with lysis buffer, once with kinase buffer (25 mmol/
l Tris–HCl, pH 7.4, 10 mmol/l MgCl2, 1 mmol/l dithiothrei-
tol, 1 μmol/l PKI, and 1 μmol/l microcystin-LR), and finally
resuspended in 20 μl of kinase buffer. For PKB kinase assay,
the reaction was started with 60 μmol/l of Crosstide
(GRPRTSSFAEG) and 20 μmol/l of [γ-32P] ATP (Amer-
sham Biosciences) in a final volume of 30 μl, incubated at
30 °C for 60 min, and stopped by addition of trichloroacetic
acid (TCA) to a final concentration of 10%. After brief
centrifugation, 20 μl aliquots were removed and spotted onto
P81 phosphocellulose paper. The paper was washed
immediately for 10 min with 75 mmol/l phosphoric acid
(4 times), dried, and 32P incorporation determined by
Cerenkov counting. For ERK1/2 kinase assay, the reaction
was started with 4 μg of myelin basic protein and 20 μmol/
l of [γ-32P] ATP in a final volume of 30 μl and incubated at
30 °C for 30 min. The reaction was terminated by addition of
SDS-sample buffer and boiled at 95 °C for 5 min. Aliquots
were subjected to SDS–PAGE (15%) followed by
Fig. 3. Phosphorylation status (panel A) and kinase activity (panel B) of protein kinase B/Akt (PKB). RepresentativeWestern blots and average density ratio of p-
PKBS473/total-PKB for each group. Data are mean±S.D. (n=4 per group). *pb0.05 vs. ISCH.
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autoradiography or 32P determination in excised gel slices.
One unit of activity was defined as the amount of enzyme
that transferred 1 pmol phosphate/min to the substrate at
30 °C.
2.7. Statistics
Data are presented as mean±S.D. For the cardiac
functional data, repeated-measures analysis of variance was
Fig. 4. Phosphorylation status of glycogen synthase kinase3β (GSK3β) (panel A). Representative Western blots and average density ratio of p-GSK3βS9/
total-GSK3β. Phosphorylation status of endothelial nitric oxide synthase (eNOS) (panel B). Representative Western blots and average density ratio of p-eNOSS1177/
total-eNOS. Data are mean±S.D. (n=4 per group). *pb0.05 vs. ISCH.
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used to evaluate differences over time between groups.
Unpaired t-test was used to compare groups at identical time
points, and paired t-test to compare within groups over time.
p values were multiplied by the number of comparisons
(Bonferroni correction). Tukey's post-hoc test was applied
for multiple comparisons of the one-way analysis of variance
for all other data. pb0.05 was considered as significant.
SigmaStat (version 2.0; SPSS Science, Chicago, IL) was
used for the analyses.
3. Results
3.1. Characterization of remodeling and hypertrophy in
diseased hearts
Heart- (HW) and body- (BW) weight as well as their ratio
(HW/BW) are summarized in Table 1 for the two disease
models. HW and HW/BW were significantly higher in the
1K1C and the MI-remodeled (permanent coronary artery
ligation) groups, as compared to the healthy and sham
groups indicating cardiac hypertrophy in both disease
models. Table 1 also shows LVDP, CF, and heart rate (HR)
ex vivo at equilibration on the Langendorff apparatus.
LVDP was significantly higher in the 1K1C and lower in
the MI-remodeled groups than in healthy or sham controls,
while CF and HR were unchanged. The higher LVDP
observed at the Langendorff apparatus corresponds to the
significantly (pb0.001) higher systolic blood pressure
measured in vivo in 1K1C (186±18 mm Hg, n=30)
compared to sham (1K) (123±10 mm Hg, n=20) and
healthy age-matched animals (120±9 mm Hg, n=10). The
post-infarct remodeling in MI-remodeled hearts has been
characterized in detail in our previous study [8]. The 1K1C
hearts displayed an increase in mRNA of about 10-fold for
ANP and 4-fold for α-skl-actin, which was accompanied by
an increase in protein levels as well (Supplementary Fig.
S1A and B). Micrographs of cross-sections of the left
ventricular free wall at the mid-ventricular level of 1K1C and
MI-remodeled hearts displayed enlarged myocytes in
comparison to sham controls (Supplementary Fig. S1C).
3.2. Cardioprotection by ischemic postconditioning is
preserved in remodeled myocardium
IPostC significantly improved functional recovery and
decreased infarct size in both the 1K1C as well as the MI-
remodeled hearts, when compared to unprotected remodeled
hearts (Fig. 2A–F and Supplementary Tables 1–3). IPostC
achieved over 80% reduction in infarct size and LDH release
in MI-remodeled and healthy hearts, while in 1K1C hearts the
reduction of both parameters was somewhat lower (69%)
(Fig. 2A and B). With regard to hemodynamics, the recovery
of LVDP was lower in 1K1C hearts as compared to MI-
remodeled and healthy controls after application of IPostC
(Fig. 2C). On the other hand, the rate of pressure rise (+dp/dt,
inotropy) was fully preserved in 1K1C, while it was lower by
38% inMI-remodeled hearts (Fig. 2D). The baseline values of
LVDP and inotropywere significantly lower inMI-remodeled
Fig. 5. Phosphorylation status of ribosomal S6 kinase (p70S6K). Representative Western blots and average density ratio of p-p70S6KT389/total-p70S6K. Data are
mean±S.D. (n=4 per group). *pb0.05 vs. ISCH.
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hearts, indicating impaired basal cardiac function (Supple-
mentary Table 3). During reperfusion, LVEDP was increased
and lusitropy was decreased in 1K1C hearts compared to
healthy hearts, indicating impaired postischemic diastolic
function in 1K1C hearts. The protection by IPostC was
completely abolished by co-administration of the PI3K
inhibitor LY294002 (Fig. 2A–F, and Supplementary Tables
1–3). LY294002 or the solvent dimethyl sulfoxide alone
administered during reperfusion did not affect functional
recovery or infarct size (data not shown). These results
provide strong evidence that PI3K-dependent protection by
IPostC is preserved and operative in both disease models.
3.3. Ischemic postconditioning in remodeled myocardium
activates PKB/Akt and its downstream targets GSK3β,
eNOS, and p70S6K in a PI3K-dependent manner
Activation of the pro-survival PI3K–PKB/Akt signaling
pathway has been shown to be important for cardioprotection
in several healthy animal models [4,5,11–14]. Here we show
that IPostC significantly increased phosphorylation of PKB/
Akt (Fig. 3A) and its downstream targets GSK3β, eNOS,
and p70S6K in remodeled hearts (Figs. 4 and 5). IPostC-
induced phosphorylation of PKB/Akt and its downstream
substrates GSK3β, eNOS, and p70S6K was suppressed by
Fig. 6. Phosphorylation status (panel A) and kinase activity (panel B) of extracellular-signal regulated kinase 1/2 (ERK1/2). Representative Western blots and
averaged density ratio of p-ERK1/2T202/Y204/total-ERK1/2 for each group. Data are mean±S.D. (n=4 per group). *pb0.05 vs. ISCH.
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LY294002. Dimethyl sulfoxide alone had no effect on the
phosphorylation of PKB/Akt when compared to the ischemia
group (data not shown). To further characterize the activation
status of PKB/Akt, an in vitro kinase assay was carried out.
Consistent with the results fromWestern blots, the activity of
PKB/Akt was significantly elevated by IPostC compared to
the ischemic control and completely abolished by LY294002
(Fig. 3B). Phosphorylation and enzyme activity of PKB/Akt
were partially increased by ischemia alone compared to the
time-matched controls in both healthy and MI-remodeled
hearts. However, this was not observed in the 1K1C hearts
(Fig. 3A and B). Taken together, the data underscore the
unique role of PKB/Akt signaling in the IPostC-mediated
protection of the remodeled myocardium.
3.4. Cardioprotection by ischemic postconditioning in the
remodeled myocardium does not primarily depend on
ERK1/2 signaling
Beside PI3K–PKB/Akt, ERK1/2 signaling presents
another component in the RISK pathways that has also
been suggested to contribute to the reduction of infarct size
with postconditioning [13]. We therefore examined whether
the protection by IPostC would be associated with activation
of the ERK1/2 pathway in the remodeled hearts. In healthy
hearts, phosphorylation of ERK1/2 was moderately increased
(p=0.033) by ischemia alone, and was further enhanced
by IPostC (Fig. 6A). In 1K1C hearts, phosphorylation of
ERK1/2 was not increased by ischemia alone but was
increased by IPostC (Fig. 6A). The elevated phosphorylation
of ERK1/2 by IPostC was reversed by LY294002 suggesting
a PI3K-dependent phosphorylation of ERK1/2. In contrast,
phosphorylation of ERK1/2 in the MI-remodeled hearts was
strongly increased by ischemia alone, but was resistant to
LY294002 and not further increased by IPostC, indicating
that a PI3K-independent mechanism was responsible for the
ischemia-induced ERK1/2 phosphorylation in the MI-
remodeled hearts. These results based on the phosphorylation
status of ERK1/2 suggest that the ERK1/2 pathway is
differentially regulated in the two types of remodeling. In
parallel, the activities of ERK1/2 were also determined by an
in vitro kinase assay. Surprisingly, there was no increase in
ERK1/2 activities by IPostC in both remodeling models as
well as in healthy hearts (Fig. 6B). Moreover, the activities of
ERK1/2 in the MI-remodeled hearts were 3-fold lower than
that in healthy and 1K1C hypertrophied hearts, suggesting
that subtle differences in the regulation of RISK pathways
may exist between the models. Collectively, our results based
on direct enzyme activity measurements indicate that the
ERK1/2 pathway is not primarily involved in IPostC-
mediated protection in both healthy and diseased hearts.
4. Discussion
Here we show for the first time that protection by IPostC
is preserved in two rat models of myocardial remodeling.
IPostC was previously reported to be ineffective in limiting
infarct size in rabbits with hypercholesterolemia and
atherosclerosis [15]. However, our results are in accordance
with a most recent clinical trial by Staat and colleagues [16],
who postconditioned hearts of patients undergoing percuta-
neous coronary interventions with four episodes of 1-min
balloon inflations starting within 1 min of reflow. Using
creatine kinase release as a surrogate marker of infarct size,
these authors found that myocardial damage could be
reduced by 36%.
Myocardial remodeling is a short-term adaptive but long-
term maladaptive process to a variety of hemodynamic
conditions associated with increased cardiac work. Character-
istic structural changes [17], alterations in metabolism [18],
and cellular signaling [19–21] put the remodeled myocardium
at particular risk for further ischemic damage. Since most
individuals who experience acute ischemic heart disease have
underlying myocardial remodeling, we addressed the impor-
tant question whether the diseased remodeled myocardium is
still receptive to protection by IPostC using two experimental
models of remodeling. While 1K1C remodeled hearts develop
eccentric hypertrophy by volume overload [10], MI-remo-
deled hearts display a far more complex architectural re-
arrangement due to (i) loss of viable tissue and scar formation
(ii) volume overload by scar expansion (iii) pressure overload
induced by increasing volume overload [20]. Nonetheless,
hypertrophy is a hallmark of both types of remodeling. Since
these structural changes are associated with alterations in
neurohormonal activation and cellular signaling, we hypoth-
esized that remodeling may abolish innate protective mechan-
isms and render the heart more susceptible to ischemia.
Previous studies identified the survival kinases PI3K–
PKB/Akt and ERK1/2 as key players in the protection
afforded by IPostC in healthy myocardium [6]. However, the
relative importance of the two kinases in mediating the
protection remains controversial. A study investigating
pharmacological postconditioning by 5′-(N-ethylcarboxa-
mido) adenosine and bradykinin suggests that PKB/Akt is
upstream of ERK1/2 [5], while results from a more recent
study stress the pivotal role of ERK1/2 but not PI3K–PKB/
Akt in IPostC-mediated protection [13]. Moreover, Schwartz
et al. [14] reported that IPostC activates both PKB/Akt and
ERK1/2 but yet failed to protect against ischemic injury in
pigs. In the present study, we show that PKB/Akt is activated
and that its downstream targets GSK3β, eNOS, and p70S6K
are markedly phosphorylated by IPostC not only in the
healthy but also in the remodeled hearts. This phosphoryla-
tion is commensurate with functional and structural protec-
tion and is sensitive to inhibition by LY294002. Importantly,
our results on PKB/Akt activation are not solely based on
Western blot analysis using phosphor-specific antibodies, but
further rely on in vitro kinase assays, which directly measure
catalytic activity. Although we observed an increase in
ERK1/2 phosphorylation by IPostC in healthy and 1K1C
hearts, the directly measured catalytic activity of ERK1/2 was
not elevated by IPostC in healthy and diseased hearts.
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Obviously, the observed phosphorylation of ERK1/2 by
IPostC was not sufficient to protect. Hence our data suggest
that PI3K–PKB/Akt but not ERK1/2 is the predominant
mediator of IPostC-induced protection in both healthy and
diseased hearts. Of note, our study is the first to measure
ERK1/2 activation in IPostC by assessing the phosphoryla-
tion status in conjunction with in vitro activity measurements.
Earlier studies on ERK1/2 activity in pre- and postcondition-
ing exclusively relied onWestern blotting, whichmay, at least
in part, explain the controversial role of ERK1/2 in IPostC.
Nonetheless, our results cannot rule out the possibility of
some cross talk between ERK1/2 and PKB/Akt, and the two
pathways may also follow different spatio-temporal routes at
the onset of reperfusion in the heart. Therefore, additional
time-course and blocker experiments will be required to
ultimately delineate the role of PKB/Akt and ERK1/2 in
IPostC-mediated protection in remodeled myocardium.
We found noteworthy alterations in PKB and ERK1/2
signaling in the different disease models. First, although the
maximal activation of PKB/Akt can be achieved by IPostC
in all three models, partial activation of PKB/Akt by
ischemia alone was lost in 1K1C hearts. This observation
may explain the observed reduced protection by IPostC in
1K1C rats. Second, the profiles of ERK1/2 phosphorylation
in both types of remodeling and the basal kinase activity of
ERK1/2 in MI-remodeled hearts were different from those
observed in healthy hearts. These alterations suggest that key
players of the RISK pathway may be differentially regulated
by different types of cardiac remodeling. Finally, we found
that the recovery of inotropy achieved by IPostC was im-
paired in MI-remodeled hearts, while both recovery of LVDP
and infarct size reduction were unaffected. The reason for
these differences is unclear. A recent study using a transgenic
mouse model of hypertrophy with cardiac-specific expres-
sion of myristoylated PKB/Akt demonstrated that activation
of PKB/Akt alone is not sufficient for protection [22]. This
implies that additional PI3K-dependent but PKB/Akt-
independent signaling components may be required for full
cardioprotection. Thus, it is possible that such alternative
mechanisms are impaired in MI-remodeled hearts.
Ischemic preconditioning has been shown to be ineffec-
tive in MI-remodeled rabbit hearts [23], but proved its
efficacy in several hypertrophy models [24–27]. Despite
these partly promising results, the concept of precondition-
ing could not be successfully established in the clinical
setting. Therefore, recent interventions aimed at modifying
reperfusion, but IPostC may further jeopardize the diseased
heart. This could be avoided by utilizing pharmacological
agents mimicking the biological process of IPostC. Hence,
the understanding of the molecular mechanisms underlying
IPostC is of paramount importance and should be exploited
in additional studies. Importantly, future studies should
particularly investigate the effects of the disease-related
alterations in signaling on cardioprotection.
In summary, using a highly controlled experimental
setting, we show in our study that remodeled rat hearts with
hypertrophy induced by infarction (permanent coronary
artery ligation) and 1K1C hypertension are still receptive to
protection by IPostC. Furthermore, we identified in these
models the PI3K–PKB/Akt signaling pathway as predom-
inant mediator of IPostC-induced cardioprotection.
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Cardiac remodelling hinders activation of
cyclooxygenase-2, diminishing protection by delayed
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Aims We tested whether delayed pharmacologic preconditioning elicited by isoﬂurane is protective in
infarct-remodelled hearts.
Methods and results Male Wistar rats were treated with the preconditioning drug isoﬂurane 6 weeks
after permanent ligation of the left anterior descending coronary artery. Twenty-four and 48 h later,
hearts were perfused on the Langendorff system and treated with cyclooxygenase-2 or 12-lipoxygenase
inhibitors before exposure to 40 min of ischaemia followed by 90 min of reperfusion. Infarct size was
determined by triphenyltetrazolium chloride staining and lactate dehydrogenase release. Cyclooxygen-
ase-2 expression and activity were measured by Western blotting and colorimetric assay. Nuclear
translocation of cyclooxygenase-2-inducing transcription factors HIF1a, CREB, STAT3, and NFkB was
determined. Post-infarct, remodelled hearts exhibit alterations in cellular signalling, time course and
extent of isoﬂurane-induced late protection. While remodelled, preconditioned hearts exhibited pro-
tection exclusively at 24 h, healthy hearts showed sustained protection for up to 48 h, which correlated
with cyclooxygenase-2 protein expression and enzymatic activity. The cyclooxygenase-2 inhibitors
celecoxib and NS-398, but not the 12-lipoxygenase inhibitor cinnamyl-3,4-dihydroxycyanocinnamate,
abolished delayed protection in both healthy and remodelled hearts, identifying cyclooxygenase-2 as
a key mediator of late protection in both models. Isoﬂurane induced nuclear translocation of HIF1a
in all hearts, but CREB was exclusively activated in healthy but not remodelled myocardium, which
expressed higher levels of the CREB antagonist ICER. Delayed protection by isoﬂurane in remodelled
hearts was more vulnerable to inhibition by celecoxib.
Conclusion Isoﬂurane failed to mobilize cyclooxygenase-2-inducing CREB in ICER-overexpressing,
remodelled hearts, which was associated with a shortening of the second window of protection.
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1. Introduction
In 1993, Marber et al.1 and Kuzuya et al.2 described a
remarkable phenomenon called delayed ischaemic precon-
ditioning of the heart, which reﬂects a late ‘window of pro-
tection’ against ischaemia, usually occurring 12–72 h after
brief repetitive ischaemic episodes. The resulting protective
phenotype of the heart is due to a profound transcriptional
reprogramming with de novo protein synthesis, and is of
great clinical relevance, as it is 30-times longer than the
early window, which only lasts 2–3 h.3 Today, we know
that early and delayed preconditioning of the heart can be
elicited more safely by pharmacologic means such as haloge-
nated ethers or opioids than by ischaemic episodes.4,5 This is
of particular relevance for the already jeopardized diseased
myocardium. Isoﬂurane-induced delayed protection was ﬁrst
reported in 2003 in a rabbit model by Toncovic-Capin et al.6
In healthy rabbit myocardium, celecoxib, a speciﬁc
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cyclooxygenase-2 (COX-2) inhibitor, abolished delayed
isoﬂurane preconditioning,7 while late isoﬂurane protection
was dependent on 12-lipoxygenase activity in healthy
murine hearts.8 Recently, molecular evidence of delayed
anaesthetic preconditioning after sevoﬂurane inhalation
has been also reported in humans.9
Most experimental studies evaluated the phenomenon of
early and delayed preconditioning in healthy juvenile
hearts, but this is far from clinical reality, as diseasedmyocar-
dium would beneﬁt most from this protection. Some studies
reported reduced protection in the early phase of precondi-
tioning in diseased hearts.10,11 Since the early phase of pre-
conditioning is based on similar signalling pathways as the
late phase, it could be speculated that protection during
the late phase would be impaired in remodelled hearts. Post-
infarct remodelled myocardium exhibits marked structural
changes,12 alterations in energy metabolism13 and cellular
signalling,14 which put the heart at particular risk for
further ischaemic damage. In contrast to this notion are our
own recent ﬁndings that post-infarct remodelled hearts
remain receptive to protection by early isoﬂurane precondi-
tioning via the same signalling pathways, as observed in
healthy hearts.15 Nonetheless, no data exist as to whether
delayed anaesthetic protection retains its effectiveness in
post-infarct myocardium. Using an established rat model of
ventricular remodelling after permanent coronary artery lig-
ation, we investigated whether ventricular remodelling
would affect late isoﬂurane protection. Speciﬁcally, we
hypothesized that remodelling would abolish late isoﬂurane
protection and increase the vulnerability of the heart to
ischaemia-reperfusion injury. This study also investigated
possiblemechanisms underlying thepostulated refractoriness
to late anaesthetic protection in remodelled hearts.
The current study shows that the isoﬂurane-induced
second window of protection shrinks to a short-lived phase
in remodelled myocardium, which would require repetition
of the preconditioning stimulus every 24 h to maintain the
heart in the protected state.
2. Methods
This animal study was performed according to the guidelines
of the Animal Care and Use Committee of the University of
Zurich, Switzerland. All experimental procedures conformed
to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH publi-
cation 85-23, revised 1996).
2.1 Post-infarct remodelled hearts
Myocardial infarction (35% of left ventricular mass) and
subsequent hypertrophic remodelling was induced in male
adult (180–200 g, 8–9 weeks old) Wistar rats by permanent
ligation of the left anterior descending coronary artery
(LAD) under anaesthesia, as previously described in
detail.16 Some animals served as control and underwent
the same procedure except that the suture was passed
under the coronary artery without ligation. Rats were sacri-
ﬁced 6 weeks after surgery, and the body weight and heart
weight were measured. Hearts were further evaluated for
their function on a Langendorff apparatus (see Supplemen-
tary material online, Table S1).
2.2 Protocol for delayed isoﬂurane preconditioning
Healthy age-matched rats and infarct rats 6 weeks after cor-
onary artery ligation were placed on a thermoregulating pad
and exposed to 2.1 vol% [1.5 minimum alveolar concen-
tration (MAC) in rats] isoﬂurane (Abbott, Bar, Switzerland)
in oxygen for 90 min by inhalation (Figure 1). Rats exposed
to 100% oxygen for 90 min served as sham control. The con-
centration of applied isoﬂurane was continuously monitored
using a gas monitor. In separate experiments, a catheter was
inserted in the femoral artery and arterial blood was with-
drawn for blood gas analysis (see Supplementary material
online, Table S2). The animals subsequently recovered in
room air (21 vol% oxygen). Twenty-four and 48 h later,
delayed protection against ischaemia-reperfusion injury
was assessed on a Langendorff apparatus (Figure 1).
2.3 Isolated perfused rat heart experiments
Rats were heparinized (500 units i.p.) and 15 min later
decapitated without prior anaesthesia. Hearts were
mounted on a non-circulating Langendorff apparatus and
perfused with Krebs–Henseleit buffer gassed with 95% O2
and 5% CO2 at pH 7.4 and 378C, as previously described.
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Five hearts were assigned to each experimental group
(Figure 1). The selective COX-2 inhibitors celecoxib (CEL,
Pﬁzer AG, Zurich, Switzerland, IC50 ¼ 0.04 mM, low dose
used 0.1 mM, high dose used 1 mM), N-2-cyclohexyloxy-
4-nitrophenyl-methanesulphonamide (NS-398, Cayman
Chemical, Ann Arbor, MI, IC50 ¼ 1.77 mM, used concentration
5 mM) and the selective 12-lipoxygenase inhibitor
cinnamyl-3,4-dihydroxycyanocinnamate (CDC, USBiological,
Swampscott, MA, IC50 ¼ 0.063 mM, used concentration
0.5 mM) were dissolved in 0.1% dimethyl sulphoxide (DMSO)
vehicle and used to perfuse the hearts for 10 min before
induction of global ischaemia (Figure 1). Infarct size was
determined by 1% 2,3,5-triphenyltetrazolium chloride stain-
ing after 90 min of reperfusion, as previously described.16,18
In addition, myocardial damage was estimated by measuring
the release of lactate dehydrogenase (LDH) from necrotic
tissue, as previously described.16 Brieﬂy, the perfusate was
collected and LDH activity was determined by the Roche/
Hitachi 917 kit (sensitivity 6 U/L, intra- and interassay coef-
ﬁcients of variance ,1%).
2.4 Western blot analysis
Separate experiments served to determine expression of
12-lipoxygenase, 5-lipoxygenase, and COX-2 in healthy and
remodelled hearts 24 and 48 h after isoﬂurane exposure by
Western blot analysis. The antibodies were from the follow-
ing sources: COX-2, Cell Signaling Technology, Beverly, CA,
USA; 12-lipoxygenase, Cayman Chemical; 5-lipoxygenase,
BD Biosciences, San Diego, CA, USA; a-tubulin, Sigma, St
Louis, MO, USA.
2.5 COX-2 activity assay
Left ventricular tissue was homogenized in cold homogeniz-
ation buffer (0.1 M Tris-HCl, pH 7.8 containing 1 mM EDTA).
After centrifugation at 10 000 g for 20 min, the supernatant
was collected for enzyme assay. COX-2 activity was
measured in the presence of a potent and selective
cyclooxygenase-1 inhibitor SC-560 (Cayman Chemical, IC50
for cyclooxygenase-1 ¼ 9 nM and for cyclooxygenase-2 ¼
Delayed preconditioning in remodelled heart 99
6.3 mM) using a chromogenic cyclooxygenase activity assay
kit according to the manufacturer’s instruction (Cayman
Chemical). This assay measures the colour reaction of
cyclooxygenase-generated hydroperoxides.19
2.6 Electrophoretic mobility shift assays
Nuclear proteins were extracted as previously described in
detail.20 Electrophoretic mobility shift assays (EMSAs) were
performed with Odysseyw IRDyew 700 infrared dye labelled
double-stranded oligonucleotides coupled with the EMSA
buffer kit (LI-COR Bioscience, Bad Homburg, Germany)
according to the manufacturer’s instructions. Brieﬂy, 10–
20 mg of nuclear extract was incubated with 1–1.5 mL of
IRDyew 700 infrared dye labelled oligonucleotides, 2 mL of
10 binding buffer, 2.5 mM DTT, 0.25% Tween, and 1 mg of
poly (dI-dC) in a total volume of 20 mL for 30 min at room
temperature. For CREB binding assay a ﬁnal concentration
of 0.05% NP-40 was added, and for STAT3 binding assay a
ﬁnal concentration of 0.05% NP-40 and 5 mM MgCl were
added. Samples were separated on a 4% polyacrylamide
gel in 0.5 tris-borate-EDTA running buffer for 2 h at 200
V. The gel was then scanned by direct infrared ﬂuorescence
detection on the Odysseyw Imaging System (LI-COR Bio-
science). Oligonucleotide sequences of the double-stranded
DNA probes used were as follows: HIF-1a, 50-AGC TTG CCC
TAC GTG CTG TCT CAG A-30; CREB, 50-AGA GAT TGC CTG
ACG TCA GAG AGC TAG-30; NFkB, 50-AGT TGA GGG GAC
TTT CCC AGG C-30; STAT3, 50-GAT CCT TCT GGG AAT TCC
TAG ATC-30. The speciﬁcity of the DNA-protein binding
signal was conﬁrmed by competition with 200-fold molar
excess of the unlabelled consensus competitor
oligonucleotide.
2.7 Real-time quantitative polymerase chain
reaction
Details are provided in the Supplementary Materials and
Methods.
2.8 Statistical analysis
Data are presented as mean+ SD. For cardiac functional
data, repeated-measures analysis of variance was used to
evaluate differences over time between groups. Unpaired
t-test was used to compare groups at identical time
points, and paired t-test to compare within groups over
time. P-values were multiplied by the number of compari-
sons (Bonferroni correction). Post-hoc Tukey test was
applied for multiple comparisons of the one-way analysis
of variance for all other data. P, 0.05 was considered as
signiﬁcant. SigmaStat (version 2.0; SPSS Science, Chicago,
IL, USA) was used for the analyses.
3. Results
3.1 Post-infarct remodelling narrows the second
window of protection after isoﬂurane
preconditioning
From the 106 rats used for coronary artery ligation, 10
animals were lost intraoperatively due to intractable ventri-
cular ﬁbrillation. Heart weight over body weight ratios
determined 6 weeks after surgery were markedly higher in
post-infarct hearts compared with age-matched healthy or
sham-operated hearts (remodelled: 5.52+0.70 g/kg,
healthy: 3.58+0.57 g/kg, sham-operated: 3.63+0.55 g/
kg, P , 0.05; see Supplementary material online, Table
S1), indicating signiﬁcant ventricular remodelling. In
addition, left ventricular developed pressure, coronary
ﬂow, and heart rate were determined ex vivo on the Langen-
dorff apparatus. Left ventricular developed pressure was
lower in remodelled hearts compared with age-matched
healthy hearts. No changes were observed between groups
for coronary ﬂow and heart rate (see Supplementary
material online, Table S1).
Preconditioning elicited by isoﬂurane inhalation at 1.5
MAC for 90 min signiﬁcantly improved functional recovery
(see Supplementary material online, Table S3 and S4) and
decreased infarct size after ischaemia-reperfusion in both
healthy and remodelled hearts (Figures 2A and 3A).
However, protection in infarct hearts was exclusively
present at 24 h after preconditioning, while in healthy
hearts the protection extended from 24 to 48 h after isoﬂur-
ane exposure. Infarct-size reduction was corroborated with
measurements of LDH release into the perfusate during
reperfusion in healthy and remodelled hearts (Figures 2B
Figure 1 Treatment protocols. Six weeks after ligation of the left anterior descending coronary artery (LAD), rats were exposed in vivo to 2.1 vol% (1.5 MAC)
isoﬂurane in oxygen or oxygen alone for 90 min. Age-matched healthy rats served as control group. Twenty-four and 48 h after isoﬂurane preconditioning, Lan-
gendorff perfused healthy and remodelled hearts were exposed to 40 min of ischaemia and 90 min of reperfusion. Blockers were administered 10 min before
index ischaemia. MAC: minimum alveolar concentration.
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and 3B). Sham groups (oxygen inhalation alone) did not
exhibit protection 24 or 48 h later in either model. The
recovery of developed pressure after delayed precondition-
ing was lower by 20% in remodelled hearts when compared
with healthy hearts, and end-diastolic pressure reached
baseline values after 90 min of reperfusion in healthy but
not remodelled hearts (see Supplementary material online,
Tables S3 and S4). Groups with celecoxib administration
before ischaemia-reperfusion exhibited increased coronary
ﬂow consistent with previous reports.21 Of note, during trig-
gering of isoﬂurane preconditioning, arterial blood gas
measurements did not show signiﬁcant differences com-
pared with animals treated with oxygen alone (see Sup-
plementary material online, Table S2). These results
provide evidence that post-infarct remodelling narrows
the second window of protection after isoﬂurane
preconditioning.
3.2 Late protection by isoﬂurane preconditioning is
more vulnerable to cyclooxygenase-2 inhibition in
remodelled myocardium
COX-2 and 12-lipoxygenase were shown to be important in
mediating delayed cardioprotection by isoﬂurane.7,8 Here
we show that delayed protection by isoﬂurane is abolished
or attenuated by inhibitors of COX-2, but not of
12-lipoxygenase (Figures 2 and 3). While delayed protection
was more resistant to celecoxib in healthy hearts, remo-
delled hearts completely lost protection in the presence of
even lower celecoxib concentrations (see Supplementary
material online, Tables S3 and S4). Dimethyl sulphoxide
alone or blockers alone had no effect on infarct size.
Taken together, the data provide evidence that delayed pro-
tection by isoﬂurane is mediated by COX-2 in both healthy
and remodelled hearts and further underscore the
Figure 2 Infarct size (A) and lactate dehydrogenase (LDH) release (B) in healthy hearts. ISO24/48: hearts exposed to ischaemia-reperfusion 24 or 48 h after
isoﬂurane preconditioning. ISO24/48_CEL_high: preconditioned hearts treated with 1 mM celecoxib. ISO24/48_CEL_low: preconditioned hearts treated with
0.1 mM celecoxib. ISO24/48_CDC: preconditioned hearts treated with 0.5 mM cinnamyl-3,4-dihydroxy-cyanocinnamate (CDC). ISO24/48_NS398: preconditioned
hearts treated with 5 mM N-2-cyclohexyloxy-4-nitrophenyl-methane-sulphonamide (NS-398). Final concentration of dimethyl sulphoxide (DMSO) was ,0.1%.
The preﬁx SHAM in group names indicates respective groups without isoﬂurane preconditioning (oxygen alone). *P , 0.05 vs. SHAM24 groups. #P , 0.05 vs.
SHAM48 groups. **P , 0.05 vs. high celecoxib concentration. Data are mean+ SD (n ¼ 5 per group).
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remarkable vulnerability of the diseased myocardium to
COX-2 inhibition.
3.3 Isoﬂurane-induced cyclooxygenase-2
expression and activity show alterations in
remodelled hearts
As expected, COX-2 was more abundant in infarct hearts
(see Supplementary material online, Figure S1).22 To charac-
terize the expression and activity of COX-2 in delayed
protection by isoﬂurane preconditioning, Western blot
analyses (Figure 4) and activity measurements (Figure 5)
were performed in isoﬂurane- and sham-treated rat hearts
24 and 48 h after triggering with isoﬂurane. In healthy
hearts, COX-2 expression was increased 24 (1.5-fold) and
48 h (2.7-fold) after isoﬂurane exposure, while in remo-
delled hearts, COX-2 expression was exclusively increased
at 24 h (three-fold) (Figure 4). Oxygen inhalation in sham
groups did not affect COX-2 expression or activity. COX-2
activity closely paralleled COX-2 expression (Figure 5). No
changes in 12-lipoxygenase and 5-lipoxygenase expression
were observed (see Supplementary material online, Figure
S2). Together, isoﬂurane-induced COX-2 showed a shortened
activation proﬁle in remodelled hearts, which closely paral-
leled structural and functional protection.
3.4 Isoﬂurane induces nuclear translocation of
HIF1a but not CREB in post-infarct remodelled
hearts
To determine the contribution of putative transcription
factors in the observed isoﬂurane-induced COX-2 expression
in healthy and remodelled hearts, nuclear translocation of
NFkB, STAT3, HIF1a, and CREB was measured 30 min after
termination of isoﬂurane inhalation (2.1 vol% for 90 min) in
additional experiments. Isoﬂurane induced nuclear
translocation of HIF1a in healthy and remodelled hearts
(Figure 6). In contrast, CREB was exclusively translocated
to nuclei in healthy hearts. None of the other transcription
factors was activated by isoﬂurane compared with sham
Figure 3 Infarct size (A) and lactate dehydrogenase (LDH) release (B) in remodelled hearts. ISO24/48: hearts exposed to ischaemia-reperfusion 24 or 48 h after
isoﬂurane preconditioning. ISO24/48_CEL_high: preconditioned hearts treated with 1 mM celecoxib. ISO24/48_CEL_low: preconditioned hearts treated with
0.1 mM celecoxib. ISO24/48_CDC: preconditioned hearts treated with 0.5 mM cinnamyl-3,4-dihydroxy-cyanocinnamate (CDC). ISO24/48_NS398: preconditioned
hearts treated with 5 mM N-2-cyclohexyloxy-4-nitrophenyl-methane-sulphonamide (NS-398). Final concentration of dimethyl sulphoxide (DMSO) was ,0.1%.
The preﬁx SHAM in group names indicates corresponding groups without isoﬂurane preconditioning (oxygen alone). *P, 0.05 vs. SHAM24 group. Data are
mean+ SD (n ¼ 5 per group).
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treatment (data not shown). In search of possible mechan-
isms for the lack of CREB activation by isoﬂurane in remo-
delled myocardium, we determined the mRNA level of the
CREB-antagonist inducible cAMP early repressor (ICER),
which was increased by 63% in remodelled myocardium:
0.026+;0.005 vs. 0.016+;0.004 (arbitrary units relative
to a-tubulin, P ¼ 0.009). These data suggest that the
failure of isoﬂurane to activate CREB in remodelled
myocardium may be due to overexpression of the
CREB-antagonist ICER in infarct hearts and thus may contrib-
ute to the observed narrowing of the second window of
protection.
Figure 4 Representative Western blots of cyclooxygenase-2 (COX-2) expression (72 kDa) in healthy (A) and remodelled (B) hearts 24 and 48 h after isoﬂurane
exposure expressed as average density ratio of COX-2 to a-tubulin (57 kDa) normalized to baseline (BL). ISO24/48: hearts exposed to isoﬂurane and harvested 24
or 48 h later. SHAM24/48: time-matched hearts exposed to oxygen alone. Data are mean+ SD (n ¼ 4 per group). *P , 0.05 vs. BL.
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4. Discussion
The salient ﬁndings of this study can be summarized as
follows. First, isoﬂurane induced a robust but narrow
second window of protection in hearts with marked
post-infarct ventricular remodelling. In these diseased
hearts, reduction in infarct size and improved functional
recovery were only present 24 h after isoﬂurane application,
while in healthy hearts protection extended for up to 48 h.
Secondly, delayed protection by isoﬂurane in rat hearts
was mediated by COX-2 but not 12-lipoxygenase in both
remodelled and healthy myocardium, and closely correlated
with increased COX-2 expression and activity levels. Hence,
isoﬂurane elicits late protection in remodelled rat myocar-
dium via similar signalling pathways as previously reported
in healthy rabbit hearts.7 While COX-2-inducing HIF-1a was
activated by isoﬂurane in healthy and remodelled hearts,
isoﬂurane failed to mobilize COX-2-inducing CREB in post-
infarct myocardium. Overexpression of the CREB-antagonist
ICER offers an explanation for the observed narrowing of the
second window of protection, a hypothesis that needs vali-
dation. Thirdly, despite increased expression of COX-2,
remodelled preconditioned hearts exhibited a remarkable
vulnerability to inhibition by the clinically used anti-
inﬂammatory drug celecoxib, which completely abolished
delayed isoﬂurane protection in these hearts, but only
partly diminished the protection in healthy hearts. Together,
we present for the ﬁrst time evidence that delayed protec-
tion by isoﬂurane preconditioning varies with the disease
state of the heart and concomitant medication (Figure 7).
Since recruitment of COX-2 is a critical innate mechanism,
whereby the heart protects itself from ischaemia,3 our ﬁnd-
ings may be of relevance for the medical management of
patients at risk of cardiovascular complications.
Delayed preconditioning is a second window of protec-
tion whereby stimulation by ischaemia or chemical agents
enhances the resistance of the heart to subsequent poten-
tially lethal stimuli 24–72 h later. It is a universal response
Figure 5 Cyclooxygenase-2 (COX-2) activity in healthy (A) and remodelled
(B) hearts 24 and 48 h after isoﬂurane exposure. ISO24/48: hearts exposed
to isoﬂurane and harvested 24 or 48 h later. SHAM24/48: time-matched
hearts exposed to oxygen alone. Data are mean+ SD (n ¼ 4 per group).
*P , 0.05 vs. baseline (BL).
Figure 6 Electrophoretic mobility shift assays of HIF1a and CREB in healthy (A) and remodelled (B) hearts (gels with corresponding densitometry). ISO30 min:
nuclear extracts from hearts exposed to isoﬂurane preconditioning harvested 30 min after termination of inhalation (2.1 vol% for 90 min). SHAM30 min: nuclear
extracts from respective sham group (oxygen alone). Gels show additional lines with ISO30 min plus 200-fold excess of unlabelled consensus competitor oligo-
nucleotide (comp. oligo) conﬁrming speciﬁcity of the detected ﬂuorescence signal for HIF1a and CREB, respectively. Data are mean + SD (n ¼ 4 per group).
*P , 0.05 vs. baseline (BL) and healthy hearts, respectively. †P, 0.05 vs. ISO30 min.
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of the heart to stress.23 In contrast to early precondition-
ing, delayed preconditioning has strong and more reliable
anti-stunning and anti-infarct effects making it more clini-
cally relevant. It causes an increase in prostaglandin bio-
synthesis in cardiac tissue via the enhanced expression of
COX-2 catalysing the conversion of arachidonic acid to
prostanoids.24 COX-2 is constitutively expressed in the
heart at lower levels25 but rapidly induced through the
activation of several transcription factors.3,23 Prostanoids
such as prostacyclin (PGI2) open mitochondrial KATP chan-
nels,26 key players in isoﬂurane-induced cardioprotec-
tion.27 Inhibition of the rate-limiting enzyme COX-2
abolishes the infarct-sparing effect of delayed precondi-
tioning,24 but also the protection by early precondition-
ing.28 Using healthy animal models from different
species, previous studies reported on late cardioprotection
after exposure to volatile anaesthetics,29,30 and identiﬁed
reactive oxygen and nitrogen species released by nitric
oxide synthase as triggers,31 inducible nitric oxide
synthase,32 12-lipoxygenase,8 and endothelial nitric oxide
synthase33 as mediators, and sarcolemmal and mitochon-
drial KATP channels as end effectors
6 of delayed anaesthetic
preconditioning. Hitherto, however, only one study with
healthy rabbit hearts investigated the role of COX-2 in
isoﬂurane-induced delayed preconditioning using the
COX-2 inhibitor celecoxib.7 Our study now conﬁrms COX-2
as an obligatory mediator in isoﬂurane-induced delayed
preconditioning of healthy rat hearts, and further extends
its critical role in cardioprotection to diseased post-infarct
remodelled myocardium.
Structural changes due to loss of viable tissue and scar for-
mation,12 alterations in metabolism,13 and cellular signal-
ling14,34,35 put the remodelled myocardium at risk for
further ischaemic damage. Experiments from muscle slices
of right atrial appendices of patients with failing hearts indi-
cate that remodelled myocardium is less amenable to innate
protection by preconditioning.36 At the molecular level, a
gene program resembling the foetal program is activated
and protective signalling pathways were reported to be
lost in various disease models associated with remodelling.37
Complete refractoriness to early ischaemic preconditioning
as opposed to pharmacologic preconditioning by diazoxide,
was reported in a rabbit infarct model, for which interrup-
tion of signal transduction between G-protein coupled
receptors and protein kinase C was found to be respon-
sible.38 Conversely, erythropoietin-mediated precondition-
ing was preserved in post-infarct remodelled rat
myocardium despite the disruption of the erythropoietin
receptor–PI3K–PKB pathway via up-regulation of the sup-
pressor of cytokine signalling protein-1.39 In this case, com-
pensatory PI3K-independent activation of ERK upstream of
the guanylyl cyclase-mitochondrial KATP channel pathway
restored the protective phenotype. To date, no data is avail-
able with respect to delayed protection after pharmacologic
or ischaemic preconditioning in post-infarct remodelled
hearts. In contrast to our previous ﬁndings on early
isoﬂurane-induced preconditioning15 and postconditioning
in remodelled myocardium,16 where protection against
ischaemia-reperfusion was fully preserved, our current
study on delayed isoﬂurane preconditioning clearly indicates
that ventricular remodelling alters protective signalling ren-
dering the heart more vulnerable to ischaemia-reperfusion
injury. In search of mechanisms for this remarkable vulner-
ability, we tested a number of COX-2-inducing transcription
factors to see whether their nuclear translocation would be
impaired in the diseased state. Increased HIF1a protein
levels were previously reported after isoﬂurane exposure
in rat myocardium40 and were similarly regulated in the
current study in healthy and diseased hearts. HIF1a is an
oxygen-dependent transcription factor activating an array
of genes required for the adaptation to hypoxia, including
COX-2. In contrast, CREB was exclusively mobilized in
healthy but not remodelled hearts, which showed increased
expression of the transcriptional repressor and
CREB-antagonist ICER.41 ICER represses transcription either
by heterodimerization with activating forms of CREB and
other bZIP domain-containing transcription factors, or by
competing with these proteins for DNA binding.42 Due to
the homology between ICER and CREB, we cannot comple-
tely rule out that both CREB and ICER bind to the CRE-
consensus oligos used in our experiments. However, the
DNA-binding activity is lower in remodelled hearts than in
healthy hearts indicating that ICER may not or only weakly
bind to CREB-oligos (data not shown). The results of our
experiments raise the possibility that the observed lack of
CREB-DNA binding in the remodelled hearts might be due
to heterodimerization of CREB with other transcriptional
factors including ICER that thereby could antagonize CREB.
This hypothesis should be proven in future experiments.
Figure 7 ‘Second window of protection’ in healthy and remodelled hearts.
The panels show the second window of protection at 24 and 48 h after isoﬂur-
ane exposure (APC) in healthy (A) and infarct remodelled (B) hearts in the
absence (solid line) and presence (dashed line) of celecoxib (0.1 mM).
Delayed preconditioning in remodelled heart 105
COX-2 inhibitors increase the number of cardiovascular
complications speciﬁcally in patients with preexisting
heart disease.43 A recent pig study impressively showed
that peri-infarct inhibition of COX-2 by celecoxib decreased
myocardial function and increased left ventricular remodel-
ling and mortality.44 In the current study, we also evaluated
the effects of low and higher concentrations of the clinically
used celecoxib on late isoﬂurane protection. The IC50 of cel-
ecoxib for COX-2 (0.04 mM) is 375-times lower than for
cyclooxygenase-1,45 but celecoxib has additional unspeciﬁc
inhibitory effects on other key enzymes.21 A single oral
administration of 200 mg celecoxib results in a plasma con-
centration of 700–1100 mg/L, whereby only a small
amount (3%) of the drug is unbound and biologically
active.45 Hence, the effective tissue concentration under
clinical conditions is close to 0.1 mM, as used in our study
in the protein-free buffer perfusing the isolated hearts.
Higher concentrations of unbound drug in the range of
1 mM are unusual, but were reported in patients with
CYP2C9 deﬁciency due to genetic polymorphisms.45 Our
results clearly show that even low concentrations of cele-
coxib sufﬁce to abolish delayed protection by isoﬂurane.
Increased expression of ICER was previously reported to
downregulate prosurvival Bcl-2,41,46 and thus might well
be responsible for the higher susceptibility of infarct
hearts to celecoxib. From a translational point of view, our
data suggest that the use of selective COX-2 inhibitors
should be minimized in at-risk patients with signiﬁcant ven-
tricular remodelling. Finally, our results imply that diseased
myocardium requires more frequent intermittent precondi-
tioning stimuli to maintain the protected state.
Although previous studies showed the signiﬁcance of CREB
in establishing delayed preconditioning,47 our experiments
cannot exclude that other factors contributed to the
shorter duration of COX-2 upregulation. Our study focused
on COX-2 in healthy and diseased rat hearts, and did not
investigate molecular cross-talk between iNOS and COX-2
or other kinases such as protein kinase B. Since ischaemic
postconditioning was recently reported to enhance
delayed preconditioning by further up-regulation of
COX-2,48 future studies should test whether ischaemic and
pharmacologic postconditioning could fully restore delayed
protection by preconditioning in post-infarct hearts. Some
previous studies showed divergent mechanisms during the
early, late and ﬁnal stage of delayed preconditioning.49
Although our ﬁndings suggest that delayed isoﬂurane pre-
conditioning is mediated via the same mechanisms through-
out its duration, we cannot exclude that other or additional
mechanisms may be involved in the ﬁnal stage (at 72 h) of
late isoﬂurane protection. Finally, timing of protection is
often species-dependent and may be different in humans.
In summary, our study shows that post-infarct remodelling
in rat hearts hinders sustained COX-2 expression and activity
after isoﬂurane preconditioning and thus narrows the second
window of protection. Isoﬂurane induces nuclear transloca-
tion of HIF1a in both healthy and remodelled hearts, but
fails to mobilize the transcription factor CREB in diseased
ICER-overexpressing hearts. The study further demonstrates
that innate protection of remodelled myocardium is excep-
tionally vulnerable to COX-2 inhibition. Hence, protection
by delayed isoﬂurane preconditioning varies with the
disease state of the heart and concomitant medication.
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BACKGROUND: Late preconditioning by volatile anesthetics evolves in response to
transcriptional changes. We hypothesized that sevoflurane inhalation would
modify the transcriptome in human blood and modulate the expression of
adhesion molecules in white blood cells consistent with the occurrence of a late
preconditioning phase.
METHODS: Five healthy male subjects inhaled sevoflurane at an end-tidal concentra-
tion of 0.5%–1.0% for 60 min. Venous blood samples were collected at baseline,
after 15 and 60 min of inhalation, and 6, 24, 48, and 72 h thereafter and immediately
processed for flow cytometry and mRNA extraction and hybridization to Af-
fymetrix U133 Plus 2.0 microarrays. Data were analyzed using Significance
Analysis of Microarray and Gene Set Enrichment Analysis and confirmed by
real-time reverse transcription polymerase chain reaction. L-selectin (CD62L) and
2-integrin (CD11b) expression was determined on granulocytes and monocytes
using flow cytometry.
RESULTS: Sevoflurane inhalation rapidly and markedly altered gene expression in
white blood cells. Key transcripts potentially involved in late preconditioning or
organ protection including paraoxonase, 12-lipoxygenase, heat shock protein 40,
chemokine ligand 5, and phosphodiesterase 5A were regulated in response to
sevoflurane. Sevoflurane further decreased transcripts involved in peroxisome
proliferator-activated receptor  coactivator-1 (PGC-1) signaling and fatty acid
oxidation. Reduced L-selectin (CD62L) expression on granulocytes accompanied
with increased resistance to inflammatory activation was present at 24 to 48 h after
sevoflurane exposure.
CONCLUSIONS: Sevoflurane at subanesthetic concentrations modifies blood transcrip-
tome and decreases the expression of the proinflammatory L-selectin (CD62L),
consistent with a “second window of protection” in humans.
(Anesth Analg 2007;105:629–40)
Preconditioning is a biological process observed in
multiple organs, whereby a transient stressful stimu-
lus induces a protective state against a more pro-
longed, potentially lethal insult. It can be induced by
brief ischemic episodes or by drugs such as volatile
anesthetics (1,2). This protection has two phases: an
early phase, immediately operating after the applica-
tion of the preconditioning stimulus and lasting for
2–3 h, and a late phase, evident after 12–24 h but
lasting for up to 3 days. Although early precondition-
ing is predominantly based on multiple, fast-acting
intracellular phosphorylation signaling steps (3), the
second window is a result of transient altered gene
activity (4) and depends on novel protein expression
(5). Volatile anesthetic-induced preconditioning was
reported to be effective in various cell types, including
cardiac myocytes (6,7), and endothelial and smooth
muscle cells (8). In addition, several experimental
studies provide evidence of a “second window of
protection” elicited by volatile anesthetics in mouse
(9), rat (10–12), and rabbit hearts (13–15). In contrast,
one study with isoflurane was unable to show delayed
cardioprotection in an in vivo dog model (16). How-
ever, it is unknown whether late preconditioning
elicited by volatile anesthetics also occurs in humans.
Recruitment of inflammatory cells to sites of isch-
emic injury contributes significantly to organ dysfunc-
tion. Focal accumulation of leukocytes is mediated by
the interaction of selectins with their endothelial coun-
terligands, while firm attachment of leukocytes and
transmigration requires activation of 2-integrin
(CD11b) (17). Using a highly controlled human in vivo
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model of endothelial dysfunction, we have recently
shown that sevoflurane inhalation at subanesthetic con-
centrations decreases activation of 2-integrin (CD11b)
on granulocytes and monocytes after ischemia-
reperfusion of the forearm in healthy volunteers,
consistent with an early preconditioning of the endo-
thelium (18). We next wanted to know whether
sevoflurane inhalation would also regulate gene and
protein expression in the blood in accordance with the
occurrence of a late window of anesthetic-induced
preconditioning in humans. Specifically, we hypoth-
esized that sevoflurane inhalation would modulate
blood transcripts potentially involved in late protec-
tion and reduce the expression of L-selectin (CD62L)
and 2-integrin (CD11b) 24–48 h later in humans.
METHODS
Study Subjects
In this study, five healthy male volunteers with
Caucasian genetic background, aged 32  5 (27–39) yr
and with a body mass index of 23  6 (21–28) kg/m2
gave informed signed consent. All participants were
nonsmokers and refrained from caffeine and dark
chocolate containing endothelium-protective flavonoids
from 24 h before until 72 h after sevoflurane inhala-
tion. The subjects fasted overnight, and were pre-
treated with a single dose of oral ranitidine (300 mg)
the evening before sevoflurane inhalation. The re-
search project was performed in accordance with the
Declaration of Helsinki (2000), and was approved by
the local ethics committee of the University Hospital
Zurich, Switzerland.
Study Protocol
Figure 1 shows the time course of the experiments.
After inserting a cannula into a cubital vein and the
administration of 500 mL Ringer solution, the subjects
inhaled sevoflurane in 50% oxygen to achieve a sub-
anesthetic end-tidal concentration of between 0.5%
and 1.0% for 60 min. Sevoflurane was inhaled by the
spontaneously breathing volunteers using a facemask
connected to the common gas outlet of an anesthesia
machine (Siemens Servo 900D ventilator, Siemens Life
Support Systems, Sona, Sweden), as previously de-
scribed (18). Blood samples were taken from the cubital
vein (opposite side of blood pressure cuff) before gas
inhalation (baseline), after 15 and 60 min of sevoflurane
administration, and 6, 24, 48, and 72 h thereafter. One
week after sevoflurane inhalation, separate experiments,
conducted in a crossover mode with the same individu-
als, served to clarify whether inhalation of 50% oxygen
without sevoflurane and administration of a single oral
dose of ranitidine (300mg)would affect gene expression.
Monitoring consisted of intermittent noninvasive arterial
blood pressuremeasurements, 5-lead electrocardiogram,
end-tidal CO2, end-tidal sevoflurane concentrations
(Hellige VICOM-SM SMU 612; PPG, Freiburg, Ger-
many), and Bispectral Index (A2000 monitorwith three
adhesive electrodes to the forehead, single channel:
Fp1–Fpz, version 3.3; Aspect Medical Systems, Natick,
Massachusetts) for depth of sedation.
Transcriptional Profiling of Human Blood Samples
Total RNA was extracted from whole blood
samples (collected in tripotassium-EDTA tubes) after
centrifugation using RiboPure™-Blood Kit (Ambion,
Huntington, United Kingdom). Microarray analysis
was performed following the “minimum information
about a microarray experiment” guidelines (19).
Briefly, the quality of the isolated RNA was deter-
mined with a NanoDrop ND 1000 (NanoDrop Tech-
nologies, Delaware) (260/280 nm ratio between 1.8
and 2.1 and 28S/18S ratio within 1.5–2). Probe labeling
and purification was achieved as previously described
(20). From four of the five subjects, samples collected
at baseline, 15 min, 1, 6, and 24 h were processed and
hybridized to an individual Affymetrix GeneChip
Human Genome U133 Plus 2.0 arrays (total of 20
arrays) for 16 h at 45°C. Arrays were washed using an
Affymetrix Fluidics Station and scanned using an
Affymetrix GeneChip Scanner 3000 at a resolution of 3
m. Normalization and computation of expression
values were performed using the robust multichip
average method (21). From the global gene expression
Figure 1. Study protocol. Sevoflurane
(SEVO) was inhaled for 60 min at
0.5%–1.0% end-tidal concentration.
Blood samples were collected at indi-
cated time points and used for mi-
croarray analysis and flow cytometry.
Separate experiments with inhalation
of 50% oxygen without sevoflurane
served as control.
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matrix, which contains the expression values of the
54675 probe sets at all time points, the expression
values at baseline and after 1 h of sevoflurane inhala-
tion (peak transcriptional change) were selected and
used to determine: 1) differentially expressed genes
using the Significance Analysis of Microarrays (SAM)
algorithm (22) and 2) differentially expressed path-
ways using Gene Set Enrichment Analysis (GSEA) 23,
as previously described in detail (20,24). In SAM, each
gene is assigned a score on the basis of its change in
gene expression relative to the standard deviation of
repeated measurements for that gene. Genes with
scores more than a threshold are deemed potentially
significant and the algorithm provides an estimate of
the false discovery rate (FDR), i.e., the expected pro-
portion of false positives among the transcripts called
significant. Conveniently, GSEA aggregates the per
gene statistics across genes within a gene set, thus
making it possible to detect situations where the genes
in a predefined set change in a small but coordinated
way. GSEA calculates an enrichment score (NES) for a
given gene set using a ranked list of all genes and
infers statistical significance (expressed as a P value
and a FDR) of each NES against NES background
distribution calculated by permutation of the original
data set. A cut-off median FDR of 3% was used in
SAM analysis, and P  0.05 was used in GSEA
analysis to obtain the ranked lists of differentially
expressed genes and pathways, respectively. To de-
fine a standardized measure of gene expression over
time (the mean centroid), we normalized the gene
expression levels of the top up- and down-regulated
genes to a mean of 0 and a variance of 1 across all 20
samples over time. Microarray analysis was per-
formed for four individuals only to decrease related
costs. All other analyses were performed for all five
study subjects.
Transcript Validation Using Real-Time Reverse
Transcriptase-Polymerase Chain Reaction
Real-time reverse transcriptase-polymerase chain
reaction (RT-PCR) was performed for four randomly
selected genes to confirm microarray data (please see
Supplementary Table S1 available at www.anesthesia-
analgesia.org), as previously described (20,25). First
strand cDNA was synthesized from 1 g of total RNA
using Superscript II reverse transcriptase (Invitrogen,
Basel, Switzerland) and oligo-dT as primer. RT-PCR
quantification of the selected genes was performed on
a Stratagene MX3000 real-time sequence detector in-
strument (Stratagene Europe, Amsterdam, The Nether-
lands) using the Brilliant SYBR green QPCR Master Mix
(Stratagene Europe). Amplification reactions were
conducted with an initial step at 90°C for 3 min
followed by 20–35 cycles. All PCR reactions were
performed in triplicates, and ribosomal 18S (a con-
stitutively expressed gene) was used as reference
control. Predicted size of PCR products was con-
firmed by agarose gel electrophoresis.
Determination of L-Selectin (CD62L) and 2-Integrin
(CD11b) Expression in the Blood Using Flow Cytometry
L-selectin (CD62L) is an early indicator of neutro-
phil activation, while 2-integrin (CD11b) expression
is a later event of the leukocyte-endothelial interaction.
Collected heparinized blood samples were immedi-
ately processed for flow cytometry. The expression of
the adhesion molecules was determined at baseline,
24, 48, and 72 h after sevoflurane exposure in all
five volunteers. Two microliters of 0.5 mM N-
formyl-methionyl-leucyl-phenylalanin (fMLP) was
added to 1 mL of collected whole blood (1 M final
fMLP concentration) and incubated for 10 min at room
temperature. Unstimulated blood served as control.
Subsequently, 3 L of the primary fluorochrome-
labeled antibody was added to 50 L of blood in
endotoxin-free tubes and incubated in the dark for 10
min at room temperature. Lysis buffer (450 L) (Bec-
ton Dickinson, Basel, Switzerland) was added and
incubated for an additional 20 min at room tempera-
ture. The lysates were fixed for 30 min in 0.5 mL 0.2%
paraformaldehyde solution at room temperature. The
samples were centrifuged, and the cell pellets were
suspended in 0.5 mL of TLR buffer, and stored at 4°C
in the dark. The FACSCalibur (Becton Dickinson)
flow cytometer was used to measure R-phycoerythrin
(PE)-fluorescence at 580 nm and FITC-fluorescence at
515 nm. White blood cells were distinguished from
each other by typical physical characteristics, resulting
in well-delineated cellular subpopulations that are
easily identified on forward and side-scatter plots.
Monoclonal antibodies for polymorphnuclear granu-
locytes (CD15, PE-labeled, clone 80H5, Immunotech,
Marseille, France) and monocytes (CD14, FITC-
labeled, clone 61D3, eBioscience, Wembley, United
Kingdom) further served for identification of cellular
subgroups. CD62L and CD11b expression were mea-
sured by fluorescence intensity of PE-conjugated
monoclonal antibodies directed against CD62L (FITC-
labeled, clone DREG56, eBioscience) and CD11b (PE-
labeled, clone 2LPM19C, DAKO, Glostrup, Denmark).
Results were compared to isotype-matched control
IgG (PE-labeled IgG, eBioscience and FITC-labeled
IgG, Becton Dickinson). A minimum of 20,000 events
was counted on each sample.
Statistical Analysis
Data are given as mean (SD). Repeated-measures
ANOVA were used for comparison. Student-
Newman-Keuls test was used for post hoc analysis. P
0.05 was considered significant. Analyses were per-
formed using StatView Version 5 (SAS Institute, Chi-
cago, IL).
RESULTS
The 60 min period of sevoflurane inhalation at
sedative concentrations (0.5%–1%) had only marginal
effects on arterial blood pressure and end-tidal CO2
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concentrations (Table 1). The participants were re-
sponsive to verbal commands or tactile stimuli at all
times. The Bispectral Index ranged between 68 and 82
on average. All subjects tolerated the procedure with-
out complications.
Sevoflurane Inhalation at Subanesthetic Concentrations
Markedly Altered Gene Expression in the Blood of
Healthy Volunteers
We first tested whether sevoflurane at subanes-
thetic concentrations is capable of modulating gene
expression in humans. For this purpose, mRNA from
whole blood was isolated at different time points after
sevoflurane application and used for gene chip hy-
bridization. Gene chip data were independently con-
firmed with RT-PCR, which showed the same results
(please see Supplementary Table S2 available at
www.anesthesia-analgesia.org). Significance Analysis
of Microarrays (SAM) revealed 74 upregulated
(changes in expression more than 35% and median
FDR 3%) and 63 down-regulated transcripts (me-
dian FDR 3%) after 60 min of sevoflurane exposure
(for complete list of transcripts, please see Supplemen-
tary Table S3 available at www.anesthesia-analgesia.
org). Three volunteers exhibited peak gene regulations
after 1 h, while one subject exhibited peak transcrip-
tional responses after 15 min of inhalation (Fig. 2).
Using microarrays covering the entire human genome
(54,000 probes for the approximately 30,000 human
genes), our data confirm the profound effects of
volatile anesthetics on the transcriptome, as previ-
ously reported in rat hearts (24,25), and further extend
these findings to human blood in response to subanes-
thetic concentrations of sevoflurane.
Our analysis detected a number of up- and down-
regulated transcripts already known to be involved in
the protection of the heart or other vital organs (Fig. 3;
please see Supplementary Table S3 available at
www.anesthesia-analgesia.org). In particular, these
included the up-regulated transcripts paraoxonase,
12-lipoxygenase, DnaJ (Hsp40), and the down-
regulated transcripts chemokine ligand 5 (a potent
neutrophil chemoattractant, also called epithelial neu-
trophil activating protein-78) and phosphodiesterase
5A. Control experiments with inhalation of 50% oxy-
gen for 1 h did not show any transcriptional regulation
of paraoxonase, 12-lipoxygenase, and acyl-CoA syn-
thase (Fig. 4). Sevoflurane inhalation down-regulated
transcripts involved in peroxisome proliferator-
activated receptor (PPAR) regulation and fatty acid
oxidation in blood cells. We have recently shown that
sevoflurane anesthesia down-regulates PPAR and its
coactivator protein, PGC-1, which transcriptionally
regulate metabolism and lead to a shift in fuel prefer-
ence away from fatty acid oxidation in the heart (20).
In the present study, GSEA confirmed the coordinate
down-regulation of genes involved in fatty acid oxi-
dation after sevoflurane inhalation (NES  0.55, P 
0.00, FDR q-value  0.08) in blood cells, which closely
correlated with PPAR-related genes (PGC-1 path-
way: NES  1.22, P  0.02, FDR q-value  0.43)
(Figs. 5A–C). Finally, a large number of regulated
transcripts emerged with yet unknown function in the
context of organ protection (please see Supplementary
Table S3 available at www.anesthesia-analgesia.org).
Sevoflurane Inhalation Reduces L-Selectin (CD62L)
Expression on Leukocytes and Induces Cellular
Resistance to Inflammatory Stimulation 24–48 h After
Exposure in Humans
To elucidate whether sevoflurane inhalation modu-
lates protein expression consistent with a “second
window” of preconditioning, we determined the ex-
pression of the important adherence molecules 2-
integrin (CD11b) and L-selectin (CD62L) from cubital
blood collected up to 72 h after sevoflurane applica-
tion. Expression levels were determined separately on
granulocytes (CD14 positive) and monocytes (CD15
positive). Sevoflurane administration significantly
reduced (approximately 25%) the expression of
L-selectin (CD62L) in granulocytes (P  0.004), but
had only a marginal effect on monocytes (Figs. 6A and
B). These changes were most evident at 24 and 48 h
after inhalation. In contrast, there was no decrease in
Table 1. Recorded Parameters at Baseline and During Inhalation of Small-Dose Sevoflurane
Subject ID V_1a,b V_2a,b V_3a,b V_4a,b V_5b
Before SEVO SBP (mm Hg) 110 112 124 111 113
HR (bpm) 72 47 50 61 65
Spo2 (%) 100 100 100 100 100
BIS 95 95 98 97 98
During SEVO ET (SEVO)c (vol %) 1.0 0.70 0.95 0.82 1.0
ET (Co2)
c (vol %) 3.8 5.0 4.5 4.4 4.2
SBPd (mm Hg) 95 108 107 100 103
HRd (bpm) 57 46 52 72 55
Spo2
c (%) 99 100 98 100 100
BISc 68 69 82 79 72
SEVO  sevoflurane; SBP  systolic blood pressure; HR  heart rate (in beats per minute or bpm); SpO2  oxygen saturation (finger tip); BIS  Bispectral Index; ET(SEVO)  end-tidal
sevoflurane concentration; ET(CO2)  end-tidal CO2.
a The blood samples of these subjects were used for gene chip analysis (N  4).
b The blood samples of these subjects were used for flow cytometry (N  5).
c Mean values during sevoflurane inhalation.
d Values recorded after 30 min of sevoflurane in 50% oxygen inhalation.
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2-integrin (CD11b) expression in monocytes and
granulocytes (data not shown). Importantly, granulo-
cytes stimulated with the bacterial oligopeptide fMLP
exhibited markedly reduced shedding of L-selectin
(CD62L) (Fig. 6C and D, P  0.009), indicating resis-
tance to inflammatory stimulation. L-selectin (CD62L)
Figure 2. Time course of relative changes in blood transcriptome in response to sevoflurane inhalation. Significance Analysis
of Microarrays identified a total of 137 transcripts, 74 up-regulated1.35-fold (Panel A) and 63 down-regulated (Panel B), that
were differentially expressed after 1 h of sevoflurane inhalation as compared to baseline. Expression levels are depicted as
color scale from red (high expression) to green (low expression). Each numbered square indicates the expression value of a
transcript (rows) in a specific subject (columns) labeled with V1 to V4 (n  4; please see Supplementary Table S2 available
at www.anesthesia-analgesia.org for more details).
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shedding was maximally inhibited 24 to 48 h after
sevoflurane exposure.
DISCUSSION
The salient findings of the present study are as
follows. First, sevoflurane inhalation, even at low sub-
anesthetic concentrations, rapidly altered the blood tran-
scriptome on a genome-wide scale in healthy subjects, a
prerequisite for late preconditioning, which depends on
de novo protein synthesis. The observed transcriptional
changes specifically involved genes with known biologi-
cal significance in the context of late preconditioning or
organ protection. In accordance with our previous find-
ings in human hearts exposed to sevoflurane (20), genes
involved in fatty acid oxidation, regulated by the
PCG1-pathway, were similarly down-regulated in the
blood. Second, 24 to 48 h after sevoflurane exposure, i.e.,
consistent with the occurrence of a late or second win-
dow of preconditioning, the expression of L-selectin
(CD62L), a key inflammatory adhesion molecule re-
sponsible for the tethering of leukocytes to the endo-
thelium (17), was reduced by approximately 25% on
granulocytes, which further exhibited an increased
resistance to inflammatory stimulation. Taken together,
using blood as a model system and standardized experi-
mental conditions, we provide for the first time molecu-
lar evidence that the anesthetic gas, sevoflurane, can
induce late preconditioning in humans. Clearly, our
Figure 2. (Continued).
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findings should be confirmed in the clinical setting with
patients.
Animal Models of Late Preconditioning by
Volatile Anesthetics
The potential of late preconditioning to provide
enduring protection (lasting 30-fold longer compared
to early preconditioning) is of potential clinical impor-
tance. However, it was elusive whether late precondi-
tioning, i.e., protection developing 24 to 48 h after the
application of the preconditioning stimulus, would
also occur in humans in response to volatile anesthet-
ics. Animal studies indicate that volatile anesthetics
offer protection from ischemia-reperfusion injury in
heart (12) and brain (26) tissue lasting for up to 48 h.
Tonkovic-Capin et al. (13) first reported successful late
preconditioning of the heart in a rabbit model using
isoflurane at 1% end-tidal concentration. Subsequent
studies confirmed these findings in rats (10–12) and
mice (9). Interestingly, emulsified formulations of
volatile anesthetics equivalent to only 0.2 MAC, and
Figure 3. Microarray expression levels of significantly regulated transcripts potentially involved in late preconditioning and
organ protection after sevoflurane inhalation (Panel A–H). Individual q-values, as obtained by Significance Analysis of
Microarrays, are given for each transcript. PON1  paraoxonase 1, 12-LO  12-lipoxygenase, EGR1  early growth response
1, DnaJA4 heat shock protein 40, member A4, NR1D2 nuclear receptor family 1D, member 2, CXCL5 chemokine ligand
5, ACSL3  acyl-CoA synthase, long-chain 3, PDE 5A  phosphodiesterase 5A. Data represent mean  sd (n  4).
Vol. 105, No. 3, September 2007 © 2007 International Anesthesia Research Society 635
with no apparent sedation markedly reduced infarct
size in rabbit hearts when administered IV 24 h before
test ischemia (15). Signaling pathways involved in
volatile anesthetic-induced late preconditioning are
reminiscent of those observed in other types of late
preconditioning (4,5), including reactive oxygen and
nitrogen species as triggers, and 12-lipoxygenase,
cycloxygenase-2, and inducible nitric oxide synthase
(iNOS) as mediators or effectors, and the magnitude of
the afforded protection is similar. In accordance with
these animal studies, the present study now provides,
for the first time, evidence of a late protective pheno-
type after sevoflurane inhalation in humans.
Genetic Reprogramming by Sevoflurane: A Prerequisite
for Late Preconditioning
Late preconditioning directly depends on transient
transcriptional or translational changes (for h), and the
delayed and prolonged protection is consistent with
altered protein expression (for days). To test our
hypothesis, we used the easily accessible blood com-
partment as a human model system, and determined
the time course of transcriptional changes after
sevoflurane inhalation in healthy volunteers. No tran-
scriptional changes were measured after inhalation of
50% oxygen alone. However, genes encoding key
protective proteins were significantly regulated after
sevoflurane inhalation within only a short period,
consistent with results obtained in humans after re-
mote ischemic preconditioning of the limb (27). The
observed changes in gene expression were only tran-
sient. Peak transcriptional changes occurred within 1 h
of sevoflurane inhalation, but most of the changes
disappeared after 24 h. This time course is character-
istic for the transcriptional changes underlying the
second window of protection in the heart. Salloum et
al. reported peak iNOS mRNA expression in mice
already 1–2 h after a single dose of sildenafil, a late
preconditioning-inducing drug (4). Subsequently, the
increase in iNOS mRNA completely vanished, but
changes in cardioprotective iNOS protein expression
were not measured before 24 h after the application of
the triggering drug (4). This contention is consistent
with our findings of an early transient transcriptional
response (within hours) followed by late more persis-
tent changes in protein expression (24–48 h later). Of
note, changes in mRNA and protein expression were
only modest (30%–40% compared to baseline) similar
to our human study, but had marked effects on infarct
size (from 30% to 6% of the area at risk). Interestingly,
12-lipoxygenase, which was recently implicated in de-
layed cardiac protection in mice (9), was upregulated.
Conversely, phosphodiesterase 5A was down-regulated
by sevoflurane. Inhibition of phosphodiesterase 5A by
sildenafil was previously shown to induce late precon-
ditioning in mice through the iNOS pathway (4). Addi-
tional potentially protective transcripts that were
regulated in the blood transcriptome included the
antioxidant paraoxonase (28), heat shock protein 40,
known to prevent cytochrome c release from mito-
chondria, and a number of transcripts with less
well-established function in the context of late pre-
conditioning, such as EGR1, a master switch coordi-
nating upregulation of stress genes, or NR1D2, a nuclear
hormone receptor acting as a link between metabolism
and inflammation (29). Collectively, our data show that
sevoflurane inhalation reprograms blood transcriptome
toward a defensive phenotype in humans.
Sevoflurane-Induced Delayed Protection Against
Leukocyte-Endothelial Activation
Leukocytes have a central role in the pathogenesis
of ischemia-reperfusion damage. In the present study,
we show that inhalation of sevoflurane decreases the
expression of L-selectin (CD62L) in granulocytes and
attenuates their responsiveness to inflammatory stimu-
lation 24 to 48 h after exposure, consistent with a
second window of protection. Extravasation of leuko-
cytes is mediated by adhesion molecules, and exacer-
bates tissue injury after restoration of blood supply to
the site of ischemia (30,31). In the dynamic interaction
between leukocytes and endothelium, the cell surface
receptor L-selectin (CD62L) and its proteolytic shed-
ding mediate the initial steps of leukocyte tethering
Figure 4. The levels of selected transcripts
(paraoxonase 1, PON1; 12-lipoxygenase
pseudogene, 12-LO; acyl-CoA synthase,
long-chain 3, ACSL3) before and after
inhalation of 50% O2 for 1 h (for primers,
please see Supplementary Table S1 avail-
able at www.anesthesia-analgesia.org).
Data represent mean  sd (n  4).
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and rolling, while 2-integrin (CD11b) facilitates sub-
sequent firm adhesion and transmigration (17).
L-selectin (CD62L) is constitutively expressed on the
surface of leukocytes. Inflammatory stimulation via
G-protein coupled receptors, as mimicked in our
study by the chemoattractant fMLP, rapidly activates
L-selectin (CD62L) by phosphorylation and subsequent
cleavage of its ectodomain, increasing the binding
Figure 5. Results from Gene Set Enrichment Analysis (GSEA). Panel A: Down-regulation of peroxisome proliferator activated
receptor  coactivator-1 (PGC-1) pathway activity. Panel B: Down-regulation of fatty acid oxidation (FAO) pathway. Panel
C: Strong correlation in expression of the PGC-1 genes and genes involved in FAO. The gene expression levels of the 25
significantly enriched PGC-1 probes and the 28 significantly enriched FAO probes were standardized to a mean of 0 and a
variance of 1 across the 8 microarrays. The mean centroid vector is the mean of these 25 and 28 expression vectors,
respectively. Expression levels are depicted as color scale from red (high expression) to green (low expression). Numbers
(V1–V4; n  4) identify individual subjects.
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activity to the endothelium (17). Thus, our findings
suggest that sevoflurane induces a resistance of leu-
kocytes against noxious stimulation. Blockade of
selectin-mediated leukocyte adhesion improves post-
ischemic function in the heart (32), while genetically
engineered mutations that prevent shedding of cell
surface receptors markedly diminish the deleterious
inflammatory response (33). In contrast to remote
ischemic preconditioning of the limb, in our study
small-dose sevoflurane did not decrease 2-integrin
(CD11b) expression or its shedding in response to the
chemoattractant fMLP. This is in agreement with
previous in vitro experiments showing that 0.5 MAC
isoflurane inhibited shedding of L-selectin (CD62L),
but not 2-integrin (CD11b), in response to chemoat-
tractants, whereas 1 MAC isoflurane affected both
adhesion molecules (34). Although L-selectin (CD62L)
was not among the differentially regulated transcripts
in our human experiments, calmodulin, a calcium regu-
latory protein, which co-precipitates with L-selectin
(CD62L) and tightly regulates its surface expression
and function (35), was markedly down-regulated after
sevoflurane inhalation (Fig. 5). This notion raises the
interesting possibility that delayed alterations in
L-selectin (CD62L) expression and function might be
indirectly caused by reduced calmodulin expression.
It has been traditionally thought that the biological
effects of fast-acting anesthetic gases with low blood-
gas solubility dissipate rapidly after exhalation. In
contrast to this belief, our study clearly demonstrates
that these gases continue to exert their potentially
protective actions long after their physical clearance
from the human body, consistent with published
results in patients undergoing coronary artery bypass
grafting surgery (36).
Gene Regulatory Control of Energy Metabolism in the
Blood Mirrors Conditions in the Heart
We have recently shown that IV and volatile anes-
thetics differentially regulate the transcriptional re-
sponse to cardiac surgery in human hearts (20). In
particular, sevoflurane shifted the metabolic fuel pref-
erence away from fatty acid oxidation, which closely
Figure 6. Expression of L-selectin (CD62L) in granulocytes (CD14 cells) (Panel A; PANOVA  0.004), and monocytes (CD15
cells) (Panel B; #P  0.024, paired t-test, comparison baseline versus 24h). Activation and shedding of granulocytes (Panel C;
PANOVA  0.009), and monocytes (Panel D; not significant) in response to N-formyl-methionyl-leucyl-phenylalanin (fMLP)
stimulation. *P  0.05 compared with baseline (Student-Newman-Keuls post hoc test). MIF  mean fluorescence intensity.
Data represent mean  sd (n  5).
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correlated with improved postoperative cardiac func-
tion. Myocardial substrate metabolism critically af-
fects cardiac function (37), and switching metabolic
fuel preference away from fatty acid oxidation im-
proves recovery after ischemia and even affects long-
term outcome (38). The present study confirms similar
metabolic changes in the blood after subanesthetic
sevoflurane inhalation, and further suggests that the
transcriptional changes in fatty acid oxidation may be
due to down-regulation of the PGC-1 pathway. This
nuclear receptor coactivator critically controls cellular
energy metabolism, and thus determines oxygen con-
sumption (39). Moreover, inhibition of the PGC-1
pathway was recently shown to reduce uptake of
oxidized low-density lipoprotein into macrophages
and to prevent their retention in atherosclerotic vessel
walls, thereby stabilizing vulnerable plaques (40).
Hence, modulation of the PGC-1 pathway, as ob-
served after sevoflurane administration, may be a
novel antiischemic and plaque-stabilizing strategy in
perioperative medicine.
Limitations
The sample size of this study is small. However, a
highly standardized protocol was used in healthy
volunteers to overcome confounding variables. In this
study, we used ranitidine to protect the participants
from the potential hazard of pulmonary aspiration,
and some previous reports suggest a role of histamine
receptors in modifying expression of adhesion mol-
ecules (41,42). However, there was no transcriptional
regulation in our control experiments after inhalation
of 50% oxygen and administration of ranitidine alone.
Also, changes in L-selectin expression exhibited the
maximum at 24–48 h after sevoflurane inhalation. At
this time, a single dose of ranitidine is cleared from the
body, making a relevant effect on adhesion molecules
unlikely. Moreover, the H2 receptor antagonist, rani-
tidine, did not affect histamine-induced expression
of adherence molecules (42), nor did it prevent
histamine-induced leukocyte rolling (41). Future stud-
ies should help to precisely delineate the underlying
signaling components. Whether the detected molecu-
lar evidence of late preconditioning by sevoflurane
successfully translates into clinical benefits requires
additional randomized controlled trials.
CONCLUSIONS
This study provides molecular evidence of late pre-
conditioning after sevoflurane inhalation in healthy vol-
unteers. Because the late phase lasts significantly longer
than the early phase, its protective potential merits
further investigation in the clinical arena.
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Gene Regulatory Control of Myocardial Energy Metabolism
Predicts Postoperative Cardiac Function in Patients
Undergoing Off-pump Coronary Artery Bypass Graft
Surgery
Inhalational versus Intravenous Anesthetics
Eliana Lucchinetti, Ph.D.,* Christoph Hofer, M.D.,† Lukas Bestmann, Ph.D.,‡ Martin Hersberger, Ph.D.,§
Jianhua Feng, M.D., Ph.D.,* Min Zhu, M.S., Lukas Furrer, M.D.,# Marcus C. Schaub, M.D., Ph.D.,**
Reza Tavakoli, M.D., Ph.D.,†† Michele Genoni, M.D.,‡‡ Andreas Zollinger, M.D.,§§ Michael Zaugg, M.D.
Background: Anesthetic gases modulate gene expression and
provide organ protection. This study aimed at identifying myo-
cardial transcriptional phenotypes to predict cardiovascular
biomarkers and function in patients undergoing off-pump cor-
onary artery bypass graft surgery.
Methods: In a prospective randomized trial, patients undergo-
ing elective off-pump coronary artery bypass graft surgery were
allocated to receive either the anesthetic gas sevoflurane (n  10)
or the intravenous anesthetic propofol (n  10). Blood samples
were collected perioperatively to determine cardiac troponin T,
N-terminal pro–brain natriuretic peptide, and pregnancy-associ-
ated plasma protein A. Cardiac function was measured with trans-
esophageal echocardiography and pulmonary artery thermodilu-
tion. Atrial biopsies were collected at the beginning and end of
bypass surgery to determine gene expression profiles.
Results: N-terminal pro–brain natriuretic peptide and preg-
nancy-associated plasma protein A blood levels were decreased
with sevoflurane treatment. Echocardiography showed pre-
served postoperative cardiac function in sevoflurane patients,
which paralleled higher cardiac index measurements. N-termi-
nal pro–brain natriuretic peptide release was predicted by
sevoflurane-induced transcriptional reduction in fatty acid ox-
idation, whereas changes in cardiac index were predicted by
preoperative gene activity of the peroxisome proliferator–acti-
vated receptor  coactivator-1 pathway. Sevoflurane-mediated
attenuation of transcripts involved in DNA-damage signaling
and activation of the granulocyte colony-stimulating factor sur-
vival pathway predicted improved postoperative cardiac index
and diastolic heart function, respectively.
Conclusions: Anesthetic-induced and constitutive gene regu-
latory control of myocardial substrate metabolism predicts
postoperative cardiac function in patients undergoing off-pump
coronary artery bypass graft surgery. The authors’ analysis
further points to novel cardiac survival pathways as potential
therapeutic targets in perioperative cardioprotection.
OFF-PUMP coronary artery bypass graft (CABG) surgery
emerged in recent years as a means to avoid the sequelae
of extracorporeal circulation such as whole-body inflam-
matory response, coagulation disorders, and multiple
organ dysfunction. However, this less invasive surgical
technique still involves manipulation of the heart and
coronaries and apparently does not eliminate irrevers-
ible myocardial injury.1 The release of some cytokines is
observed in off-pump CABG surgery to a similar degree
as with cardiopulmonary bypass, although with delayed
kinetics.2 Therefore, improving the perioperative man-
agement by decreasing myocardial ischemia–reperfusion
damage remains of paramount importance and would
affect outcome.
Experimental work and recent data from clinical trials
provide strong evidence that modern ether-derived ha-
logenated anesthetic gases elicit pronounced protection
against myocardial ischemia.3 In contrast to intravenous
anesthetics such as propofol, anesthetic gases exert a
multitude of protective effects including pharmacologic
preconditioning and postconditioning, two of the most
powerful treatments to reduce infarct size and improv-
ing postischemic recovery.4 In a double-blinded placebo-
controlled study, brief administration of sevoflurane on
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the cardiopulmonary bypass immediately before induc-
tion of cardioplegia improved postoperative cardiac
function5 as well as long-term cardiovascular outcome in
patients undergoing CABG surgery.6 Moreover, adminis-
tration of anesthetic gases throughout CABG surgery
decreased perioperative troponin I release and the dura-
tion of intensive care unit and hospital stay.7
Using a genome-wide approach, we previously re-
ported that distinct genetic programs are activated by
anesthetic gases in isolated rat hearts, which attenuate
the adverse consequences of prolonged ischemia.4,8 This
notion is consistent with the concept that anesthetic
gases elicit a “second window of protection,”9,10 which
directly depends on altered gene expression.3 Prelimi-
nary results from atrial biopsies suggest that similar
genomic reprogramming may occur in patients.6 To
date, no direct comparisons between intravenous anes-
thetics and anesthetic gases have been performed in
human hearts at the gene expression level. In accor-
dance with the reported differences in cardioprotection
between various anesthetics, we hypothesized that
sevoflurane and propofol would elicit differential
genomic responses to cardiac surgery in human hearts.
Transcriptional changes were correlated to clinically im-
portant cardiovascular biomarkers and to physiologic
parameters of cardiac function.
Materials and Methods
The institutional ethics committee of the University
Hospital Zurich (Zurich, Switzerland) and the Triemli
Hospital (Zurich, Switzerland) approved the study, and
written informed consent was obtained from all patients.
Twenty patients scheduled to undergo elective off-pump
CABG surgery were enrolled between January and June
2005.
Study Criteria
Inclusion criteria were being scheduled for elective
off-pump CABG surgery, three-vessel coronary artery dis-
ease, male sex, and age of 50–80 yr. Exclusion criteria
were diabetes mellitus, concomitant noncardiac surgery,
myocardial infarction less than 2 months before CABG
surgery, elevated plasma concentrations for cardiac en-
zymes within 24 h before surgery, unstable angina, left
ventricular ejection fraction less than 40%, hemody-
namic instability with the need for medical or mechani-
cal inotropic support, serum creatinine greater than 150
M, and administration of corticosteroids or precondi-
tioning-mimicking/blocking agents such as diazoxide,
nicorandil, theophylline, and sulfonylurea drugs, respec-
tively.
Study Protocol
The patients were randomly allocated to the sevoflu-
rane (Sevorane; Abbott, Baar, Switzerland) or the propo-
fol (Diprivan 2%; AstraZeneca, Zug, Switzerland) group
(fig. 1). Fentanyl, midazolam, and rocuronium or pancu-
ronium were administered before intubation. Anesthesia
was maintained with midazolam, fentanyl, and remifen-
tanil in all patients until the first atrial biopsy was taken
(baseline biopsy at T1). Subsequently, anesthesia was
maintained with the anesthetic gas sevoflurane or the
intravenous anesthetic propofol until the second atrial
biopsy was collected shortly before chest closing (bi-
opsy at T2). Sevoflurane and propofol were adjusted to
maintain blood pressure and heart rate within 20% of
baseline values. During surgical manipulations on the
heart, conversion to cardiopulmonary bypass was con-
sidered if one of the following criteria was present for at
least 15 min: (1) cardiac index less than 1.5 l · min1 ·
m2, (2) mixed central venous saturation less than 60%,
(3) mean arterial pressure less than 50 mmHg, (4) ST-
Fig. 1. Study protocol. CABG  coro-
nary artery bypass grafting; cTnT 
cardiac troponin T; ICU  intensive
care unit; NT-proBNP  N-terminal
pro brain natriuretic peptide; PAPP-A
 pregnancy-associated plasma pro-
tein A.
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segment alterations indicative of new myocardial isch-
emia, or (5) severe arrhythmias. After completion of
bypass grafting, remifentanil infusion and repetitive
doses of midazolam were used in both groups for seda-
tion until extubation in the intensive care unit. Standard
transesophageal echocardiography, tissue Doppler imag-
ing, and hemodynamic measurements using pulmonary
artery thermodilution were obtained (fig. 1). Patients
from both groups received the same postoperative care.
Cardiac Surgery and Assessment of Myocardial
Function
Median sternotomy and pericardiotomy were per-
formed, and the first sample of the right atrium was
immediately collected before preparing the grafts. Dur-
ing the surgical manipulation of the heart, hemodynamic
stability was achieved by repeated doses of norepineph-
rine, nitroglycerin, positioning of the operating table,
and sequential epicardial stimulation of the heart at a
rate of 90 beats/min. After securing the operating field
with the aid of a stabilizer (Octopus; Medtronic, Minne-
apolis, MN), the coronary artery was opened and an
intracoronary shunt, which was withdrawn at the end of
suturing, was introduced to preserve distal perfusion.
The left mammary artery was used to revascularize the
left anterior coronary artery. Venous grafts were used for
the inferior myocardial wall, and the right internal mam-
mary artery was used for the circumflex branches either
through the transverse sinus behind the aorta and con-
nected in situ to the circumflex branch, or, if too short,
used as a T-graft from the left internal mammary artery.
Proximal anastomoses were performed using the heart
string device (Guidant, Indianapolis, IN). The quality of
all bypasses was controlled by flow measurement (Me-
distim, Oslo, Norway).
Echocardiographic measurements were obtained be-
fore surgery and after completion of coronary bypass
grafting. Standard transesophageal echocardiography
and tissue Doppler imaging using a Philips SONOS
5500 system with an Omniplane III-TOE probe (Phil-
ips Medical Systems, Andover, MA) were performed
by a single experienced examiner. The echocardio-
grams were stored digitally and analyzed post hoc
without knowing the clinical data or group assign-
ment. Left ventricular end-diastolic area and left ven-
tricular end-systolic area were measured by manual
planimetry of the area circumscribed by the leading
edge of the endocardial border in the left ventricular
transgastric midpapillary short axis view. Left ventric-
ular end-diastolic area was determined as the largest
left ventricular cross-sectional area after the R wave,
and left ventricular systolic area was determined as the
smallest left ventricular cross-sectional area after the T
wave. Left ventricular fractional area change (percent)
was calculated as 100  (left ventricular end-diastolic
area  left ventricular systolic area)/left ventricular
end-diastolic area. Pulsed wave Doppler measure-
ments of transmitral blood flow were obtained with
the probe in the midesophageal four-chamber view
after placing the sample volume between the tips of
the mitral leaflets. Peak early mitral inflow velocity (E
wave), deceleration time, peak atrial filling velocity (A
wave), and E/A ratio were also measured. Assessment
of color M-mode flow propagation was performed
with the M-mode cursor aligned parallel to the left
ventricular inflow. Main aliased velocity was deter-
mined after adjustment to obtain the longest flow
column. Tissue Doppler imaging was also obtained
from the midesophageal four-chamber view to quan-
tify regional myocardial contractility. Myocardial ve-
locities of the left ventricular septum, the lateral wall,
and the mitral annulus were measured. Early systolic,
early diastolic, and late diastolic peak velocities were
determined using QLAB advanced quantification soft-
ware version 2.0 (Philips Ultrasound, Bothell, WA). All
echocardiographic measurements were recorded as
the mean of three consecutive cardiac cycles. Con-
comitant hemodynamic measurements were obtained
before surgery, after completion of coronary bypass
grafting, 4 h after arrival in the intensive care unit, and
at discharge from the intensive care unit using pulmo-
nary artery thermodilution as the mean of three con-
secutive ice-water bolus injections.
Diagnosis of Adverse Events
Medical charts were reviewed, and the caregivers were
interviewed daily for the occurrence of adverse events.
Adverse events (as opposed to myocardial and renal
injury markers determined at the end of the study) were
diagnosed by the independently managing clinicians.
Twelve-lead electrocardiograms were obtained postop-
eratively every day. The diagnosis of a new postoperative
myocardial infarct required a new Q wave, persistent
ST-T-segment changes as defined by Minnesota Codes,11
and/or cardiac troponin T (cTnT) greater than 2.0 g/l.
The diagnosis of a cerebrovascular injury required the
presence of clinical symptoms and/or positive comput-
er-assisted tomography scan. The diagnosis of significant
postoperative renal dysfunction required newly estab-
lished postoperative hemodialysis or hemofiltration.
Determination of Cardiovascular Biomarkers
Blood samples were obtained preoperatively, at arrival
in the intensive care unit, and 24, 48, and 72 h after
surgery and were used to determine cTnT and N-termi-
nal pro brain natriuretic peptide (NT-proBNP) plasma
levels. Pregnancy-associated plasma protein A (PAPP-A)
and cystatin C plasma levels were only determined pre-
operatively and after 72 h after surgery. The collected
blood samples were stored at 80°C until analysis. The
following parameters were determined using the Roche
Modular Analytics P or the Roche Modular Analytics
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E170 (Roche Diagnostics, Mannheim, Germany): NT-
proBNP (electrochemiluminescence sandwich immuno-
assay)—sensitivity greater than 5 ng/l, intraassay and
interassay coefficients of variance less than 3%, normal
value (97.5th percentile for men aged  50 yr) less than
334 ng/l; cTnT (electrochemiluminescence sandwich
immunoassay)—sensitivity greater than 0.01 g/l, in-
traassay and interassay coefficients of variance greater
than 2.5%, normal value less than 0.01 g/l. PAPP-A
assays were purchased from Brahms, Henningsdorf, Ger-
many (immunometric assay based on time resolved am-
plification cryptate emission)—sensitivity 0.004 U/l, in-
traassay and interassay coefficients of variance less than
2%, normal range (healthy male) less than 0.01 U/l.
Cystatin C assays were purchased from Dako A/S, Gold-
strup, Denmark (particle-enhanced turbidimetric as-
say)—sensitivity greater than 0.2 mg/dl, intraassay and
interassay coefficients of variance less than 3.5%, normal
range 0.63–1.61 mg/l.
Genomic Analysis of Human Atrial Samples
Microarray analysis was performed following the
“minimum information about a microarray experi-
ment” (MIAME) guidelines.12 Total RNA was prepared
from the frozen cardiac tissue using RNeasy Mini Kit
(Qiagen AG, Basel, Switzerland). The quality of the
isolated RNA was determined with a NanoDrop ND
1000 (NanoDrop Technologies, Wilmington, DE; 260
nm/280 nm ratio between 1.8 and 2.1 and 28S/18S
ratio within 1.5–2). Total RNA samples (100 ng) were
reverse-transcribed into double-stranded complemen-
tary DNA (cDNA) with a Two-Cycle cDNA Synthesis
Kit (Affymetrix Inc., Santa Clara, CA). The double-
stranded cDNA was purified using a Sample Cleanup
Module (Affymetrix Inc.). The purified double-
stranded cDNA were in vitro transcribed in the pres-
ence of biotin-labeled nucleotides using an IVT Label-
ing Kit (Affymetrix Inc.). The biotinylated
complementary RNA (cRNA) was purified using a Sam-
ple Cleanup Module (Affymetrix Inc.), and its quality
and quantity was determined using NanoDrop ND
1000 and Bioanalyzer 2100. Biotin-labeled cRNA sam-
ples (15 g) were fragmented randomly to 35–200 bp
at 94°C in Fragmentation Buffer (Affymetrix Inc.) and
were mixed in 300 l hybridization buffer containing
a hybridization Control cRNA and Control Oligo B2
(Affymetrix Inc.), 0.1 mg/ml herring sperm DNA, and
0.5 mg/ml acetylated bovine serum albumin in 2-(4-
morpholino)-ethane sulfonic acid (MES) buffer at pH
6.7. Each sample (for a total of 40 samples) was hy-
bridized to an individual Affymetrix GeneChip Human
Genome U_133 Plus 2.0 arrays for 16 h at 45°C (Af-
fymetrix Inc.). Arrays were washed using an Af-
fymetrix Fluidics Station 450 EukGE-WS2v5_450 pro-
tocol and scanned using an Affymetrix GeneChip
Scanner 3000 (Affymetrix Inc.) at a resolution of 3
m. Raw data processing was performed using the
Affymetrix GCOS 1.2 software (Affymetrix Inc.), and
all arrays were subjected to quality control according
to the parameters established by Affymetrix, such as
the assessment of average background and noise
value, exogenously added prokaryotic hybridization
controls, percent present calls, scaling factors, and
internal control genes. Normalization and computa-
tion of expression values were performed using the
robust multichip average method.13 The microarray
data are available at the Gene Expression Omnibus
Database## under the series number GSE4386. For
each patient, two atrial samples were collected and
used for hybridization. No samples were pooled, i.e.,
40 samples corresponding to 40 chips were used in
the final analysis. The global gene expression matrix
containing the expression values of the 54,675 probe
sets for all 40 cardiac samples was used as input for
Gene Set Enrichment Analysis (GSEA).14 GSEA consid-
ers predefined gene sets representing pathways of
interest and determines whether the members of
these sets are overrepresented in a list of genes that
has been ordered by their correlations with a specific
phenotype or class distinction. The output is a nor-
malized enrichment score that represents a measure of
the degree of enrichment of the gene set at the top
(highly correlated) or bottom (highly inversely corre-
lated) of the ordered gene list. The normalized enrich-
ment score is used to produce a P value that measures
the significance of the score itself. The gene sets used
for the current analysis (a total of 547) were obtained
from the GSEA home page*** or were manually cu-
rated. Additional information regarding this is avail-
able on the ANESTHESIOLOGY Web site at http://
www.anesthesiology.org.
In a first analysis, the “GSEA phenotypes” were defined
as follows: SEVO (t  T1), samples collected in the
sevoflurane group at time T1; SEVO (t  T2), samples
collected in the sevoflurane group at time T2; PROP (t
T1) and PROP (t  T2), samples collected in the propo-
fol group at times T1 and T2, respectively. To define a
standardized measure of gene expression (the mean cen-
troid), we normalized the gene expression levels of the
enriched genes within a pathway to a mean of 0 and a
variance of 1 across all 40 samples. The mean centroid
vector of a given pathway is computed as the mean of
the normalized expression vectors of each gene in the
pathway. A second GSEA analysis was performed using
the computed fold changes from T1 to T2 for all Af-
fymetrix probe sets. In this case, two phenotypes (SEVO
and PROP) were defined.
## GEO database. Available at: http://www.ncbi.nlm.nih.gov/geo/. Accessed
March 8, 2006.
*** Available at: http:// www.broad.mit.edu/GSEA. Accessed October 30,
2005.
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Validation of Chip Data Using Real-time Reverse-
transcriptase Polymerase Chain Reaction
As an independent method of measuring levels of
gene expression, real-time reverse-transcriptase poly-
merase chain reaction was performed for eight se-
lected genes to confirm microarray data (table S1 on
the ANESTHESIOLOGY Web site). For this purpose, ran-
domly chosen transcripts with a wide range of fold
changes (0.12– 8.0), as obtained by gene chip analysis,
were selected. First-strand cDNA was synthesized
from 1 g total RNA using Superscript II reverse
transcriptase (Invitrogen, Basel, Switzerland) and
oligo-dT as primer. Real-time reverse-transcriptase
polymerase chain reaction quantification of the se-
lected genes was performed on a Stratagene MX3000
real-time sequence detector instrument (Stratagene
Europe, Amsterdam, The Netherlands) using the Bril-
liant SYBR green QPCR Master Mix (Stratagene Eu-
rope). Amplification reactions were conducted with
an initial step at 90°C for 3 min followed by 20 –35
cycles. Samples were run in triplicates, and ribosomal
18S (a constitutively expressed gene) was used as
reference control. Predicted size of amplified prod-
ucts was confirmed by agarose gel electrophoresis.
Statistical Analysis
Sample size was calculated based on the results for
NT-proBNP reported previously.5 For biochemical and
physiologic parameters, two-way analysis of variance
for repeated measures followed by appropriate multi-
ple comparison procedures (Bonferroni t test) was
used to evaluate differences over time between
groups. An unpaired t test was used to compare
groups at identical time points, and a paired t test was
used to compare within groups over time. All other
data were analyzed using unpaired t tests for paramet-
ric data or Mann–Whitney tests for nonparametric
data. Categorical variables were summarized by pro-
portions and compared using the Fisher exact test or
the chi-square test, if appropriate. P values were mul-
tiplied by the number of comparisons that were made
(Bonferroni correction), and corrected P  0.05 was
considered significant. Data are given as mean  SD or
median and quartiles, if appropriate. Forward step-
wise linear regression (with F-to-Enter  4.000 and
F-to-Remove  3.996) was applied using functional/
biochemical outcome variables as dependent variables
and gene expression measures (mean centroids or fold
changes) and clinical data as the independent vari-
ables. Adjusted squared correlation coefficients (R2adj)
were reported. Analyses were performed using Sig-
maStat Version 2 (SPSS Science, Chicago, IL) and Stat-
View version 5 (SAS Institute, Chicago, IL).
Results
Demographics, Perioperative Data, and Clinical
Outcome
Patient characteristics and perioperative data are listed in
table 1. The sevoflurane and propofol groups were similar
with regard to all preoperative data including medical ther-
apy and comorbidity. Intraoperative data were comparable
between groups except for the longer anesthesia and sur-
gery time and the smaller amount of administered remifen-
tanil in the sevoflurane group. The cumulative doses of
norepinephrine and nitroglycerin used to stabilize hemo-
dynamics during the surgical manipulations were similar in
both groups (table 1). None of the patients required con-
version to cardiopulmonary bypass or had postoperative
myocardial infarction, cerebrovascular injury, or renal dam-
age. No postoperative mechanical or medical inotropic
support was needed.
Biomarkers for Contractile Dysfunction (NT-
proBNP) and Coronary Plaque Instability (PAPP-A)
Indicate Superior Protection by Sevoflurane
Sevoflurane markedly reduced postoperative NT-
proBNP release (fig. 2A). Mean peak postoperative NT-
proBNP was 3,442  1,458 ng/l in propofol patients
compared with 1,392  881 ng/l in sevoflurane patients
(P  0.0013). In contrast, no difference was observed in
postoperative cTnT release (fig. 2B). However, two
propofol patients but none of the sevoflurane patients
had a peak postoperative cTnT concentration greater
than 0.65 g/l, indicative of major perioperative myocar-
dial damage. None of the patients experienced postop-
erative deterioration of renal function (postoperative
cystatin C plasma concentrations in sevoflurane patients:
0.63 0.16 mg/l vs. propofol patients: 0.64 0.18 mg/l;
P  0.55; fig. 2C). Preoperative baseline PAPP-A plasma
concentrations were increased in all patients indicating
an active inflammatory process in atherosclerotic
plaques. Sevoflurane but not propofol abolished the
postoperative PAPP-A elevation (mean change in
PAPP-A: 1.10  1.10 mU/l in sevoflurane patients vs.
6  1.05 mU/l in propofol patients; P  0.001; fig.
2D).
Transesophageal Echocardiography and
Hemodynamic Measurements Show Improved
Postoperative Myocardial Function after
Sevoflurane Anesthesia
Sevoflurane but not propofol preserved inotropy (pre-
dominantly lateral wall) and early diastolic lusitropic
function (annulus and septum) after CABG surgery (table
2) and thereby successfully maintained global early post-
operative cardiac function as determined by cardiac in-
dex measurements (table 3). Sevoflurane patients, as
opposed to propofol patients, also exhibited increased
postoperative ejection fractions compared with preop-
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erative values (table 2). Late postoperative hemody-
namic measurements obtained in the intensive care unit
showed an increase in postoperative cardiac index com-
pared with preoperative measurements in both sevoflu-
rane and propofol patients. However, this increase was
more pronounced in sevoflurane patients and further
accompanied with a reduced systemic vascular resis-
tance (table 3).
Gene Expression Profiling Shows Pronounced
Responses to Off-pump CABG Surgery and Unveils
Subtle Differences in Background Energy
Metabolism among Patients
For each patient, two atrial samples were collected, the
first sample immediately after chest opening (110 45 min
after induction of anesthesia; T1) and the second sample
shortly before chest closing (180  40 min after obtaining
Table 1. Patient Characteristics and Perioperative Data
Propofol Group (n  10) Sevoflurane Group (n  10)
Age, yr 66.9  7.3 65.2  7.6
Euroscore 2.9  1.5 3.0  2.4
Parsonnet score 4.9  5.0 4.0  4.4
Preoperative ejection fraction, % 66  10 (45–75) 60  13 (42–76)
Previous myocardial infarction, No. of patients 2 2
Preoperative medication, No. of patients
 Blocker 10 9
Ca2 blocker 3 5
Nitrates 4 5
ACEI 2 3
ATA 4 4
Statins 6 5
Diuretics 6 7
No. of grafts 3.4  0.8 (2–5) 3.9  0.7 (3–5)
Anesthetic drugs
Propofol, mg* 1,128  364 —
Sevoflurane, vol% end-tidal — 1.9  0.5 (0.6–2.5)
Midazolam, mg 22.4  6.3 24.5  6.1
Fentanyl, mg 1.4  0.4 1.2  0.4
Remifentanil, mg 4.4  1.5 2.6  0.7‡
Vasoactive drugs
Norepinephrine, g 661  936 (0–3,400) 662  881 (0–2,510)
Nitroglycerin, mg 4.84  3.41 (0.6–10) 5.45  2.63 (0.7–8.6)
Volume replacement, ml† 4,272  1,887 (1,830–6,677) 5,090  1,540 (3,430–8,400)
Surgery time, min 222  37 266  44‡
Anesthesia time, min 295  46 352  52‡
Elapsed time between first and second atrial biopsy, min 203  39 174  37
Data are mean  SD (range), if not otherwise indicated.
* Propofol infusion rate during maintenance of anesthesia: 0.5–2.5 mg  kg1  min1. † Total intraoperatively replaced volume (blood products, colloids, and
crystalloids). ‡ P  0.05 compared with propofol.
ACEI  angiotensin-converting enzyme inhibitor; ATA  angiotensin II antagonist.
Fig. 2. Cardiovascular biomarkers. Peri-
operative levels of N-terminal pro brain
natriuretic peptide (NT-proBNP) were
significantly (time effect P < 0.001; treat-
ment effect P  0.002) more elevated in
the propofol (PROP) group as compared
with the sevoflurane (SEVO) group (A).
No difference between groups was found
in cardiac troponin T (cTnT) (B) and in
cystatin C (C), whereas pregnancy-associ-
ated plasma protein A (PAPP-A) was ex-
clusively increased (time effect P< 0.001;
treatment effect P  0.02) postopera-
tively in the PROP group (D). * Signifi-
cantly increased compared with baseline
values (P < 0.05; multiple comparison
procedure, Bonferroni-corrected t test).
 Significantly different between groups
(P < 0.05; multiple comparison proce-
dure, Bonferroni-corrected t test). Data
are mean  SD in A and B, and medians
and 25th and 75th percentile in C and D.
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the first sample; T2). Sample T1 reflects the background
gene expression profile before exposure to sevoflurane or
propofol (constitutive background activity), whereas sam-
ple T2 mirrors the gene responses to surgery in the two
anesthetic groups. The existence and direction of gene
expression changes were reliably detected by the microar-
ray technology, as confirmed by real-time quantitative poly-
merase chain reaction (tables S1 and S2 on the ANESTHESIOL-
OGY Web site). As a first step, the single genes, which were
differentially regulated over time (T1–T2) between the two
anesthetic groups, were determined (see fig. S1, showing
the 50 top-ranked up- and down-regulated genes, on the
ANESTHESIOLOGY Web site). Off-pump CABG surgery induced
pronounced changes in genes involved in transcriptional
regulation and proinflammatory and antiinflammatory ac-
tions. Next, the comparison of the differentially and jointly
regulated pathways over time (T1–T2) in sevoflurane- and
propofol-treated patients showed a similar number of en-
riched pathways in propofol and sevoflurane patients (fig.
3A and table 4). At T1, GSEA further detected subtle differ-
ences (approximately 15%) in activity of genes involved in
the peroxisome proliferator–activated receptor  coactiva-
tor 1 (PGC-1) pathway among patients (normalized en-
richment score  1.37; nominal P value  0.04, false
discovery rate q value  0.26; fig. 3B). As expected, the
PGC-1 pathway correlated with genes involved in oxida-
tive phosphorylation (R2adj  0.71, P 0.00001) and fatty
acid metabolism (uptake and oxidation) (R2adj 0.70, P
Table 2. Echocardiographic Parameters
Before CABG After CABG
Propofol Sevoflurane Propofol Sevoflurane
LV-ESA, cm2 9.2  3.2 9.6  2.3 7.9  3.4 8.2  3.2
LV-EDA, cm2 18.3  3.4 18.4  3.2 16.9  4.8 18.8  6.0
LV-FAC, % 50  10 50  10 51  9 56  10*
Diastolic inflow
E wave, cm/s 62.3  15.2 54.5  16.2 52.1  24.3 50.9  15.2
A wave, cm/s 46.7  20.3 45.3  23.4 40.9  19.1 45.1  15.6
E/A ratio 1.6  0.9 1.5  0.9 1.7  1.4 1.3  0.5
Peak mitral annulus velocity
Systolic, cm/s 3.8  1.3 3.2  1.0 2.9  1.1 4.2  1.5*
Early diastolic, cm/s 3.7  2.3 3.6  2.2 2.1  1.4* 3.9  1.6†
Late diastolic, cm/s 4.2  2.4 3.5  1.5 3.8  1.4 4.4  1.4*
Myocardial velocity septal
Systolic, cm/s 2.1  0.8 2.0  1.2 2.1  0.9 3.1  1.8*
Early diastolic, cm/s 2.7  1.0 2.3  0.8 1.7  0.5* 2.9  1.3†
Late diastolic, cm/s 2.4  1.1 2.0  1.1 2.5  1.2 2.3  1.4
Myocardial velocity lateral
Systolic, cm/s 2.4  1.1 2.3  1.2 1.5  0.5 2.5  0.8†
Early diastolic, cm/s 2.3  1.7 2.4  0.6 1.2  0.6* 2.6  0.9†
Late diastolic, cm/s 2.2  1.2 2.1  1.0 1.5  0.7 1.8  1.0
Data are mean  SD.
* P  0.05 with values before coronary artery bypass grafting (CABG). † P  0.05 compared with propofol.
A wave  peak late mitral inflow velocity; E wave  peak early mitral inflow velocity; EDA  end-diastolic area; ESA  end-systolic area; FAC  fractional area
change; LV  left ventricular.
Table 3. Hemodynamic Data
Before CABG After CABG ICU ICU Discharge
Propofol Sevoflurane Propofol Sevoflurane Propofol Sevoflurane Propofol Sevoflurane
HR, beats/min 57  9 54  6 89  11* 84  7* 91  14* 86  11* 86  11* 82  7*
MAP, mmHg 81  11 82  8 70  24 73  8 76  7 74  8 78  6 77  10
MPAP, mmHg 19  7 24  20 20  7 22  4 22  5 22  6 18  4 17  4
CVP, mmHg 8  6 8  5 8  5 11  4 6  2 9  3 5  2 7  4
PCWP, mmHg 10  5 11  3 10  5 11  4 8  4 9  2 8  4 9  3
CI, l  min1  m2 3.4  0.6 3.5  0.9 2.9  0.5* 3.8  1.1† 3.9  0.7‡ 5.0  1.0*†‡ 3.7  0.9‡ 4.7  0.7*†‡
SVR, dyn  s  cm5 919  249 928  296 985  237 702  171*† 745  99 558  94*† 846  179 627  174*†
PVR, dyn  s  cm5 116  58 168  222 150  73 120  39 145  67 109  38 134  94 65  39
Data are mean  SD.
* P  0.05 compared with values before coronary artery bypass grafting (CABG). † P  0.05 compared with propofol. ‡ P  0.05 compared with values after
CABG.
CI  cardiac index; CVP  central venous pressure; HR  heart rate (hearts were paced at 90 beats/min during CABG and the early postoperative period); ICU
 intensive care unit; MAP  mean arterial pressure; MPAP  mean pulmonary arterial pressure; PCWP  pulmonary capillary wedge pressure; PVR 
pulmonary vascular resistance; SVR  systemic vascular resistance.
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0.00001) (fig. 3C) and hence was subsequently used in the
multivariate analysis as an indicator of the myocardial back-
ground energy metabolism (fig. S2 on the ANESTHESIOLOGY
Web site).
Sevoflurane Favorably Modifies the Transcriptional
Responses to Off-pump CABG Surgery
In accordance with the study protocol, short-term
changes in gene expression between T1 and T2 should be
due to the different anesthetics used. To specifically deter-
mine the genomic effects of the anesthetics and to correct
for the differences in baseline transcriptional activity, GSEA
was applied to fold changes in gene expression between
T1 and T2. From this analysis, three major pathways
emerged, including fatty acid oxidation (normalized enrich-
ment score 1.53; nominal P value 0.02, false discovery
rate q value  0.33), DNA-damage signaling (normalized
enrichment score  1.68; nominal P value  0.02, false
discovery rate q value  0.11), and granulocyte-colony
stimulating factor (G-CSF) survival pathway (normalized
enrichment score  1.79; nominal P value  0.00, false
discovery rate q value  0.10). Compared with propofol,
the anesthetic gas sevoflurane reduced transcriptional ac-
tivity of genes involved in fatty acid oxidation (t test P 
0.008) and DNA-damage signaling (t test P  0.002) but
activated the G-CSF survival pathway (t test P 0.017) (fig.
4; for complete list of transcripts, see table S3 on the
ANESTHESIOLOGY Web site). Interestingly, the lower activity of
transcripts involved in fatty acid oxidation, as observed in
sevoflurane patients, was closely correlated with low DNA-
damage signaling (P  0.001) and high G-CSF survival
pathway activity (P  0.006), implying a possible link
between the metabolic phenotype and cardioprotection
(fig. 5).
Anesthetic-induced and Constitutive Gene
Regulatory Control of Myocardial Energy
Metabolism Predicts Postoperative Cardiac
Function in Patients Undergoing Off-pump CABG
Surgery
Next, we correlated the anesthetic-induced short-term
transcriptional changes and the observed differences in
constitutive background energy metabolism to postopera-
tive cardiac function. Cardiac function was measured with
three independent methods, including NT-proBNP, trans-
esophageal echocardiography, and pulmonary artery ther-
modilution. Forward stepwise linear regression analysis
was applied to determine the best predictors of postoper-
ative cardiac function. Figure 6 shows the regression plots
with the best predictors of NT-proBNP, cardiac index, and
Fig. 3. (A) Pathways (gene sets) up-regu-
lated and down-regulated at T2 in re-
sponse to off-pump coronary artery by-
pass graft surgery in the two anesthetic
treatments. The Venn diagrams show the
number of enriched pathways (see also
table 4). (B) Peroxisome proliferator–ac-
tivated receptor  coactivator-1 (PGC-
1) pathway activity at baseline (t  T1).
Each numbered square indicates the ex-
pression value of the indicated transcript
in a specific patient. Subtle differences
(approximately 15%) in PGC-1 activity
were detected among patients. (C)
PGC-1 pathway regulates genes in-
volved in oxidative phosphorylation
(OXPHOS) and fatty acid (FA) metabolism
and was therefore used to express back-
ground energy metabolism in the heart
(see also fig. S2 on the ANESTHESIOLOGY
Web site). CaMK II   calcium/calmod-
ulin-dependent protein kinase II ; CaMK
II   calcium/calmodulin-dependent
protein kinase II ; ERR  estrogen-re-
lated receptor ; HDAC5  histone
deacetylase 5; MEF 2A  myocyte en-
hancer factor 2A; MEF 2B  myocyte en-
hancer factor 2B; MEF 2D  myocyte en-
hancer factor 2D; NRF1  nuclear
respiratory factor 1; PPAR  peroxi-
some proliferator activated receptor ;
PPP3CC  calcineurin A ; PROP 
propofol patients; SEVO  sevoflurane
patients.
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peak diastolic velocity, a marker of left ventricular relax-
ation. Interestingly, the G-CSF survival pathway consis-
tently predicted left ventricular diastolic function at differ-
ent anatomical sites in the hearts. No correlation was found
between transcriptional phenotypes and peak systolic ve-
locities. PAPP-A and cTnT did not correlate with cardiac
function and transcriptional phenotypes. Together, these
data indicate that short-term (by anesthetics) and long-term
(constitutive) gene regulatory control of myocardial energy
metabolism predicts postoperative cardiac recovery.
Discussion
Here we show for the first time on a genome-wide
basis that anesthetics differentially modulate the tran-
scriptional response to cardiac surgery in human
hearts. The volatile ether sevoflurane, as compared
with the intravenous anesthetic propofol, decreased
fatty acid oxidation, which tightly associated with
reduced DNA-damage signaling and enhanced activa-
tion of the G-CSF survival pathway. These favorable
transcriptional changes closely correlated with and
predicted improved cardiac functional recovery, as
determined by NT-proBNP release, cardiac index, and
peak diastolic velocity. However, beside these rather
acute transcriptional effects, chronic preoperative
background activity of PGC-1 pathway–regulated
genes involved in oxidative phosphorylation and fatty
acid metabolism, independently predicted postopera-
tive cardiac function. Collectively, our data imply that
gene regulatory control of myocardial energy metab-
olism, either as constitutive background activity or as
short-term therapeutic target, plays a pivotal role in
perioperative cardioprotection.
We used high-density oligonucleotide microarrays to
assess global changes in cardiac gene expression that
Table 4. Induced (Positive NES) and Repressed (Negative NES) Pathways in Off-Pump CABG Surgery
SEVO PROP
GSEA Pathway Description NES
Nom.
P Value
FDR
q Value NES
Nom.
P Value
FDR q
Value
etsPathway (Biocarta) The Ets transcription factors
promote macrophage
differentiation
1.69 0.00 0.14 1.94 0.00 0.00
stressPathway (Biocarta) Tumor necrosis factor–related
inflammation and stress-
activated kinases
1.67 0.00 0.13 1.69 0.00 0.02
CR_transcription_factors51 Cancer related genes that are
also transcription factors
1.61 0.00 0.25 1.83 0.00 0.02
MAPK_Cascade
(Biocarta)
Mitogen-activated protein
kinase pathway
1.56 0.03 0.18 1.67 0.00 0.02
SERUM_INDUCED_MKL_
INDEP_SRF52
Serum inducible genes
identified as a subset of
serum response factor (SFR)
target genes that are MKL
(SRF-specific transcriptional
coactivator) independent
1.56 0.00 0.19 1.81 0.00 0.02
LEM_HSC53 Stem cell molecular signature 1.54 0.02 0.19 1.78 0.00 0.01
IL6Pathway (Biocarta) IL-6–related kinases and
transcription factors
1.57 0.02 0.19 1.57 0.00 0.06
G-CSF (manually
curated)
G-CSF survival pathway 1.46 0.02 0.24 1.52 0.02 0.07
CR_repair51 Cancer-related genes involved
in DNA repair
1.58 0.00 0.32 1.62 0.00 0.20
IL7Pathway (Biocarta) B- and T-cell development
and proliferation
1.35 0.03 0.68 1.50 0.00 0.43
atrbrcaPathway
(Biocarta)
Double-stranded break repair 1.52 0.03 0.36 1.58 0.02 0.29
Fatty_acid_metabolism
(GenMAPP)
Fatty acid metabolism 1.48 0.04 0.14 1.24 0.1 0.48
OXPHOS (GenMAPP) Respiratory chain enzymes 1.41 0.03 0.20 1.32 0.15 0.43
Fatty acid metabolism and oxidative phosphorylation (OXPHOS) were significantly enriched (P  0.05) in the SEVO group only.
FDR  false discovery rate (FDR is the estimated probability that a set with a given NES represents a false positive finding); G-CSF  granulocyte
colony-stimulating factor; GSEA  Gene Set Enrichment Analysis*; IL-6  interleukin 6; MAPK  mitogen-activated protein kinase; MKL  myocardin-related
family of proteins (myocardin, megakaryoblastic leukemia 1, and megakaryoblastic leukemia 2); NES  normalized enrichment score (positive NES indicates
up-regulation at T2; negative NES indicates down-regulation at T2); nom.  nominal; PROP  propofol patients; SEVO  sevoflurane patients; SRF  serum
response factor.
* For pathway information, refer to Web Enhancement and http://www.broad.mit.edu/GSEA (accessed October 30, 2005).
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result from two widely used anesthetics to gain insight
into the underlying mechanisms of perioperative cardio-
protection. Based on previously reported differences be-
tween the cardioprotective effects of anesthetic gases
and intravenous anesthetics,5,7,15–17 we sought for dif-
ferential genomic responses in human hearts, which
could be correlated to biochemical and functional out-
come measures. To broaden the applicability of our
results, off-pump CABG surgery was used as a model of
human myocardial ischemia, which more closely mimics
the situation of general surgical patients experiencing
ischemia during noncardiac surgery. To assess the wide
spectrum of interacting genes and the complex redun-
dant and antagonistic patterns of transcriptional activa-
tion and suppression, we used GSEA, a sophisticated tool
for pattern recognition.14 Single gene approaches are
limited to assessing complex pathophysiologic networks
and miss important effects on entire pathways. In con-
trast, GSEA evaluates the microarray data on the level of
functionally related genes based on previous biologic
knowledge. The unique concept underlying GSEA re-
lates to the fact that even small but coordinate changes
in a majority of genes encoding members of a pathway
(gene set) may dramatically alter the flux through the
pathway. Using this more holistic approach, we were
able to track the molecular footprints of anesthetics in
the myocardium on a genome-wide basis and to gain
novel insights into the mechanisms of perioperative car-
dioprotection.
In this study, we identified gene regulatory control of
myocardial energy metabolism as the major determinant
of postoperative cardiac function. A large body of liter-
ature supports the concept that myocardial substrate
metabolism critically affects cardiac function in the
acute and chronic disease state,18 and that therapeutic
strategies switching the metabolic fuel preference away
from fatty acid oxidation can indeed improve contractile
recovery after ischemia and affect long-term outcome.19
Under normoxic conditions, the heart predominantly
(approximately 60–80%) uses fatty acids as fuel
source.18 However, cardiac substrate utilization is mark-
edly altered during ischemia with glucose as the pre-
ferred fuel. Conversely, in the postischemic myocar-
dium, fatty acid oxidation prevails and nearly provides
100% of the cellular adenosine triphosphate (ATP) re-
quirements.20 Although we did not observe transcrip-
tional changes in glucose transport, glycolysis, or glu-
cose oxidation pathways, the reduction in fatty acid
oxidation, per se leads to a relative increase in glucose
utilization via activation of the pyruvate dehydrogenase
complex (the glucose–fatty acid cycle by Randle21). Fa-
voring the energetically economical glucose (3.17 ATP/
oxygen molecule) over fatty acid oxidation (2.83 ATP/
oxygen molecule) may be particularly beneficial in the
diseased and mechanically stressed heart with only lim-
ited oxygen supply. Therefore, high-level fatty acid oxi-
dation either by propofol anesthesia or as constitutive
metabolic phenotype may put the heart at higher risk of
postoperative contractile dysfunction.
Our study now demonstrates that this protective met-
abolic phenotype can be induced on a short-term basis in
human hearts using anesthetic gases. We previously re-
ported that isoflurane, another halogenated ether, pro-
foundly reduced fatty acid oxidation in an in vitro rat
heart model (fig. S3 on the ANESTHESIOLOGY Web site),8
which is consistent with positron emission tomography
results from isoflurane-anesthetized mice exhibiting
strong and selective myocardial glucose uptake.22 Like-
wise, our study patients with constitutive cardiac down-
regulation of the PGC-1 pathway may have shifted the
Fig. 4. Anesthetic-induced modulation of gene expression. Us-
ing fold changes in gene expression between T1 and T2, Gene
Set Enrichment Analysis identified three major pathways,
which were differentially regulated by sevoflurane (SEVO) and
propofol (PROP). (A) Fatty acid (FA) oxidation pathway. (B)
DNA-damage signaling pathway. (C) Granulocyte colony-stimu-
lating factor (G-CSF) survival pathway. The average fold change
of all enriched transcripts in the respective pathways was cal-
culated (table S3 on the ANESTHESIOLOGY Web site). The individual
dots represent changes in pathway activity of each patient.
Horizontal lines indicate mean values.
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metabolic fuel preference away from fatty acid oxidation
and thus exhibited reduced mitochondrial respiration
and oxidative phosphorylation gene activity. The
PGC-1 pathway encloses the transcription factors per-
oxisome proliferator–activated receptor , estrogen-re-
lated receptor , the nuclear respiratory factors, and the
transcriptional coactivator PGC-1, which critically or-
chestrate control of cellular energy metabolism.23 Al-
though the PGC-1 pathway promotes a high energy
state with increased contractility,24 the PGC-1–induced
high ATP turnover may be detrimental under oxygen
restriction.25 Accordingly, hearts lacking peroxisome
proliferator–activated receptor , a key transcription fac-
tor of the PGC-1 pathway, exhibit improved ischemic
tolerance, whereas hearts with peroxisome proliferator–
activated receptor  overexpression only recover poorly
after ischemia–reperfusion because of their inability to
switch energy substrate.26 Interestingly, reduced mito-
chondrial respiration resembles a state of metabolic hi-
bernation, previously identified as a typical feature of the
preconditioned state.27,28 On the other side, anesthetic
gases activate ATP-dependent potassium channels,29,30
key players in the preconditioning process, which are
tightly regulated by intermediary metabolites.31 To-
gether, our data shed new light on the intricate interplay
among cellular metabolism, preconditioning, and peri-
operative cardioprotection and further suggest that mod-
ulation of the PGC-1 pathway may be used as a novel
anti-ischemic strategy.
DNA-damage signaling and the G-CSF survival pathway
closely correlated with fatty acid oxidation. An impor-
tant question raised by our findings relates to the possi-
ble links between these pathways. In the case of DNA-
damage signaling, the correlation may merely reflect the
protection resulting from metabolic fuel shift. Among
others, this pathway encloses the proinflammatory tu-
mor necrosis factor  and the tumor suppressor p53 and
the ataxia telangiectasia-mutated (a protein kinase that
Fig. 5. Relation between anesthetic-in-
duced metabolic changes in fatty acid
(FA) oxidation and DNA-damage signal-
ing (A), and granulocyte colony-stimulat-
ing factor (G-CSF) survival signaling (B),
respectively. PROP  propofol patients;
SEVO  sevoflurane patients.
Fig. 6. Regression plots between transcriptional phenotypes and postoperative cardiac function. Multivariate analysis including the
explanatory variables peroxisome proliferator activated receptor  coactivator-1 (PGC-1) pathway (an index of long-term energy
metabolism) and the anesthetic-induced short-term changes in gene expression was used to determine the best predictors of
postoperative cardiac function. (A) Perioperative changes in N-terminal pro brain natriuretic peptide (NT-proBNP) were best
predicted by changes in fatty acid (FA) oxidation pathway activity. (B) PGC-1 pathway status best predicted perioperative changes
in cardiac index (CI), whereas DNA-damage signaling best predicted postoperative CI (C). Granulocyte colony-stimulating factor
(G-CSF) survival signaling best predicted postoperative early diastolic (ED) function measured at the septum (D), the mitral annulus
(E), and the lateral wall (F). PROP  propofol patients; SEVO  sevoflurane patients.
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acts as a tumor suppressor) checkpoint recently shown
to be important in ischemia–reperfusion injury in pa-
tients undergoing cardiac surgery.32 In contrast, the G-
CSF survival pathway may have a direct causal role in
cardiac fuel selection by regulating STAT3-mediated in-
sulin sensitivity in the heart.33 Representative members
of this pathway are JAK2/3, STAT3, vascular endothelial
growth factor, and protein kinase B or Akt, which pro-
mote cell survival and angiogenesis.34,35 STAT3 is known
to elicit early preconditioning36 but also has an obliga-
tory role in the context of late preconditioning.37 Inter-
estingly, changes in left ventricular diastolic function
were best predicted by G-CSF survival pathway activity.
The diastolic phase of the cardiac cycle imposes the
highest energetic demand on the heart, and thus may be
particularly sensitive to ischemia but also receptive to
protection by this pathway. G-CSF further exerts antiin-
flammatory actions,38 which is consistent with our find-
ing that PAPP-A, a marker of coronary plaque inflamma-
tion and instability,39 was not elevated postoperatively in
sevoflurane-treated patients. Finally, G-CSF has positive
effects on the mobilization and cardiac homing of bone
marrow stem cells, which could accelerate postopera-
tive endothelial and myocardial recovery.40,41 Recent
clinical studies emphasize the important role of PAPP-A
in the detection of plaque rupture in patients with acute
coronary syndrome, even in the absence of biomarkers
of necrosis, potentially identifying high-risk patients
whose plaque instability might have been otherwise
undetected.42 PAPP-A was also identified as an indepen-
dent predictor of future cardiovascular events and of the
need for future angioplasty or CABG surgery.43
Study Limitations
This study is an observational study and does not allow
ultimate interpretation of the causal relations. Some of the
observed immediate beneficial effects by sevoflurane may
be due to direct signaling events related to preconditioning
(“first window”), whereas other more medium- and long-
term beneficial effects occurring within hours or days after
exposure to sevoflurane may be well—at least in part—
explained by genomic reprogramming. Our study can not
distinguish between these possibilities, but associates the
transcriptional changes to functional and biochemical out-
comes. The current study was powered to detect differ-
ences in postoperative NT-proBNP levels between the
SEVO and PROP groups but not to detect differences in
clinical outcome measures. Although the DNA microarray
technology has limitations with respect to sensitivity, accu-
racy, specificity, and reproducibility of results, the cur-
rently available data suggest that for abundant transcripts
the existence and direction of expression changes can be
reliably detected by this method.44 Given the small number
of samples compared with the high number of probes on
the microarray (tens of thousands), the uncertainty about
the statistical power in microarray analysis remains a limi-
tation of large-scale transcriptional profiling. We have used
state-of-the-art bioinformatics tools to address these con-
cerns, particularly with respect to correction for multiple
comparisons. Nonetheless, our results should be tested in
randomized controlled clinical trials. This study is a short-
term assessment of myocardial gene expression. However,
we have previously shown in patients undergoing on-
pump CABG surgery that favorable short-term changes in
gene expression elicited by sevoflurane were associated
with improved long-term cardiovascular outcome.6 Al-
though we carefully selected the patients, there always
remains a high biologic variability in human studies com-
pared with well-controlled animal experiments. In particu-
lar, medication could have affected myocardial substrate
metabolism and biased our findings. In fact, sevoflurane
patients received less remifentanil, a preconditioning-mim-
icking opioid, than propofol patients.45 However, this
should have favored cardiac protection in the propofol
patients. Furthermore, despite proper randomization and
selection of the patients, our analysis showed that the
PGC-1 pathway was differentially regulated at baseline
between groups. Therefore, we included this pathway in
the multivariate analysis. Despite these caveats, we were
able to detect robust functional patterns extending beyond
this variability. A relatively healthy population of cardiac
surgical patients was selected for the study, which might
limit the general application of our findings. End-tidal
sevoflurane concentrations were measured, whereas
propofol concentrations in the blood were not determined,
which might complicate the direct comparison between
the two anesthetics. However, sevoflurane and propofol
were administered in clinically relevant doses to maintain
blood pressure and heart rate within 20% of baseline val-
ues. The implications of comparing a lipid-based anesthetic
(propofol dissolved in Intralipid) with a lipid-free anes-
thetic on myocardial energy metabolism are unclear. It
could be speculated that the lipid component of propofol
but not the anesthetic itself might be responsible for some
of the observed differences in cardiac energy metabolism.
However, most studies showed that the effects of propofol
on cardioprotection are independent of the solvent used.46
Also, experimental data in mice provide evidence that vol-
atile anesthetics per se reduce fatty acid oxidation in the
heart.22 Messenger RNA levels do not always directly trans-
late into changes in protein or functional levels, because
additional regulatory mechanisms on the posttranslational
level exist. However, the gene expression profile underly-
ing the cellular protein contents of enzymes and transport-
ers is an important determinant of the metabolic pheno-
type. Finally, for ethical reasons, we used human atrial
samples rather than ventricular biopsies to examine gene
expression changes. Although there are clearly many dis-
parities (but also many similarities) between human atrial
and ventricular tissue, it remains elusive whether the gene
expression results from atrial samples in this study can be
directly extrapolated to left ventricular tissue. However,
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one study found that only approximately 1% of genes,
predominantly related to contractile function, were differ-
entially expressed between atrium and left ventricle.47 Us-
ing the Affymetrix chips, Barth et al.48 reported a predom-
inance of gene expression related to energy metabolism
and oxidative phosphorylation in ventricles, whereas atrial
tissue was prominently expressing transcripts related to
signal transduction pathways, which might be specifically
sensitive to changes in hemodynamic load and neuroendo-
crine activity. Of note, in the latter study, significant tran-
scriptional differences were also reported between differ-
ent regions within the same ventricle, and some chamber-
specific markers such as the atrial natriuretic factor were
also induced in ventricular tissues. Finally, using Affymetrix
U95Av2 arrays, Ohki-Kaneda et al.49 were able to predict
left ventricular ejection fraction from right atrial gene ex-
pression patterns, implying that the atrial transcriptional
profiles of our study are likely of clinical significance with
respect to left ventricular gene expression and function.
Conclusions
Considerable effort has been focused on improving peri-
operative outcome in high-risk surgical patients. In a recent
landmark article discussing the need for translation of basic
science into clinical practice, anesthetic gases were pro-
posed as readily available model drugs to successfully re-
produce cardioprotection in patients.50 Our data clearly
support this view and provide a strong rationale for anes-
thetic gases in the perioperative management of cardiac
surgical patients. In summary, using an integrative physio-
logic approach, we were able to link anesthetic-induced
and constitutive gene regulatory control of myocardial en-
ergy metabolism to postoperative cardiac function in pa-
tients undergoing off-pump CABG surgery. Our analysis
further points to the PGC-1 pathway and the G-CSF sur-
vival pathway, integral components of the protective pro-
gram in the heart, as potential therapeutic targets in peri-
operative cardioprotection.
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Infarct-remodeled Myocardium Is Receptive to Protection
by Isoflurane Postconditioning
Role of Protein Kinase B/Akt Signaling
Jianhua Feng, M.D., Ph.D.,* Gregor Fischer, D.V.M.,† Eliana Lucchinetti, Ph.D.,* Min Zhu, M.S.,‡
Lukas Bestmann, Ph.D.,§ David Jegger, M.S., Margarete Arras, D.V.M.,† Thomas Pasch, M.D.,#
Jean-Claude Perriard, Ph.D.,** Marcus C. Schaub, M.D., Ph.D.,†† Michael Zaugg, M.D.‡‡
Background: Postinfarct remodeled myocardium exhibits nu-
merous structural and biochemical alterations. So far, it is un-
known whether postconditioning elicited by volatile anesthetics
can also provide protection in the remodeled myocardium.
Methods: Myocardial infarct was induced in male Wistar rats
by ligation of the left anterior descending coronary artery. Six
weeks later, hearts were buffer-perfused and exposed to 40 min
of ischemia followed by 90 min of reperfusion. Anesthetic post-
conditioning was induced by 15 min of 2.1 vol% isoflurane. In
some experiments, LY294002 (15 M), a phosphatidylinositol
3-kinase inhibitor, was coadministered with isoflurane. Mas-
son’s trichrome staining, immunohistochemistry, Western blot
analysis, and reverse-transcription polymerase chain reaction
served to confirm remodeling. In buffer-perfused hearts, func-
tional recovery was recorded, and acute infarct size was mea-
sured using 1% triphenyltetrazolium chloride staining and lac-
tate dehydrogenase release during reperfusion. Western blot
analysis was used to determine phosphorylation of reperfusion
injury salvage kinases including protein kinase B/Akt and its
downstream targets after 15 min of reperfusion.
Results: Infarct hearts exhibited typical macroscopic and
molecular changes of remodeling. Isoflurane postconditioning
improved functional recovery and decreased acute infarct size,
as determined by triphenyltetrazolium (35 5% in unprotected
hearts vs. 8  3% in anesthetic postconditioning; P < 0.05) and
lactate dehydrogenase release. This protection was abolished by
LY294002, which inhibited phosphorylation of protein kinase
B/Akt and its downstream targets glycogen synthase kinase 3,
endothelial nitric oxide synthase, and p70S6 kinase.
Conclusions: Infarct-remodeled myocardium is receptive to
protection by isoflurane postconditioning via protein kinase
B/Akt signaling. This is the first time to demonstrate that anes-
thetic postconditioning retains its marked protection in dis-
eased myocardium.
REMODELING is a maladaptive response to chronic hemo-
dynamic sequelae occurring after large myocardial infarcts
and leading to left ventricular dilatation and compensatory
hypertrophy of the residual intact cardiac tissue. Apoptosis
and fibrosis participate in this chronic process, which has
a high propensity for arrhythmogenesis, including sudden
cardiac death, and ultimately leads to congestive heart
failure.1,2 In remodeled hearts, left ventricular dysfunction
does not only occur in infarcted cicatrized areas, but also
occurs in residual intact myocardium. Beside many dra-
matic macroscopic and microscopic structural changes as-
sociated with remodeling, significant alterations in metab-
olism were previously reported, including a shift toward
anaerobic metabolism and a depletion in high-energy phos-
phates putting the diseased myocardium at particular risk
for further ischemic injury.3
Postconditioning by volatile anesthetics (“anesthetic
postconditioning”) is a most effective therapeutic strategy
of reducing infarct size after prolonged ischemia. Similar to
ischemic postconditioning,4,5 anesthetic postconditioning
enhances the activity of the reperfusion injury salvage ki-
nase (RISK) protein kinase B (PKB)/Akt at the time of
reperfusion,6–8 thereby preventing mitochondrial perme-
ability transition through inhibition of glycogen synthase
kinase 3 (GSK3) and reducing infarct size.7 Because the
onset of reperfusion is predictable and under the control of
the operator, this novel therapeutic strategy is particularly
promising for the clinical setting.
To date, all experimental studies have evaluated the phe-
nomenon of cardiac postconditioning in healthy juvenile
hearts. However, this is far from clinical reality, because
diseased myocardium would benefit most from protection
by postconditioning. On the other side, some clinical9,10
and experimental11 studies provide evidence that diseased
myocardium may be less amenable to protection by pre-
conditioning, the most powerful endogenous protective
mechanism, which is at the opposite site of ischemia but
shares many signaling steps with postconditioning.12
Therefore, we tested the hypothesis whether protection by
* Postdoctoral Fellow, Institute of Anesthesiology, University Hospital Zurich,
and Center of Integrative Human Physiology, University Zurich. † Veterinarian,
Institute of Laboratory Animal Sciences, †† Professor Emeritus, Institute of
Pharmacology and Toxicology, University Zurich. ‡ Ph.D. Student, Institute of
Anesthesiology, University Hospital Zurich, and Center of Integrative Human
Physiology, University Zurich. § Head General Analytics, Institute of Clinical
Chemistry, # Professor, Institute of Anesthesiology, University Hospital Zurich.
 Ph.D. Student, Department of Cardiovascular Surgery, University Hospital
Lausanne, Lausanne, Switzerland. ** Professor, Institute of Cell Biology, Swiss
Federal Institute of Technology Zurich. ‡‡ Privatdozent and Director, Cardio-
vascular Anesthesia Research Laboratory, Institute of Anesthesiology, University
Hospital Zurich, and Center of Integrative Human Physiology, University Zurich.
Received from the Institute of Anesthesiology, University Hospital Zurich,
Zurich, Switzerland; the Center of Integrative Human Physiology, University
Zurich, Zurich, Switzerland; and the Institute of Cell Biology, Swiss Federal
Institute of Technology Zurich, Zurich, Switzerland. Submitted for publication
November 3, 2005. Accepted for publication January 26, 2006. Supported by
grant No. 3200B0-103980/1 from the Swiss National Science Foundation, Berne,
Switzerland; the Swiss University Conference, Berne, Switzerland; a grant from
the Swiss Heart Foundation, Berne, Switzerland; a grant from Abbott Switzerland,
Baar, Switzerland; a grant from the Swiss Society of Anaesthesiology and Reani-
mation, Berne, Switzerland; a grant from the Olga Mayenfisch Foundation, Zu-
rich, Switzerland; a grant from Novartis Foundation, Basel, Switzerland; and the
5th Frontiers in Anesthesia Research Award from the International Anesthesia
Research Society, Cleveland, Ohio. Drs. Feng and Fischer contributed equally to
this work.
Address correspondence to Dr. Zaugg: Cardiovascular Anesthesia Research
Laboratory, Center of Clinical Research, Institute of Anesthesiology, University
Hospital Zurich, Ra¨mistrasse 100, CH-8091 Zurich, Switzerland.
michael.zaugg@usz.ch. Individual article reprints may be purchased through the
Journal Web site, www.anesthesiology.org.
Anesthesiology, V 104, No 5, May 2006 1004
pharmacologic postconditioning elicited by isoflurane
would be diminished or lost in markedly remodeled postin-
farct myocardium. Additional experiments served to delin-
eate the specific role of PKB/Akt among other RISK com-
ponents in the protection by isoflurane postconditioning
(fig. 1).
The data provided in this study show for the first time
that protection by anesthetic postconditioning is fully
preserved in postinfarct remodeled myocardium. They
further underscore the unique role of PKB/Akt in the
cardioprotection by isoflurane postconditioning in the
severely diseased heart.
Materials and Methods
This study was conducted in accordance with the
guidelines of the Animal Care and Use Committee of the
University of Zurich, Zurich, Switzerland.
Induction of Myocardial Infarct In Vivo to Promote
Cardiac Remodeling
Infarct or sham operations were performed in 200-g
male Wistar rats (8–9 weeks old) kept in a 12-h light–
dark cycle on commercial rat chow and water ad libi-
tum. Ligation of the left anterior descending coronary
artery was performed in the intubated rats during isoflu-
rane anesthesia, as previously described.13 Briefly, the
fourth intercostal space was opened, the heart was ex-
teriorized, and the pericardium was cut. The left anterior
descending coronary artery was ligated between the left
atrium and the pulmonary outflow tract using a 6.0 silk
suture. Successful ligation was verified by regional cya-
nosis of the myocardial surface and ischemic ST-segment
changes in the electrocardiogram. The heart was re-
placed into the thoracic cavity, which was drained from
remaining air, and the chest was immediately closed. At
the end of operation, all animals received 0.02 mg/kg
subcutaneous buprenorphine for postoperative analge-
sia (with subsequent doses every 12 h for the first 3
postoperative days), and 10 mg/kg subcutaneous enro-
floxacin as an antibiotic prophylaxis. A microchip was
implanted subcutaneously for identification. Sham-oper-
ated animals underwent the same procedure except that
the suture was passed under the coronary artery without
ligation. A series of separate experiments served to verify
the occurrence of an effective remodeling process 6
weeks after ligation. Because successful remodeling and
impairment of left ventricular function can be expected
only if infarct size reaches approximately 30% of the left
ventricular mass,13,14 acute infarct size was determined
12 h after coronary artery ligation using 1% 2,3,5-tri-
phenyltetrazolium chloride (n  5). In additional exper-
iments, sham-operated hearts and infarcted hearts were
evaluated for their function on the Langendorff appara-
tus, as well as for morphologic changes and biochemical
markers of remodeling on the messenger RNA (mRNA)
and protein level (n  5).
Langendorff Preparation of Rat Hearts and
Experimental Protocols
Six weeks after ligation of the left anterior descending
coronary artery, rats were heparinized (500 U intraperi-
toneal) and 15 min later decapitated without previous
anesthesia. Hearts were removed and perfused in a non-
circulating Langendorff apparatus with Krebs-Henseleit
buffer (155 mM Na, 5.6 mM K, 138 mM Cl, 2.1 mM
Ca2, 1.2 mM PO4
3, 25 mM HCO3, 0.56 mM Mg
2,
11 mM glucose) gassed with 95% O2–5% CO2 (pH 7.4,
temperature 37°C). Perfusion pressure was set to 80
mmHg, and left ventricular end-diastolic pressure was
set at 10 mmHg after equilibration. Left ventricular de-
veloped pressure and derivatives (dp/dt), left ventric-
ular end-diastolic pressure, epicardial electrocardiogram,
coronary flow, and perfusion pressure were recorded, as
previously described.15 After equilibration, spontane-
ously beating hearts were exposed to 40 min of global
test ischemia (fig. 2). Anesthetic postconditioning was
induced by isoflurane administered for 15 min at 1.5
minimum alveolar concentration (MAC; 2.1 vol%) right
at the onset of reperfusion. The buffer was equilibrated
with isoflurane using an Isotec 3 vaporizer (Datex-Ohm-
eda, Tewksbury, MA) with an air bubbler. Isoflurane
concentrations were also measured in the buffer before
entering the aortic cannula using a gas chromatograph
(Perkin-Elmer, Norwalk, CT): 0.50  0.04 mM. In the
blocker experiments, 15 M of the phosphatidylinositol
3-kinase (PI3K) LY294002 (Alexis, Lausen, Switzerland),
Fig. 1. Investigated signaling components in isoflurane postcon-
ditioning in the infarct-remodeled rat heart. Protein kinase B
(PKB)/Akt is downstream of phosphatidylinositol 3-kinase
(PI3K), a key enzyme in the reperfusion injury salvage kinase
cascade (full arrows). Phosphorylated PKB/Akt activates 70-kd
ribosomal protein S6 kinase (p70S6K) and endothelial nitric
oxide synthase (eNOS) and inactivates glycogen synthase ki-
nase 3 (GSK3) by phosphorylation. Activation of protein
kinase C  (PKC-), p38 mitogen-activated protein kinase (p38
MAPK), and extracellular signal–regulated protein kinases
(ERKs), potentially involved in cardioprotection from reperfu-
sion injury (dashed arrows), were also assessed. LY294002:
specific inhibitor of PI3K.
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dissolved in dimethyl sulfoxide at a final concentration
of less than 0.1%, was coadministered with isoflurane or
given alone during the first 15 min of reperfusion.5,7
Dimethyl sulfoxide alone did not affect functional recov-
ery, infarct size, or the phosphorylation status of any of
the measured kinases. Hearts subjected to ischemia and
reperfusion alone served as ischemic control. For each
experimental group, five hearts (n  5) were prepared,
and functional parameters were recorded (fig. 2). To
characterize myocardial function 6 weeks after induc-
tion of infarct, additional Langendorff perfusion studies
were performed as described to asses cardiac function
ex vivo in infarct-remodeled and sham-operated hearts
(n  5 in each group).
Determination of Infarct Size and Myocardial Damage
Infarct size was determined by 2,3,5-triphenyltetrazolium
chloride staining after 90 min of reperfusion. Briefly, hearts
were frozen at20°C for 2 h at the end of the experiment
and sliced into five 2-mm cross sections. The sections were
incubated at 37°C for 30 min in 1% 2,3,5-triphenyltetrazo-
lium chloride in 0.1 M phosphate buffer (pH  7.4), fixed
in 10% formaldehyde, and digitally photographed. Plani-
metric analysis was performed using ImageJ 1.33.§§
Briefly, the chronic infarct (bright white) was subtracted
from the total left ventricular slice area to obtain the area at
risk. Infarct size was determined by dividing the freshly
necrotic area (salmon pink) of the left ventricle by the area
at risk. Therefore, areas infarcted in vivo by coronary
ligation (chronic infarct) were excluded from subsequent
infarct size analysis. In addition, myocardial damage was
estimated by measuring the release of lactate dehydroge-
nase (LDH) from necrotic tissue. For this purpose, the
perfusate was collected, and LDH was determined by the
Roche/Hitachi 917 (sensitivity 6 U/l, intraassay and interas-
say coefficients of variance  1%; Hitachi Corp., Tokyo,
Japan).
Western Blot Analysis
Separate experiments served to determine the activi-
ties of kinases after 15 min of reperfusion (n  5 in each
group; fig. 1). The following antibodies were used for
Western blot analysis: polyclonal antibody specific for
atrial natriuretic peptide and protein kinase C  (PKC-)
(Santa Cruz, Biotechnology, Inc., Santa Cruz, CA); poly-
clonal antibodies specific for phospho-PKB/Akt (Ser-
473), GSK3, phospho-GSK3 (Ser-9), p70S6 kinase
(p70S6K), phospho-p70S6K (Thr-389), extracellular sig-
nal–regulated kinase1/2 (ERK1/2), phospho-ERK1/2
(Thr-202/Tyr-204), p38 mitogen-activated protein ki-
nase, phospho-p38 mitogen-activated protein kinase
(Thr-180/Tyr-182), endothelial nitric oxide synthase
(eNOS), and phospho-eNOS (Ser-1177) (Cell Signaling
Technology, Beverly, CA); polyclonal phospho-PKC-
(Ser-729) antibody (Upstate, Milton Keynes, United King-
dom); monoclonal anti–pan-actin (Chemicon, Temecula,
CA); monoclonal anti–-tubulin (Sigma, St. Louis, MO).
Monoclonal antibodies against myosin heavy chain  and
 (- and -MHC) were a gift from Simon M. Hughes,
Ph.D. (Division of Cell and Molecular Biology, The Ran-
dall Institute, King’s College London, London, United
Kingdom). Polyclonal anti-PKB/Akt antibody was a gift
from Brian A. Hemmings, Ph.D. (Friedrich Miescher In-
stitute, Basel, Switzerland). Polyclonal antibody against
-skeletal actin was a gift from Christine Chapponier,
Ph.D. (Department of Pathology, University of Geneva,
Geneva, Switzerland). After 15 min of reperfusion, left
ventricular tissue at risk was taken and frozen in liquid
nitrogen. Subsequently, it was powdered and homoge-
nized in lysis buffer containing 62.5 mM Tris-HCl at pH
6.8, 2% sodium dodecyl sulfate, 4 mM EDTA, and 7%
sucrose. Extracts were boiled at 95°C for 5 min followed
by 30 min centrifugation at 12,000g. Protein concentra-
tions in the supernatants were determined by the Brad-
ford method. Extracts were resolved by sodium dodecyl
sulfate polyacrylamide gel electrophoresis and trans-
ferred to polyvinylidene diflouride membranes (Amer-
sham Biosciences, Buckinghamshire, United Kingdom).
Membranes were blocked with phosphate-buffered sa-
line (PBS) containing 5% nonfat dry milk and 0.05%§§ http://rsb.info.nih.gov/ij/. Accessed December 1, 2004.
Fig. 2. Treatment protocols. Anesthetic postconditioning
(PostC)  isoflurane administered for 15 min (1.5 minimum
alveolar concentration [MAC]) right at the onset of reperfusion
after 40 min of test ischemia; CTRL time-matched perfusion of
remodeled hearts; ISCH  unprotected remodeled hearts ex-
posed to 40 min of ischemia alone; LY  LY294002. LY294002
dissolved in dimethyl sulfoxide (DMSO; < 0.1%) was coadmin-
istered with isoflurane during early reperfusion. Reperfusion
injury salvage kinases (RISKs) were assayed after 15 min of
reperfusion, and infarct size was determined after 90 min of
reperfusion. Five hearts were used in each group.
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Tween-20 for 1 h and then incubated with the primary
antibody. The membranes were washed and incubated
with horseradish peroxidase–conjugated goat antirabbit
immunoglobulin G (Pierce, Rockford, IL). After exten-
sive washing, the blots were exposed to films (Fuji Photo
Film Co., Kanakawa, Japan) for 10 s up to 1 min to obtain
a linear response by the enhanced chemiluminescence
method (Pierce, Rockford, IL). The quantity of the im-
munoreactive bands was determined by densitometry
using ImageJ 1.33.§§
mRNA Extraction and Real-time Quantitative
Polymerase Chain Reaction
Total RNA was prepared using an RNeasy Mini Kit (Qia-
gen, Hombrechtikon, Switzerland). First strand comple-
mentary DNA (cDNA) was synthesized from 1.0 g total
RNA using SuperScript II reverse transcriptase (Invitrogen,
Basel, Switzerland) and oligo-dT as a primer. Real-time poly-
merase chain reaction was accomplished with the specific
primers at an annealing temperature of 55°C on a Strat-
agene MX3000 real-time sequence detection instrument
using the Brilliant SYBR Green QPCR kit (Stratagene Eu-
rope, Amsterdam, The Netherlands). The following prim-
ers were used: atrial natriuretic peptide: 5=-ATCAC-
CAAGGGCTTCTTCCT-3= (sense) and 5=-TGTTGGACACC-
GCACTGTAT-3= (antisense); brain natriuretic peptide: 5=-
GGAAATGGCTCAGAGACAGC-3= (sense) and 5=-CGGTCT-
ATCTTCTGCCCAAA-3= (antisense); -MHC: 5=-TCTTG-
TGCTACCCAACCCTAA-3= (sense) and 5=-TTGGCTTG-
AAGGAAAATTGC-3=; -MHC: 5=-GCAGAAAATGCA-
CGATG-3= (sense) and 5=-TACAGGCAAAGTCAAGC-3=
(antisense); -skeletal-actin: 5=-CACGGCATTATCAC-
CAACTG-3= (sense) and 5=-CCGGAGGCATAGAGAGA-
CAG-3= (antisense). The expression levels were measured
in triplicates of the first strand cDNA, and -tubulin was
used for normalization of the data. The sense and antisense
primers for -tubulin were 5=-CCATGCGTGAGTG-
TATCTCC-3= and 5=-GTGCCAGTGCGAACTTCATC-3=, re-
spectively.
Histologic Assessment
Left ventricular tissue samples were placed in optimal
cutting temperature medium (Tissue-Tek; Sakura Finetek
Inc., Torrance, CA), frozen in liquid nitrogen, and stored
at 70°C. Cryosections (5 m) were collected on gela-
tin-precoated slides and air dried. The sections were
fixed in precooled methanol at 20°C for 10 min. After
washing with PBS, the sections were blocked with 5%
normal goat serum at room temperature for 1 h. The
sections were incubated at 4°C overnight with the fol-
lowing primary antibodies in 1% normal goat serum and
PBS: mouse monoclonal anti–N-cadherin (Zymed, Basel,
Switzerland), mouse monoclonal antidesmin (DakoCyto-
mation AG, Baar, Switzerland), mouse monoclonal anti–
-MHC and anti–-MHC (a gift from Simon M. Hughes,
Ph.D., The Randall Institute, King’s College London,
United Kingdom). Subsequently, the sections were
washed in PBS and incubated with Alexa Fluor-488–
labeled anti-mouse immunoglobulin G (Molecular
Probes, Eugene, OR) and 4=-6-diamidino-2-phenylindole
(DAPI, 10 ng/ml; Sigma-Aldrich, Buchs, Switzerland) in
1% normal goat serum with PBS at room temperature in
the dark for 1 h. After several steps of washing, the
sections were mounted in Lisbeth’s mounting medium
(33 mM Tris, pH 9.5, 70% glycerol, 50 mg/ml n-propyl
gallate) and examined using an epifluorescence micro-
scope Axiovert M200 (Zeiss, Jena, Germany). Additional
conventional histologic staining including hematoxylin–
eosin and Masson’s trichrome was performed. Hearts
were perfused with 4% paraformaldehyde and embed-
ded in paraffin. Sections of 3 m were cut, mounted, and
stained.
Statistics
All data are presented as mean  SD. For hemody-
namic data and LDH release, repeated-measures analysis
of variance was used to evaluate differences over time
between groups. An unpaired t test was used to compare
groups at identical time points, and a paired t test was
used to compare within groups over time. P values were
multiplied by the number of comparisons that were
made (Bonferroni correction). For all other data, one-
way analysis of variance with post hoc Tukey test was
used for multiple comparisons. P 0.05 was considered
significant. SigmaStat (version 2.0; SPSS Science, Chi-
cago, IL) was used for analysis.
Results
Postinfarct Remodeled Hearts Exhibit Characteristic
Macroscopic and Ultrastructural Changes
Ligation of the left anterior descending coronary artery
induced extended infarcts (35  5%), which were suffi-
cient to initiate and promote myocardial remodeling in
Table 1. Characteristics of Sham-operated and Infarcted
Hearts
Sham Rats Infarct Rats
Body weight, g* 296  17 288  20
Heart weight (wet), g* 1.21  0.07 1.66  0.11‡
Heart weight/body weight, g/kg 4.07  0.37 5.70  0.56‡
Infarct size, % of left ventricular wall — 35  5†
Heart rate, beats/min 302  13 294  10
LVDP, mmHg 100  6 73  8‡
Coronary flow, ml/min 14.5  1.0 15.0  0.8
Baseline hemodynamics were determined on the Langendorff apparatus 20
min after initiating buffer perfusion. Cardiac function was measured under
similar conditions of 10 mmHg left ventricular end-diastolic pressure.
* Body and heart weights as determined 6 weeks after ligation of the left
anterior descending coronary artery (n  5). † Individual infarct sizes were
as follows: heart 1  41%; heart 2  32%; heart 3  37%; heart 4  28%;
heart 5  36%. ‡ P  0.05.
LVDP  left ventricular developed pressure.
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the postinfarct healing period (table 1). The ratio of
heart weight over body weight was significantly in-
creased 6 weeks after ligation in the infarcted hearts
(table 1) compared with sham-operated hearts, indicat-
ing compensatory hypertrophy, predominantly in the
septal area of the heart (fig. 3A). Of note, heart weight
(1.63  0.13 g) and heart weight/body weight ratio
(5.80  0.33 g/kg) were also markedly increased in all
animals used for experimentation. Consistent with loss
of viable myocardium and hypertrophy was the ob-
served reduced contractile function of the remodeled
hearts as determined ex vivo on the Langendorff appa-
ratus under control conditions (left ventricular diastolic
pressure set at 10 mmHg) (table 1). At the mRNA level,
transcript levels for atrial natriuretic peptide, brain na-
triuretic peptide, and -skeletal-actin were increased,
whereas the transcript for -MHC was nearly absent (fig.
3B). Similarly, at the protein level, atrial natriuretic pep-
tide and -skeletal-actin were overexpressed, and -MHC
was markedly reduced (fig. 3C). Masson’s trichrome
staining of whole heart longitudinal and transverse sec-
tions exhibited increased amounts of collagen in the
chronic infarct scar and compensatory hypertrophy with
dilated spherical left ventricular cavities (fig. 4). Detailed
immunohistochemical analysis including markers of
cell–cell interaction (N-cadherin), contractile filaments
- and -MHC, and extracellular matrix (desmin) re-
vealed differences between sham-operated and infarcted
hearts (fig. 4). Comparable to previous studies with sim-
ilar models,16–18 there was no difference in the phos-
phorylation status of PKB/Akt and ERK1/2 between
sham-operated and infarcted hearts 6 weeks after oper-
ation (data not shown). Together, the results of these
experiments demonstrate significant morphologic
changes at the macroscopic and microscopic levels in
chronically remodeled postinfarct myocardium.
Fig. 3. Cardiac remodeling. Left anterior descending coronary
artery was ligated, and infarct size was determined after 12 h
using 1% triphenyltetrazolium chloride staining (A, upper
panel). Viable myocardium is stained brick-stone red,
whereas freshly infarcted myocardium is stained salmon
pink. Note the black ties on the two basal transverse heart
sections. A mean infarct size of 35  5% was obtained (see
also table 1). Six weeks after ligation, necrosis was replaced
by scar tissue, and compensatory hypertrophy developed (A,
lower panel). Chronic infarct is stained bright white. Tran-
script levels of remodeling markers (B): atrial natriuretic
peptide (ANP), brain natriuretic peptide (BNP), - and -my-
osin heavy chains (- and -MHC), -skeletal-actin (-skl-
actin). Western blot analysis of remodeling markers (C): ANP,
BNP, - and -MHC, -skl-actin. Alpha-tubulin and total actin
(pan-actin) were used as loading controls. Remod  postin-
farct remodeled hearts; sham  sham-operated hearts. Data
are given as mean  SD (n  5 in each group). * P < 0.05
versus sham.
Fig. 4. Histochemistry of remodeled myo-
cardium. Masson’s trichrome staining and
immunohistochemical stainings for - and
-myosin heavy chain (- and -MHC), N-
cadherin, and desmin were used to visual-
ize macroscopic and ultrastructural
changes in remodeled hearts. Representa-
tive sham-operated hearts 6 weeks after
operation are shown on the left (A), and
postinfarct remodeled hearts 6 weeks after
ligation are shown on the right (B). Note
the spherical shape of the remodeled
hearts with infarct wall thinning and ven-
tricular dilatation in contrast to the ellip-
soid shape of the sham-operated hearts.
Transverse sections were prepared from
tissue taken at the midpapillary level. The
fluorescence intensity was increased in the
remodeled myocardium for -MHC, N-
cadherin, and desmin but markedly re-
duced for -MHC. N-cadherin was accumu-
lated at intercalated disks (arrowhead) in
remodeled myocardium. Bar represents
distance of 50 m.
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Protection by Isoflurane Postconditioning Depends
on PI3K-PKB/Akt Signaling Pathway in the
Remodeled Myocardium
To determine whether isoflurane postconditioning
would also provide protection in the diseased remodeled
myocardium, chronically infarcted hearts were exposed
to 40 min of ischemia. Anesthetic postconditioning with
isoflurane (1.5 MAC) administered for 15 min immedi-
ately at the onset of reperfusion significantly improved
functional recovery and decreased infarct size when
compared with unprotected remodeled hearts (table 2
and fig. 5). Protection by isoflurane postconditioning
was completely abolished by coadministration of the
PI3K inhibitor LY294002. LY294002 (or dimethyl sulfox-
ide) alone administered during reperfusion did not fur-
ther deteriorate postischemic recovery, nor did it affect
infarct size (table 1 and fig. 5A). To independently cor-
roborate the results of infarct size determinations by
triphenyltetrazolium, LDH release was measured in the
perfusate during reperfusion. LDH release was signifi-
cantly reduced by isoflurane postconditioning, and this
protection was abolished by LY294002 administration
Table 2. Hemodynamics
Reperfusion
Baseline Preocclusion Value‡ 15 min 30 min 90 min
LVDP, mmHg
CTRL 69  7 71  8 70  8 72  10 73  10
ISCH 68  6 73  9 6  3*† 17  4*† 16  3*†
ISCH  LY 65  8 70  12 7  2*† 15  3*† 17  4*†
PostC 67  5 69  8 21  4*† 53  7*† 56  4*†
PostC  LY 70  9 72  5 5  2*† 16  4*† 15  4*†
DMSO 65  10 68  4 7  3*† 18  5*† 14  3*†
LVEDP, mmHg
CTRL 9  2 8  1 9  2 10  1 9  1
ISCH 8  2 9  2 42  9*† 47  7*† 39  8*†
ISCH  LY 9  1 10  3 40  8*† 45  5*† 39  6*†
PostC 8  1 9  2 19  5*† 19  1*† 16  2*†
PostC  LY 10  2 8  1 41  6*† 41  8*† 39  7*†
DMSO 10  1 10  3 42  8*† 41  3*† 40  5*†
dp/dt, mmHg/s
CTRL 2,060  200 2,100  159 2,080  220 2,070  190 1,880  210
ISCH 1,900  300 2,076  200 160  100*† 570  320*† 720  200*†
ISCH  LY 1,867  240 1,900  230 130  50*† 550  290*† 800  250*†
PostC 2,160  181 2,190  200 460  100*† 1,260  200*† 1,588  75*†
PostC  LY 1,936  307 2,076  280 1,650  100*† 600  300*† 720  250*†
DMSO 1,960  305 2,070  282 130  100*† 550  310*† 700  240*†
dp/dt, mmHg/s
CTRL 1,540  114 1,400  234 1,454  160 1,400  100 1,580  130
ISCH 1,600  310 1,520  400 80  30*† 224  123*† 264  112*†
ISCH  LY 1,650  400 1,440  170 80  25*† 180  95*† 260  200*†
PostC 1,670  300 1,480  200 350  120*† 800  120*† 1,070  205*†
PostC  LY 1,600  400 1,700  400 85  40*† 214  100*† 274  100*†
DMSO 1,400  210 1,580  420 62  40*† 234  120*† 294  111*†
CF, ml/min
CTRL 13.0  1.3 13.4  2.3 12.0  1.4 12.6  1.1 12.5  1.5
ISCH 12.0  1.5 11.6  1.5 2.8  1.6*† 3.4  1.1*† 3.8  0.4*†
ISCH  LY 12.8  0.8 12.0  1.8 2.4  1.1*† 2.6  1.5*† 3.6  1.6*†
PostC 13.4  2.0 12.2  2.0 9.8  1.3*† 10.6  1.1*† 11.2  0.8*†
PostC  LY 13.6  1.7 12.8  0.8 2.2  0.8*† 3.4  1.2*† 2.6  0.8*†
DMSO 12.8  1.0 12.4  2.1 2.4  1.1*† 2.8  1.3*† 3.0  1.8*†
HR, beats/min
CTRL 283  6 306  19 300  23 285  20 300  18
ISCH 300  25 292  16 180  60*† 192  27*† 204  21*†
ISCH  LY 296  11 294  15 134  50*† 150  33*† 196  30*†
PostC 296  20 296  11 192  18*† 246  12*† 243  11*†
PostC  LY 282  15 302  21 136  33*† 196  20*† 204  13*†
DMSO 300  27 291  20 138  30*† 190  27*† 210  12*†
Data are presented as mean  SD (n  5 for each group).
* Significantly (P  0.05) different from baseline (intragroup comparison). † Significantly (P  0.05) different from respective value in CTRL and ISCH (intergroup
comparison). ‡ Before test ischemia.
dp/dt  inotropy; dp/dt  lusitropy; CF  coronary flow; CTRL  control (time-matched perfusion of remodeled hearts); DMSO  dimethyl sulfoxide (
0.1%); HR  heart rate; ISCH  test ischemia without postconditioning; LVDP  left ventricular developed pressure; LVEDP  left ventricular end-diastolic
pressure; LY  LY294002; PostC  isoflurane postconditioning.
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(fig. 5B). These results provide strong evidence that
protection by isoflurane postconditioning is preserved
and operative in this model of postinfarct myocardium.
Isoflurane Postconditioning Activates PKB/Akt,
Which Subsequently Phosphorylates the
Downstream Targets GSK3, eNOS, and p70S6K in
a PI3K-dependent Manner
It has been well demonstrated that GSK3 is a major
downstream target of PKB/Akt and that phosphorylation
of the N-terminal Ser-9 residue by PKB/Akt leads to
inhibition of GSK3.7 Similar to our previous results in
healthy myocardium, we here show that 40 min of test
ischemia alone increased phosphorylation of PKB/Akt
and GSK3 to a certain extent when compared with
time-matched perfusion (figs. 6A and B). However, when
isoflurane was administered during the early reperfusion
phase, a significant additional increase in phosphoryla-
tion of PKB/Akt and GSK3 was observed (figs. 6A and
B). Both ischemia-reperfusion–induced and isoflurane-
induced phosphorylation of PKB/Akt and GSK3 were
strongly suppressed by LY294002, a specific inhibitor of
PI3K. In contrast, eNOS and p70S6K, downstream tar-
gets of PKB/Akt, were only marginally activated by isch-
emia–reperfusion alone, but strikingly enhanced by
isoflurane administration and completely abolished by
LY294002 (figs. 6C and D). LY294002 (or dimethyl sul-
foxide) alone administered during reperfusion did not
alter phosphorylation of the investigated enzymes when
compared with ischemic control (data not shown).
Taken together, these experiments show for the first
time a PI3K-dependent activation of three important
highly protective downstream targets of PKB/Akt includ-
ing GSK3, eNOS, and p70S6K in response to isoflurane
postconditioning. The data further provide evidence that
PKB/Akt signaling is functional in remodeled myocar-
dium.
Profile of Potential RISKs Does Not Reveal
Additional Kinases Involved in the Protection by
Isoflurane Postconditioning in This Postinfarct Rat
Heart Model
In sharp contrast to PKB/Akt and its downstream sig-
naling targets, ischemia-reperfusion–induced activation
of ERK1/2 and p38 mitogen-activated protein kinase was
not altered by isoflurane. Also, no change was detected
in the PKC- phosphorylation status of the various ex-
perimental protocols, implying that the role of these
kinases may be of limited importance in mediating the
protection by isoflurane postconditioning (fig. 6E). The
data clearly underscore the unique role of PKB/Akt sig-
naling in the protection of the remodeled myocardium
by isoflurane postconditioning.
Discussion
Here, we show for the first time that isoflurane post-
conditioning retains its protection against ischemia in
the severely diseased myocardium. Our experimental
model of a postinfarct remodeled myocardium exhibited
macroscopic and ultrastructural changes consistent with
marked architectural rearrangements of the myocar-
dium, which were accompanied with characteristic al-
terations at the gene and protein expression level. De-
spite this profound remodeling process, the diseased
hearts were still receptive to functional and structural
protection by anesthetic postconditioning. Of note, in-
farct size reductions by isoflurane postconditioning, as
measured by triphenyltetrazolium staining, were corrob-
orated by a reduced release of the necrosis marker LDH
into the perfusate during reperfusion. Furthermore, the
preserved protection in the postinfarct remodeled hearts
completely depended on activation of PI3K and was
commensurate with enhanced phosphorylation of the
Fig. 5. Infarct size was determined using
1% triphenyltetrazolium chloride stain-
ing, as described in the Materials and
Methods section. Areas infarcted in vivo
by coronary artery ligation were ex-
cluded from infarct size determination
(A). The scarred chronic infarct (white)
resulting from coronary ligation was
clearly distinguished from fresh infarcts
(salmon pink). Release of lactate dehy-
drogenase (LDH) during reperfusion (B)
served as an independent method to es-
timate infarct size (see Materials and
Methods). Transverse sections of repre-
sentative experiments (C). DMSO  di-
methyl sulfoxide (< 0.1%; used to dis-
solve LY294002); ISCH  unprotected
remodeled hearts exposed to ischemia–
reperfusion alone; LY  LY294002 (15
M); PostC  anesthetic postcondition-
ing. Data are given as mean  SD (n  5
in each group). * P < 0.05 versus ISCH.
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prosurvival PKB/Akt and its protective downstream sig-
naling targets GSK3, eNOS, and p70S6K. This confirms
and further extends previous work6–8,19 showing the
unique role of PKB/Akt signaling in the cellular protec-
tion by volatile anesthetics not only in the healthy but
also in the diseased heart. Our observation of a func-
tional anesthetic postconditioning mechanism in se-
verely diseased myocardium is of great clinical impor-
tance, because an increasing number of elderly patients
with hypertension, coronary artery disease, or conges-
tive heart failure and concomitant myocardial remodel-
ing must undergo high-risk cardiac or noncardiac sur-
gery.
Postconditioning: Old Concept Behind a Novel
Term?
Postconditioning was first established in 2003 by
Vinten-Johansen’s group.20,21 It is a mechanical process
whereby brief cycles of alternating ischemia and reper-
fusion right at the onset of reperfusion markedly de-
crease ischemic heart damage. Beneficial effects by grad-
ual reperfusion or administration of postconditioning-
mimicking agents at the time of reperfusion
(“pharmacologic postconditioning”) including volatile
anesthetics22 have been known since the 1980s (for
review, see Vinten-Johansen et al.23). However, postcon-
ditioning is not simply a passive form of gentle con-
trolled or chemically modified reperfusion, but rather an
active biologic process recruiting prosurvival signaling
pathways.12 Yang et al.24 reported a 70% reduction in
infarct size using six cycles of 10 s reperfusion–10 s
ischemia starting at the beginning of reperfusion in buff-
er-perfused rabbit hearts, a magnitude of protection sim-
ilar to the one previously reported for ischemic25 and
anesthetic26,27 preconditioning. The current study now
shows that administration of 1.5 MAC isoflurane during
the first 15 min of reperfusion can achieve comparable
protection in remodeled hearts.
Cardioprotection in Remodeled Myocardium
Loss of functional myocardium imposes deleterious
biomechanical and neurohumoral stress on the residual
tissue, leading to compensatory hypertrophy but also
additional myocyte death and slippage. This vicious cir-
cle, also called remodeling, ultimately results in ventric-
ular dilatation and pump failure. Remodeling is charac-
terized by activation of the fetal gene program and is
accompanied by misexpression and rearrangement of
myofibrillar, cytoskeletal, and extracellular proteins.28
Our postinfarct hearts clearly exhibited marked remod-
eling, with -skeletal-actin, -MHC, and desmin being
up-regulated. Increased micromechanical stress at cell–
cell contacts could be directly visualized by accumula-
tion of N-cadherin at adherens junctions.29 In accor-
dance with our study, previous experimental data
showed that 6 weeks after a large infarction, contractile
Fig. 6. Western blots analysis. Phosphorylation status of protein
kinase B/Akt (PKB, 60 kd, phosphorylation at Ser-473) (A),
glycogen synthase kinase 3 (GSK3, 46 kd, phosphorylation at
Ser-9) (B), endothelial nitric oxide (eNOS, 140 kd, phosphory-
lation at Ser-1177) (C), ribosomal S6 kinase (p70S6K, 70/85 kd,
phosphorylation at Thr-389) (D), extracellular signal–regulated
kinase 1/2 (ERK1/2, 44 and 42 kd, phosphorylation at Thr-202/
Tyr-204), p38 mitogen-activated protein kinase (p38 MAPK, 43
kd, phosphorylation at Thr-180/Tyr-182), and protein kinase C
 (PKC-, 95 kd, phosphorylation at Ser-729) (E) were analyzed
with specific phospho-antibodies. CTRL  time-matched perfu-
sion; ISCH  unprotected remodeled hearts exposed to isch-
emia/reperfusion alone; LY  LY 294002 (15 M); PostC 
anesthetic postconditioning. Data are given as mean  SD (n 
5 in each group). * P < 0.05 PostC versus ISCH.
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dysfunction and hypertrophy consistently evolve in
rats.30 In the clinical setting, angina before myocardial
infarction, a clinical correlate to ischemic precondition-
ing, protects against left ventricular remodelling.31 Re-
cently, we reported that anesthetic preconditioning but
not postconditioning effectively suppressed the early
activation of the deleterious remodeling program after
ischemia.27 Vice versa, remodeling may disrupt signaling
pathways and abolish innate protective cellular strate-
gies such as preconditioning and postconditioning, and
render the myocardium refractory to protection and
more susceptible to ischemia. Results from muscle slices
of human right atrial appendices of patients with failing
hearts indicate that failing myocardium is less amenable
to protection by ischemic preconditioning.11 In fact, loss
of preconditioning and postconditioning may be in-
volved in the poor prognosis of patients with postinfarct
ventricular remodeling.32 In line with this observation
are findings from a study investigating the effects of
preconditioning in postinfarct rabbit hearts, demonstrat-
ing complete failure of ischemic but not diazoxide-in-
duced preconditioning to protect the remodeled heart.33
Refractoriness of the remodeled myocardium to precon-
ditioning was explained by interruption of signal trans-
duction between G-protein and PKC-.34 Other condi-
tions such as hyperglycemia35 and aging36 were also
found to diminish anesthetic preconditioning. On the
other hand, functional preconditioning was reported in
severely atherosclerotic ApoE/LDLr/ knockout mice
and several rat heart models of hypertrophied myocar-
dium (for review, see Zaugg et al.37). Our study now
extends these observations and fills a gap showing pro-
tection by isoflurane postconditioning in postinfarct re-
modeled hearts. Whether postconditioning is more ef-
fective than preconditioning in the remodeled heart
remains to be investigated in future studies.
Signaling in Postconditioning: Current
Controversies
Both preconditioning and postconditioning activate
RISKs.38 In ischemic preconditioning, Hausenloy et al.12
previously reported that inhibition of PKB/Akt and
ERK1/2 during the first 15 min of reperfusion com-
pletely abolished protection. In ischemic postcondition-
ing, Tsang et al.5 and Yang et al.4 recently uncovered the
importance of PKB/Akt but also ERK1/2 signaling. Simi-
larly, da Silva et al.39 showed the pivotal role of ERK1/2
during reperfusion in isoflurane preconditioning, while
three recent studies unequivocally demonstrate the de-
pendence of isoflurane postconditioning on activation of
the PI3K-PKB/Akt pathway.6–8 However, the relative
importance of PKB/Akt and ERK1/2 in mediating the
protection of postconditioning is still controversial. A
study in isolated perfused rabbit hearts of regional isch-
emia reports that activation of ERK1/2 but not PKB/Akt
is required.40 Conversely, another study investigating
pharmacologic postconditioning by bradykinin suggests
that PKB/Akt is upstream of ERK1/2.41 The authors also
found that bradykinin administered at reperfusion
caused only a brisk transient increase of ERK1/2 in half
of the hearts. These obviously divergent observations
may depend on species, the site of tissue sampling
(transmural vs. epicardial/endocardial), or both but cer-
tainly require additional investigation. Consistent with
previous reports showing a complex multiphase time
course of PKB/Akt and ERK1/2 activation in hypertro-
phied, ischemic, and failing hearts,16–18 we could not
observe activation of these kinases 6 weeks after coro-
nary ligation when compared with sham-operated
hearts.
In addition to RISKs, preconditioning and postcondi-
tioning share other signaling components, such as the
triggers adenosine and opioids,8 reactive oxygen spe-
cies, nitric oxide, and the end-effectors adenine trinucle-
otide phosphate–dependent potassium channels42,43
and the mitochondrial permeability transition pore.7,44
We recently demonstrated that anesthetic postcondition-
ing prevents opening of the mitochondrial permeability
transition pore via inhibition of GSK3.7 The current
study now also shows the phosphorylation of the PKB/
Akt downstream targets eNOS and p70S6K in anesthetic
postconditioning, confirming that most of the critical
signaling entities are shared between ischemic and an-
esthetic postconditioning.5 Activation of eNOS improves
endothelial function, whereas activation of p70S6K facil-
itates protein synthesis. Taken together, activation of
survival signaling by anesthetic postconditioning is pre-
served in postinfarct remodeled hearts and successfully
marshaled by PKB/Akt.
Clinical Implications
Reduction of infarct size is clinically important because
it directly correlates with survival. We have previously
shown that brief administration of sevoflurane on the
fully established cardiopulmonary bypass before induc-
tion of cardioplegia significantly improves postoperative
cardiac function45 as well as long-term cardiovascular
outcome46 in patients undergoing coronary artery by-
pass graft surgery. The concept of postconditioning now
shows that reperfusion per se is a major factor contrib-
uting to ischemic damage and opens the clinically attrac-
tive possibility to successfully treat “ischemic” damage at
the time of reperfusion. A recent landmark study inves-
tigated ischemic postconditioning in patients undergo-
ing coronary angioplasty and stenting for acute myocar-
dial infarction.47 In this study, creatine kinase release
was markedly decreased by 36% in patients treated with
four episodes of 1-min balloon inflations starting within
1 min of reflow. Similarly, De Hert et al.48 showed
beneficial cardiac effects of anesthetic postconditioning
in patients undergoing on-pump coronary artery bypass
grafting. Interestingly, in this study the combination of
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anesthetic preconditioning and postconditioning was
most protective in accordance with a recent in vivo
animal study43 and the molecular findings by Lucchinetti
et al.27 demonstrating differential but potentially syner-
gistic protective gene expression patterns after anes-
thetic preconditioning and postconditioning. Because
ischemic postconditioning by repetitive clamping or bal-
loon inflation may lead to embolization or endothelial
damage, pharmacologic postconditioning by volatile an-
esthetics should be preferred in the clinical setting. An-
esthetic postconditioning of remodeled human hearts
may particularly hold promise in nonsurgical coronary
artery interventions.
Limitations of the Study and Specific Comments
The following remarks should be added. (1) Although
ERK1/2 and PKC- were not activated by isoflurane post-
conditioning in our study, we can not rule out some role
of these kinases in mediating the protection by isoflu-
rane, because phosphorylation was determined in whole
tissue extracts, which does not consider the possible
accumulation of phosphorylation at specific subcellular
targets. In fact, ERK1/2 has been reported to form sig-
naling modules with mitochondrial PKC-,49 which con-
fers cardioprotection through inhibition of the mito-
chondrial permeability transition pore. Also, there may
be a complex time course of activation of RISKs, which
we could not follow up by determining phosphorylation
at a single time point. (2) We have noted increased
phosphorylation of eNOS and p70S6K in a PI3K-depen-
dent manner. Therefore, further studies are required
using specific blockers to test whether these changes are
only epiphenomena or active components of the protec-
tion. (3) Future studies should evaluate the optimal dos-
ing of volatile anesthetics to obtain maximal protection
during reperfusion. With this regard, it is interesting to
note that Obal et al.26 obtained maximal protection after
only a 2-min period of sevoflurane application immedi-
ately at the onset of reperfusion. Any prolongation of
sevoflurane administration rather decreased the protec-
tion. (4) As always pertinent to animal experiments, no
direct extrapolation into the clinical setting should be
made.
Conclusions
Using a highly controlled experimental model of
postinfarct rat hearts, we were able to show that recruit-
ment of PKB/Akt signaling at early reperfusion is a uni-
versal cardioprotective strategy, which is functional not
only in healthy but also in the remodeled myocardium.
This is the first demonstration to show that pharmaco-
logic postconditioning by isoflurane retains its profound
protection in severely diseased myocardium.
The authors thank Astrid Morger (Technician for Histology, Department of
Surgery, University Hospital Zurich, Zurich, Switzerland) for helpful assistance
with some of the staining procedures.
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